<span class="tex2jax_ignore"><div class="entities" style="line-height: 2.5; direction: ltr">)</br></br></br></br></br></br></br>The AASM Manual for the Scoring of Sleep and Associated Events</br>RULES, TERMINOLOGY AND TECHNICAL SPECIFICATIONS</br></br></br></br></br>r</br>..._</br>VERSION 2.5</br></br>Richard B. Berry,MD (Chair); Claude L. Albertario, AST, RPSGT; Susan M. Harding, MD; Robin M. Lloyd, MD; David T. Plante, MD; Stuart F.Quan, MD; Matthew M.Troester, DO; Bradley V.Vaughn, MD; for the American Academy of Sleep Medicine</br></br></br></br></br></br></br></br></br></br></br></br>..</br></br>ASt.l A American Academy of</br>1::	IYI SLEEP  MEDICINE&quot;'</br>)</br></br>J</br>)</br>:..J</br>)</br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	1</br>(</br>Copyright 1D 2018 American Academy of Sleep Medicine, 2510 North Frontage Road, Darien, IL 60561, U.S.A.	r</br>(</br>Yearly subscriptions to the online manual are available at www.aasm.org.	c</br>All rights reserved. Unauthorized reproduction or transmission of this manual or any portion thereof in any	(</br>form or by any means, mechanical or electronic, is strictly prohibited.	(</br>(</br>Correspondence regarding copyright permissions should be directed to the American Academy of Sleep</br>Medicine, 2510 North Frontage Road, Darien, IL 60561, U.S.A. Translations to other languages must be authorized by the American Academy of Sleep Medicine, U.S.A.</br>(</br>Recommended Citation:</br>Berry RB, Albertario CL, Harding SM, et al.; for the American Academy of Sleep Medicine. The AASM Mamialfor the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications.</br>Version 2.5. Darien, I L: American Academy of Sleep Medicine; 2018.	c</br>c c c c c c c</br>(</br>c c c c c c</br>(</br>c c c c c c</br>(_</br>l</br>(</br>(</br>(</br>c c</br>(_</br>2	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>Table of Contents</br></br></br></br>Contributors	4</br></br></br>..	Dedication	6</br>,....</br>....</br>User Guide	7</br></br></br>Parameters to be Reported for Polysom nography	8</br></br></br>Technical and Digital Specifications	12</br></br>	</br>Sleep Staging Rules</br>Part 1:Rules for Adults	17</br>Part 2: Rules for Children	33</br>0	Part 3:Rules for Infants	37</br>D</br></br></br>Arousal Rule	46</br></br></br>Cardiac  Rules	47</br></br></br>D	VII. Movement Rules	49</br>,..	 	</br>....</br>Respiratory Rules</br>D	Part l: Rules for Adults	56</br>Part 2: Rules for Children	62</br></br></br>Home Sleep Apnea Testing (HSAT) Rules for Adults</br>Part 1: HSAT Utilizing Respi ratory Flow and/or Effort Parameters	66</br>                 Part 2:HSAT Utilizing Peripheral Arterial Tonometry (PAT)	72</br>Development Process	75</br></br></br>:J	XI. Procedural Notes	76</br></br></br>::J	XII. Glossary of Terms	88</br></br>All Content © 2016 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	3</br></br>Contributors</br></br>Editors</br></br>V ERSION 2.5 (2018)</br>Richard B.Berry. MD, Chair Claude L. Albcrtario, RST, RPSGT Susan 1\1. Harding, M D</br>Robin M. Lloyd. M D Da\'id T. Planle, M D S1uar1 F. Quan, MD Mallhcw M. Troester, DO Bradley V. Vaughn, MD</br>Sherene M. Thomas, PhD. Staff</br>VERSION 2.4 (2017)</br>Richard B. Berry, MD, Chair Rita Brooks. M Ed, RST, RPSGT Charlene E. Gamaldo, MD</br>Susan r.·I.Harding, M D</br>Robin M. Lloyd, MD Stuarl F.Quan. M D Mallhew M.Troester, DO</br>Bradley V. Vaughn, M D</br></br></br></br></br></br>Task Forces</br>FIRST EDITION  (2007-2011) A ROUSA L</br>Michael H. Bonnet, PhD, Chair</br>Wright Stale U11i1·ersi1y. Duyton.OH</br></br>Karl Doghramji, MD</br>Tlromas Jefferscm Unii'er.fi ty, Philaclelp!tia, PA</br>Timo1hy Roehrs, PhD</br>ll'ap1e State U11i1·ersity, Detroit, Ml</br></br>Stephen Sheldon, DO. FAAP</br>Children's Memorial Hmpital. Chimgo. IL</br>Edward J. Slepanski, PhD</br>Rush Unfrersit.1· Medical 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ccmer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, Chicago, IL</br></br>Ar1hur S. Walters, MD</br>NJ Ne11roscie11cc hmi111tc at JFI\ .llcclicc1I Ccntr:r. Edison, NJ</br>Merrill S. Wisc, M D</br>Methoclisl Healthcare Sleep Disorders Ce/I/er, Memphis. TN</br>(</br>r</br>(</br>(</br>DIGITA L</br>Thomas Penzel, PhD, Chair	(</br>Uni1·ersity Hospital, Dl!partmem of .lledicine. Sleep laboratory. ,l/arb11rg, Germany</br>Max Hirshkowilz, PhD, Co-Chair	(</br>Baylor College of Meclici11e a11d l'AMC. Ho11.rto11. TX</br>Nie Bulkov, RPSGT	(</br>Sclrool of Clinical Polysc&gt;11111ography ..llcdford. OR	c</br>Ronald D. Chcr\'in. M D. MS</br>Unfrersity of .llichiga11, A1111 Arbor, .Ill</br></br>Meir Kryger. MD</br>Unfrersity of Manitoba. ll'i1mipeg. ,\/8 Ca11acla	(</br>Clcle A. Kushida, MD. PhD. RPSGT</br>Sta11ford Unil·ersity, Stanford. CA</br>Be1h A. Malow, MD, MS	c</br>l'arulerbilt Unin!rsity. Nas/noj/f f!, TN</br></br>Michael H. Silber, MBChB</br>Mayo Clinic Colfoge of .lledici11e, Rocl1cster, .llN</br>Michael V. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Vitello
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, PhD	c</br>U11frer.fi ty of ll'ashi11g1tm, Scartle, ll'A	c</br></br>V ERSION  2.0.2-2.3 (2013-2016)</br>Richord B. Berry. M D</br>Rila Brooks. MEd. RST. RPSGT Charlene E. Gumaldo, M D</br>Andrew L. Chesson Jr, M D</br>LSU Health Scie11ces Cc11tcr i11 Shrel'eport, Shre1•eport, LA</br></br>CA R DIAC</br>Andrew L. Chesson Jr, MD LSU Health Science.f Cemcr Slrre1·eport. LA</br></br>GER IATR IC</br></br>i11</br>Slrre1·epor1.	c c c</br></br>Susan M. Harding, MD Robin M. Lloyd, M D Carole L. Marcus, MBBCh Bradley V. Vaughn. M D</br>V ERSION  2.0-2.0.1 (2012-2013)</br>R ichard B. Berry. M D</br>Rila Brooks, MEd. RST, RPSGT Charlene E. Gamaldo, MD</br>Susan M. Harding, MD Carole L. Marcus. MBBCh Bradley V. Vaughn, MD</br>FI RST EDITION (2007-2011)</br>Conrad 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lber
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, MD</br>Sonia Ancoli-lsrael, PhD Andrew L. Chesson Jr, MD</br>S1uar1 F.Quan, M D 	</br></br>Consultants</br></br>V E RSION 2.2 (2014-2015)</br>IN FANT SLEEP STAGI NG</br>Madeleine Grigg-Damberger, MD</br>U11il'asity of Nell' Mexico School of Mcclici11e. Alb11q11crq11e, NM</br></br>Mark S. Scher, MD</br>Case Western Reser1·e U11i1-crsity, Cle1·e/cmd. OH</br>Scan M. Caples, DO, Chair</br>Mayo Clinic College of Medicine. Roe/rester..lfN</br>Virend K. Somers, M D,PhD, Co-Chair</br>Mayo Clinic College of Medicine, Roclre.fter, ,\/N</br>Michael E. Adams, Research Associate</br>f/olston Valley Mediml Cell/er, l\ingsport. TN</br>William G. Colts, MD</br>Nortlnrcstcrn Unfrersi f.1'. Chicago, IL</br>Par\'in Doroslkar, MD</br>Rainbcm·Babies 'md Childre11's Hospital, C/e1·elmul.OH</br>Thomas Kara, MD</br>Mayo Clinic College of .lfedici11e, Rochester. MN</br>Timo1hy I. Morgenthaler, M D</br>Mayo Clinic Collcge of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    .llcclicine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, Rochester, MN</br>Carol L. Rosen, MD</br>Rainboll' Babies and Children's Hospital. Cle1·ela11d, OH</br>Edward J. Stepanski, Ph D</br>Rush Uni1wsity Medical Cell/er, Chicago. IL</br></br>Win K. Shen. MD</br>Mayo Clinic College of Mcdicinc, Rochester, Ml\'</br>Kalyanam Shivkumar, MD</br>Da1·/d Gcffe11 School of Medicine at UCLA, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lo.r
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 A11geles, CA</br>Conrad lbcr, M D</br>He11nepi11 Co11111y Medical Cell/er ancl U11i1·ersit.1 of M/111re.rnta Meclical School, Minncapoli.f, MN</br>Sonia Am:oli·lsrael, PhD, Chair</br>Un/l'ersi11 of Cali.fim1111, San Diego. Cl</br>Donalll L. Bliwise, PhD	c</br>Emory Um1·er.wy McdicCJI School, Atlama.GA</br></br>Susan Redline, M D, M Pl-1</br>Cmc ll'estcrn Reser1·e U11il'ersi1_1. Cle1·c/and. OH</br>Ed\\ard Stepanski, PhD</br>Rmh Unfrersit _1 ,\/ec/ical Center, Chicago. IL</br>Michael V. Vitiello, PhD</br>U11frcrsi 11·of ll'ashingltm, Seal/le, 11';1</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Timolhy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 I. Morgenlhaler, MD</br>.ltayo Clinic College of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mcclici11c
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rochcsll!r
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, .\IN</br></br>MOVEM ENTS</br>Arlhur S. Wailers, MD, Chair</br>JFI\ Medical Centcr, Edison.NJ</br>R ichard P. Allen, Ph D</br>Johns Hopkins U11frer.fit) \Baltimorc..llD</br>Donald L. Blh,isc. PhD</br>Emory Unil'ersity ,\/edim/ Sclwol, Atlama, GA	c</br>Sudhansu Chokrovcrly, M D, FRCP</br>NJ Ne11roscie11ce l11slit11te at JFK Medical Center, Edison, NJ</br>Wayne A. Hcning, MD, PhD	(_</br>U\/DNJ - Rll' Jo/111sm1 Medical School, Neu·</br>Ortmrnick. NJ</br>Clclc A. Kushida, MD, PhD, RPSGT	(_</br>Stanford Unfrersit ,I '.Stanford Crl</br>(</br></br>4	AASM Scoring Manual Version 2.5</br>AU Conti!nl      2018 American Academy of Sleep Medicine	(_</br>..</br></br></br></br></br></br>0</br>.,..</br>0</br>0</br>0</br>•r</br>r</br>0</br>0</br>0</br>0</br>r</br>L</br>0</br>(</br>D</br>0</br>[)</br>0</br>D</br></br>0</br></br>Gilles Lavigne, DMD, PhD, FRCD</br>U11il'C!rsilC! de! Momreol Slet•p Disorder lc1boratory, Sacre Coeur Hospitof, M0111reul. QC Cu11e1cla</br>Daniel Picchielli, !'.-ID</br>U11il'erf.ily of //li11ois, Urba11a, IL</br></br>Sonia Ancoli·lsracl, PhD</br>U11i1•ersity of Cc1/ifomw. Scm DiL•go, CA</br></br>PEDI ATR IC</br>Madeleine Grigg·Damberger. M D, Chair U11in:rsi1_1• of New .lfexico Sc/mo/ of ,\/edici11e. Alb11q11erq11e.  NM</br>Dadd Goza!, MD, Co-Chair</br>U11i1'C!rsi1,1• of lo11isl'11le, lo111.1Tille. Kr</br>Carole L. Marcus, M BBCh</br>U11irersi1y of Pe11myfru11iu, Pltif adelpltit1, PA</br>Timothy I. Morgenthaler, M D</br>Mayo Clinic Colli:gi: of Mi:dicinc, Rocftester, MN</br>Carol L. Rosen, MD</br>Ruiflbcm Babie.f u11d Cltifdre11: Hospital. Cle1·e/c111d. OH</br>Stephen Shddon, DO, FAAP</br>Chilclre11'.f Memorial Hospitc1/. Cl1icago. IL</br>Stuart F. Quan. M D</br>Brig/tam uml ll'cm1e11'.1·Ho.fpita f 011d Hwl'Clrd Meclical Sclwol, Bosio/I, ,\IA</br></br>R ESPI RATORY</br>Richard B. Berry.M D, Chair</br>U11il'ersity of Florie/a Heu/tit Science Ce111er, Gui11Sl'il/e. Fl</br>Caroli: L. Marcus, MBBCh</br>Uflil'er.m_1·of Pcmr.fylrnma , Plt/ladelpltiu  PA</br></br>Vishesh K. Kapur,MD. MPH</br>UIJ' Medicine Sleep Ccllfer, U11i1·ersi1y of IJ'a.rltington, Seaule, II</br>Rohit 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Budhiraja
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. MD</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    So111lter11
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Ari:rma l',1 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    /Jt•tiltltrnrc
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 System. Soutltem Ari:niro. Trtc.wm. Al</br>Susan Redline, M D,MPH</br>Brig/ram a11cl ll(Jmen '.r Hmpite1I. Betit Israel Deaccmes.r Medical Center and Harl'arcl.\/eclirnl Scltnol, Boston,  .llA</br></br>VISUA L (SLEEP STAGI NG)</br>Michael H. Silber. MBChB, Chair</br>Mayo Clinic College of .lfedicine, Roc/1e.rtcr. ,\IN</br>Sonia Ancoli-lsrael, Ph D</br>U1111·ersity cif Califomia, Sm1 Diego, CA</br>Michael H. Bonnet, PhD</br>IJ'r1gl11 State U11frersi1y , Da\'f on, OH</br>Sudhansu Chokroverty, M D. FRCP</br>NJ Ne11roscie11ce /m1i1111e at JFK Medical Cellfer. Ecliso11, NJ</br>Madeleine Grigg-Damberger, MD</br>U11frersi1y of Ne11·,\/exicoSdrool of Medicine. All111q11erq11e , NM</br>Max Hirshkowitz, PhD</br>Baylor College of Medici11e cmcl l',4 MC. Ho11.rtm1, TX</br>Sheldon Kapen, MD</br>IJ'uy11e Sw1c U111n:rsit_1• \/ec/1ce1/ School and</br>f  l.l/C. Detroit. ,\//</br>Sharon Keenan, PhD.ABSM. RPSGT, R EEGT</br>Tlw Sc/toolfor Sleep Meclici11e, Inc , Palo A 110. CA</br>Meir Krygcr, M D</br>Unfrer.rit1 ·of Ma11i1oba Winnipeg ,\/B Ccmada</br></br></br>Acknowledgements</br>The American Academy of Sleep Medicine acknowledges 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thc
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 2017 -201R Board of Directors that served o\ er the course of this prnJcct and prO\ 1ded direction and support:</br>Ilene M. Rosen. MD. MS Douglas Kirsch, M D</br>Ronald D. Chervin, MD. MS Kelly A. Carden. M D. MBA</br>R. Nisha Aurora, !'.ID David Kristo, MD Raman Malhotra. M D Jennifer Marun, Ph D Eric Olson, M D Kannan Ramar, MD Carol Rosen, MD James Rowley, MD Steve Van Hout</br>£rec111il'e Dirccwr</br></br>AIIscoring schematics that prm ide illustration of sleep staging. n&quot;.Spiratory and movement sconng</br>rules were provided by R1d1ard a.Berry,MD.</br></br>0	Sairam Parthasarathy, MD</br>r	SAVAHCS a11cl Unil'ersit1 11/ Ari:mra.T11cso11, Al</br>L.</br>Conrad l bcr.MD</br>He1111epi11 C011111y Mecliml Cellfer a11cl U11frersity</br>Cl	of Milmesotu ,\/eclical Sc/tool, ,\/i1111eapolis, ,\/.\'</br>Reena Mehra, MD, MS</br>Case Western Resern: U11ircrs11y. Clerelaml, OH</br>Daniel J. Gottlieb. MD</br>l'A Bosio/I Healthcare .S)stem cmcl Bosto11 U1111'ersi1y Sc/tool of ,\/edici11e, Bos1011, MA</br>Kingman Strohl, M D</br>Case Western Rescr1·c U11il'crsitl', Clel't:lund, OH</br>Stuart F.Quan, MD</br>Brigham and Women'.1· Hosp11t1/ cmd Harn1rd Medical School. Bos/cm  MA</br>Sally L. Da\·1dson Ward, MD</br>Clti/
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    clren
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 'sHospital of Los Angeles, Keck School of Medicine, U11il'ers1f.1 of Sn11tl1em California lo.f A11geles, CA</br>Thomas Penzel, PhD</br>Unfrer.ritl' Hospital. Departmelll of .\fedici11£'. Sleep laborC11or.1'. ,\farb11rg  Germum·</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mark Pressman
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 , Ph D</br>lc111kena11 011d Paoli Hospital.I', 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ll)·1111e1rnocl
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 PA</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Conrad
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lber
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. MD</br>He1111epi11 Co11111y Medical Cemer um/ U11il'ersit1· of Mi1111esota Medical Sc/tool. MN</br></br>...	David Goza!.MD</br>Col'11er Children's Hospital and U11il'er.1·i1_1• of Chicago. Cltiwgo, IL</br></br></br>All Content © 2018 American Academy of Sleep Medicine</br>AASM Scoring Manual Version 2.5	5</br>(</br>(</br>Dedication	l</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>The Scoring Manual Editorial Board acknowledges the invaluable service of our colleague andfri end, Carole L. Marcus, MBBCh, who served on this Board from  2012-2016.</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>6	AASM Scoring Manual Version 2.5	AU Content © 2018 American Academy of Sleep Medicine</br>c</br>(</br>(</br>(</br>c c c c c</br>(</br>(</br>(</br>(</br>c</br>(_</br>(</br>c c c</br>(</br>c c c c</br>(_</br>c c c c c c</br>(_</br>c c</br>(_</br>c c c</br>\.._</br>(.</br>r</br>0	I.User Guide</br>0</br>0</br>[	Organization of the Manual</br>0	The AASM Manual for the Scoring of Sleep and Associated Events is designed to guide users through the technical aspects of (	conducting routine polysomnography (PSG) testing as well as the analytic scoring and interpretation of PSG results. The rules for PSG testing and scoring are divided over seven chapters (II-VIII) of the manual. Chapter II specifies all of the parameters</br>(	that should be reported in a routine PSG test. Chapter Ill details the digital and filter settings that are recommended for routine PSG recording. Chapters IV-VIII provide add itional technical specifications as well as scoring rules for the major categories of testing: sleep staging, arousal, cardiac, movement, and respiratory. Chapter IX provides technical specifications and scoring</br>0	rules for home sleep apnea testing including those utilizi ng respiratory flow and/or effort and those utilizi ng peripheral arterial</br>tonometry (PAT). Chapter X (Development Process) details the process by which the rules were developed. An outline of the</br>evidence level and decision-making process for each rule may be found in chapter XI (Procedural Notes). Lastly, chapter XII is</br>0	a glossary of the terminology used throughout the manual.</br>0	While the rules in most chapters apply to patients of all ages, rules for adult and pediatric populations are separated in chapters</br>0	IV (Sleep Staging Rules) and VIII ( Respiratory Rules) due to critical age-specific differences in testing and scoring.</br>0	The ru les within each chapter are organized into categories designated by an upper case letter. The rules themselves are num­</br>0	bered and may have several components that are identified by lower case letters.</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0	 	</br>Sleep Facility Accreditation</br></br>AASM sleep facility accreditation requires compliance with all of the rules, definitions, and notes in this manual. According to the AASM, rules specified to be recommended,  acceptable, or optional are all acceptable methods for scoring. Based</br>r	on the discretion of the clinician or investigator, a specific center or laboratory may use the acceptable rule in place of the recommended rule without any risk to accreditation. Optional ru les may be followed in addition to the recommended and</br>r	acceptable rules without any risk to accred itation. For further information please contact the accreditation department at the</br>0	AASM (accreditation@aasm. org).</br>,</br>0</br>r</br>u</br>All Cont    :©	16 American Academy of Sleep Med crne	AASM Scoring Manual Version 2.5	7</br>(</br>II.Parameters to be Reported for Polysomnography	r</br>Recommended parameters must be reported. Optional parameters may be monitored at the	(</br>discretion of the clinician or investigator and if monitored, should be reported.	(_</br>c</br>(</br>General Parameters		c</br>(</br></br>Electroencephalogram  (EEG) derivations</br></br></br>Electrooculogram (EOG) derivations</br></br></br>Chin electromyogram (EMG)</br></br></br>Leg electromyogram  (EMG) 				 5.AirHow  signals	_ _	_  	 	    ,</br>    6. Respi ratory effort signals 	</br></br>Oxygen saturation	 	</br></br>Body position</br>RECOMMENDED</br>(</br>RECOMMENDED	(</br>RECOMMENDED	c</br>(</br>RECOMMENDED	c</br>RECOMMENDED	c</br>RECOMMENDED	c</br>RECOMMENDED	c</br>RECOMMENDED	c</br>c</br></br>Electrocardiogram  (ECG)</br> 	RECOMMENDED 		c</br></br> 		c</br></br>Sleep Scoring Data</br></br>Lights out clock time (hr:mi n)</br></br>Lights on clock time (hr:min)</br></br>Total sleep time (TST; time spent in NI + N2 + N3 + R, in min)</br></br>Total record ing time (TRT; &quot;lights out&quot; to &quot;lights on&quot; in min)</br></br>Sleep latency (SL; lights out to first epoch of any sleep in m in)</br></br>Stage R latency (sleep onset to first epoch of stage R in min)</br>c</br>c</br>RECOMMENDED	c</br>c</br>1	RECOMMENDED	c</br>RECOMMENDED	c</br>RECOMMENDED	c</br>c</br>RECOMMENDED	c</br>RECOMMENDED	c</br>c</br></br>Wake after sleep onset (WASO; TRT	SL	TST, in min)</br> 	RECOMMENDED	c</br></br>Percent sleep efficiency (TST I TRT x 100 )</br>-- -------------</br>Time in each stage (in min)</br>------- --</br>to. Percent of TST in each stage (time in each stage  TST) x 100</br>RECOMMENDED	c</br>RECOMMENDED	c</br>c</br>RECOMMENDED	c</br>c</br></br>Note I. Wake after sleep onset includes all wake activity, including ti me out of bed. Time with the patient	c</br>discon nected from the recording equipment should be scored as stage W. Brief episodes of sleep during this ti me, if they occur, are not considered significant for the stage scoring summary.</br></br>8	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy o1 Sleep Medicine	(</br>r</br></br></br></br>Arousal Events</br></br>Number of arousals</br></br> 	- - - -- - -- - - 	</br>RECOMMENDED</br></br></br></br>2. Arousal index (Ari; nu mber of arousals x 60 I TST)</br></br>RECOMMENDED</br></br></br></br></br>...	D. Cardiac Events</br></br>D	1. Average heart rate during sleep</br>0</br>0	2. Highest heart rate during sleep</br>0	3.Highest heart rate du ring recording</br>D</br>4. Occurrence of bradycardia (if observed); report lowest heart rate</br>0</br>0	5. Occurrence of asystole (if observed); report longest pause</br>0	6. Occu rrence of sinus tachycard ia du ring sleep (if observed); report highest heart rate	_J</br>c	7. Occu rrence of nurrow complex tachycardia (if observed); report highest heart rate	 	</br>0	8. Occu rrence of wide complex tachycardia (if observed); report highest heart rate</br>0</br>0	9.Occurrence of atrial fibrillation (if observed); report average heart rate</br>0	JO. Occurrence of other arrhythmias (if observed); list arrhythmia</br>0</br>0</br>0	E. Movement Events</br></br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br>0	I.Number of periodic limb mo,·emcnts of sleep (PLMS)</br>0</br>0	2. Number of periodic limb movements of sleep (PLMS) with arousals</br>0	3.PLMS index (PLMSI; PLMS x 60 I TST)</br>0</br>4. PLMS arousal index (PLMSArl; PLMS with arousals x 60 I TST)</br>0</br>0</br>0</br>0</br>0</br>0</br>G</br>0</br>(</br>- 1-</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMENDED</br></br></br>RECOMMEND!D</br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	9</br>••• •  -• -• • •.,. ,.-·- ·- -.,. r • -,.._.._. , ... _ _ _ _    •  - .. -</br></br></br></br>Respiratory Events &quot;1</br></br>Number or obstructive apneas</br></br></br>Number or mixed apneas</br></br>Number of central apneas</br></br>Number of hypopneas</br></br>Number of obstructive hypopneas</br></br></br>Number of central hypopneas 7.Number of apneas + hypopneas</br>Apnea index (Al; (# obstructive apneas + # central apncas +# mixed apneas) x 60 I TST)</br></br>Hypopnea index (HI; # hypopneas x 60 I TST)</br></br>to. Apnea-hypopnea index (AHi; (# apncas + # hypopneas) x 60 I TST)</br></br>l t. Obstructive apnca-hypopnea index (OAHI; (# obstructive apneas + # mixed opncas +</br># obstructive hypopneas) x 60 I TST)</br></br>Central apnea-hypopnea index (CA HI; (# central apneas + # central hypopneas) x 60 I TST}</br></br>Number of respiratory effort-related arousals (RERAs)</br>Respiratory effort-related arousal index (R ERA index;# of RERAs x 60  TST)	</br>Respiratory d isturbance index (ROI; (# apneas + # hypopneas + # R ERAs) x 60  TST)</br></br>Number of oxygen desaturations ;::31/1e, or  4%:-;2</br></br>17.Oxygen desaturation index 2::3'Vo or :::4°/., (ODI; # oxygen desaturations   3% or   4° o x 60  TST)</br></br>18. Arterial oxygen  saturation, mean  value 19.Minimum oxygen saturation during sleep:-.-.i</br>Occu rrence of hypoventilation  during diognostic study :-.-4 Adults</br>Child ren</br></br>Occurrence of hypovcntilation during PAP titration &quot;4</br></br>Adults Children</br>Occurrence of Cheyne-Stokes breathing in adults&quot;</br>10  AASM Scoring Manual Version 2.5	8</br></br>(</br>[&quot;</br>(</br>RECOMMENDED</br>(</br>RECOMMENDED	c</br>RECOMMENDED</br></br>RECOMMENDED	c:</br>OPTIONAL	(</br>(</br>OPTIONAL	c</br>RECOMMENDED</br></br></br>RECOMMENDED</br>(</br>RECOMMENDED	c</br>RECOMMENDED</br>(</br>OPTIOHAL	c</br>c</br>OPTIONAL</br>OPTIONAL	c</br>OPTIONAL</br></br>OPTIONAL	c</br>OPTIONAL	c</br>c</br>OPTIONAL</br>RECOMMENDED	c</br>RICOMMENDED</br>(</br>c</br></br></br>(</br>RECOMMENDED	c</br>c</br>(</br>OPTIONAL</br>(</br>OPTIONAL	(_</br>RECOMMENDED	c</br>c c c</br>(</br>./</br></br></br></br></br>Duration of Cheyne-Stokes breathing (absolute or us a percentage of total sleep time) or the nu mber of Cheyne-Stokes breathing events.</br></br>RECOMMENDED</br></br></br>Occu rrence of period ic breathing in children	RECOMMENDED</br>Occu rrence of snoring	OPTIONAL	J</br></br></br></br></br></br></br></br></br>0</br>0</br>0</br>[</br>0</br>0</br>0</br>0	G. Summary Statements</br>0</br>0	1. Findings related to sleep diagnoses</br>I</br>0	- - --- ----------------l;,</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>RECOMMENDED</br></br>2. EEG abnormalities	RECOMMENDED</br></br></br>0	3.ECG abnormalities</br></br>RECOMMENDED</br></br></br></br>I</br>4. Behavioral observations</br></br></br>RECOMMENDED</br></br>0</br>0	5. Sleep hypnogram</br>c</br>c</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>G</br>(</br>(</br>---------- - -</br>I</br>_ _	L  OPTIONAL</br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	11</br>\</br>Ill.Technical and Digital Specifications</br></br></br>Digital Specifications for Routine PSG Recordings</br>t. Maximum Electrode Impedances :5 K n	RECOMMENDED</br></br>2. Minimum Digital Resolution :12 bits per sample  RECOMMENDED</br></br>J.Sampling Rates</br></br></br>Desirable</br></br>	</br>EEG	500 Hz</br></br>EOG'			500 Hz</br>(</br>(</br>c c c c c</br>Minimal -,	c</br>200 Hz	RECOMMENDED	c</br>(</br>200 Hz	RECOMMENDED	c</br></br>EMG '</br>500 Hz</br>200 Hz	RECOMMENDED	(</br></br>ECG	500 Hz</br></br>Airflow		100 Hz</br></br></br>Oximetry,Transcutaneous PCOi		25 Hz Nasal Pressure, End-Ttdal PC02, PAP Device Flow	--1	I00 Hz</br>   Esophageal   Pressure	_L I00 Hz</br>200 Hz	RECOMMENDED	c</br>(</br>25 Hz	RECOMMENDED	c</br>10 Hz	RECOMM   NC&gt;m	c</br>25 Hz	RECOMMENDED	c</br>25 Hz	RECOMMENDED	c</br></br></br>Body Position</br></br>I Hz</br>IHz	RECOMMENDED	c</br>c</br></br>Snoring Sounds'	500 Hz</br>200 Hz	RECOMMENDED	c</br></br></br>Rib Cage and Abdominal Movements'11</br></br>Routinely Recorded Filter Settings	 	</br></br>100 Hz</br>25 Hz	RECOMMENDED	c</br>c</br>(</br></br>Low-Frequency	High-Frequency</br>Filter	Filter</br>EEG :-;.:-.n	0.3 Hz	35 Hz	RECOMMENDED	c</br>c</br>EOG &quot;'u	0.3 Hz	35 Hz	RECOMMENDED</br>_ _i	.</br>IOO Hz	RECOMMENDED	c</br>ECG:\'I	0.3 Hz	70 Hz	RECOMMENO£D	c</br>Oronasal Thermal Flow, Thoracoabdominal  Belt Signals	0.1 Hz	I S Hz	RECOMMENDED</br>---1</br>Nasal Pressure	Direct current (DC)	100 Hz	RECOMMENDED</br>or ::;0.03 Hz</br>PAP Device Flow	DC	DC	RECOMMENDED	c</br>                                                                         (_</br>Snoring	10 Hz	100 Hz	RECOMMENDED	(</br>c</br>12	AASM Scoring Manual Version :?.5	All Contert	2018 Amer can Acad '
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    l'ly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 or S1     p II/ d c1re	(</br></br></br>,-</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Note
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 I.</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Note
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 2.</br></br>Note 3.</br></br>Note 4.</br></br>Note 5.</br></br>Note 6.</br>In the absence of clear preferences, use similar settings among leads to simplify technical implementation.</br>This applies to measured EEG and EOG electrode impedance. Electrode impedances should be rechecked during a recording when any pattern that might be artifact ual appears.</br>For EEG, 500 Hz sampling rate could improve resolution of spikes in the EEG and better maintain details of the waveform.</br>For more detailed EEG analysis, sampling rate and high-frequency filter settings may be increased. I n these circumstances, the sampling rate should be at least 3 times the highest frequency of interest.</br>For EOG, using the 500 Hz desirable EEG sampling rate also allows the reflection of the EEG in th is lead as an EEG backup and may better define some artifacts in these leads.</br>This applies to submental and leg EMG. Higher sampling rates better define waveforms; while the waveform itself is not an issue, a better-defi ned waveform can help avoid amplitude attenuation as the envelope of the rapidly oscillating signal is interpreted.</br></br>Note 7. For ECG, 500 Hz sampling rate can better define pacemaker spikes and ECG waveforms, however, pacemaker spikes can be seen at 200 Hz, and the evaluation of card iac ischemia by ECG waveform is not a common PSG issue. Higher frequencies may be required for complex waveform analysis and research appl ications.</br>Note 8. For oximetry, 25 Hz sampling is desirable to assist with artifact evaluation.</br>Note 9. For nasal pressure transducer technology (especially with settings which identify snoring occurring on top of the airflow waveform), this higher frequency may be of benefit for better definition of vibration and snoring.</br>Note 10. The body position channel is exempt from the digital resolution standard. However, the recommended sampling rate of I Hz remains i n effect.</br>Note 11. For snoring sound, 500 Hz sampling rate can better define amplitude variation by clearer waveforms with more accurate amplitude determination as the envelope of the rapid ly oscillating signal is interpreted, (as for EMG). If a preprocessing of snoring results i n a continuous sound loudness level or i n a sound intensity level, then a much lower sampling rate is acceptable. That sampling rate is not specified because it depends on the preprocessing of the sound i n order to produce loudness.</br>0	Note 12. For rib cage and abdominal movements using inductance plethysmography, cardiogenic oscillations can be</br>0	better seen and may result i n better artifact assessment at a higher sampling rate.</br>Note 13. To accommodate older equipment, filter settings in the range of 30-35 Hz may be used to comply with the recommendations of 35 Hz. This applies most specifically in the context of EEG and EOG h igh filter settings.</br>Note 14. For ECG, low-frequency settings and wide bandwidth mini mizes distortion i n a 12 lead ECG; however in</br>0	PSG recording with single-channel modified lead II used for identifying basic heart rates and dysrhythmias,</br>it may not be as necessary. Advanced cardiac assessment may be more optimal using a [ow-frequency filter</br>of 0.3 Hz for slower parts of the cardiac cycle. The channel is susceptible to artifacts at this setting due to patient movement, perspiration, muscle activity and electrode displacement. Artifact is less l ikely at these settings when standard ECG leads are used for cardiac monitoring.</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>(</br>(</br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	13</br>\</br></br>PSG Recording Featu res</br></br>t. A toggle switch permitting \'isual (on-screen), standard, negative 50 pV DC calibration</br>signal for all channels to demonstrate polarity, amplitude and time constant settings for each recorded  parameter</br></br>A separate 50/60 Hz filter control for each chan nel</br></br>The capability of selecting sampling rates for each channel</br></br>A method of measu ring actual ind ividual electrode impedance against a reference (the latter may be the sum of all other applied electrodes)</br></br>The capability of retaining and viewing the data in the exact manner in which it was recorded by the attending technologist (ie, retain and display all derivation changes, sensitivity adjustments, filter settings, temporal resolution)</br></br>The capability of retaining and viewing the data in the exact manner it appeared when it was scored by the scoring tech nologist (ie, retain and display all derivation changes, sensitivity adjustments, filter settings, temporal resolution)</br></br>A filter design for data collection which functionally simulates or replicates conventional (analog-style) frequency response curves rather than removing all activity and harmonics within the specified bandwidth</br></br>An electrode selector process with the Oexibility for choosing and/or changing electrode</br>(</br>(</br>(</br>RECOMMENDED	c</br>(</br>RECOMMENDED	c</br>(</br>RECOMMIND!O	(</br>RECOMMENDED	c</br>I RECOMMENDED	c</br>c</br>RECOMMENDED	c</br>c</br>RECOMMENDED	c</br>c c</br></br> 	input signal derivations without relying on a com mon reference electrode		c</br>c</br>Use Systems with the Following PSG Display and Display Manipulation Features	c</br>The display for scoring and review of sleep study data must meet or exceed the following</br>RECOMMENDED</br>criteria: 15 inch screen size, 1,600 pixels horizontal and 1,050 pixels vertical</br></br></br>Histogram with stage, respiratory events, leg movement events, 02 saturation, body position (cg, supine, prone, lateral) and arousals, with cursor positioning on histogram and ability to jump to the page</br></br>Ability to view a screen on a time scale ranging from the entire night to windows as small as 5 seconds</br></br>Recorded video data must be synch ronized with PSG data and have an accuracy of at least one video frame per second</br></br></br>Page automatic turning and automatic scrolling</br></br>Channel-off control key or toggle 7.Channel-invert control key or toggle 8.Change order of channel by click and drag</br>Display setup profiles (including colors) which may be activated at any time</br></br>Fast Fourier Transformation or spectral analysis on specifiable interval (omitting segments marked as data artifact)</br>· ···=l	c</br>AECOMMENDED	c</br>(_</br>RECOMMENDED	c</br>c</br>OPTIONAL	c</br>OPTIONAL	(</br></br>OPTIONAL	c</br>OPTIONAL	l</br>DPTIONAL	c</br>l</br>OPTIONAL	c.</br>c</br></br>14	AASM Scoring Manual Version 2.5	All Content CC&gt; 2018 Am r can Academy of Sleep Medicine	c</br></br></br>Perform the Following Digital Analyses of PSG</br></br></br>Ability to display whether sleep stage scoring was performed visually or computed by the system</br></br>2. Ability to turn off and on, as demanded, highlighting of EEG patterns used to make sleep stage decisions (for example sleep spindle, K complex, alpha actiYity)</br></br>,..	3.Ability to turn off and on, as demanded, highlighting of patterns identifying respiratory events (for example apneas, hypopneas, desaturations)</br></br>4. Ability to turn off and on, as demanded, highlighting of patterns identifying identifying the</br>D		movement  analysis (for example PLMs) 	</br></br>RECOMMENDED</br></br></br></br></br>OPTIOHAL</br></br></br></br></br>OPTIONAL</br></br></br></br></br>OPTIONAL</br></br></br></br></br>Perform the Following Calibrations to Docu ment Appropriate System Response -.i.:-.:1</br></br></br>D	1. Perform and document an impedance check of the EEG, EOG and EMG electrodes&quot;'</br>D</br>0	2. Record a m inimum of 30 seconds of EEG with patient awake lying quietly with eyes open :'li4</br>(</br>3. Record a min imum of 30 seconds of EEG with patient lying quietly with eyes closed &quot;4</br></br>(	4. Ask the patient to look up and down without moving head ( x5)</br>0</br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br>0	5. Ask the patient to look left and right without moving head ( x5)	RECOMMENDED</br></br>0	6. Ask the patient to blink ( x5)</br>0</br>0	7.Ask the patient to grit teeth and/or chew (5 seconds)'!!</br></br></br>8.Ask the patient to simulate a snore or hu m (5 seconds) '-h</br>0</br>0	9. Ask the patient to breathe normally and assure that airflow and effort channel signals 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arc
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DOSAGE</span>
</mark>
 
<mark class="entity" style="background: #f032e6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    synch ron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ROUTE</span>
</mark>
 ized</br>0</br>0	10. Ask the patient to perform a breath hold (JO seconds) &quot;1	 	</br>0	11. Ask the patient to breathe normally and upon instruction to take a breath in and</br>c	out-check polarity and mark the record IN and OUT accord ingly &quot;1     	</br>0	12. Ask the patient to breathe th rough the nose only (JO seconds) 7</br>0</br>13.Ask the patient to breathe through the mouth only (JO seconds)&quot;''</br>----------</br>(	14. Ask the patient to take a deep breath and exhale slowly</br>(prolonged expiration -JO seconds) &quot;1</br>0</br>(_	15.Ask the patient to flex the left foot/raise toes on left foot ( x5) &quot;11</br></br>Ask the patient to flex the right foot/raise toes on right foot ( xS) 1</br>C.</br>Ask the patient to flex/extend the fingers on the left hand, as appropriate, if upper extrem ity</br>EMG is recorded'1  9</br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>OPTIONAL</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br></br>OPTIONAL</br></br></br></br>RECOMMENDED</br></br></br></br>RECOMMENDED</br></br></br>OPTIONAL	_l</br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	15</br>Ask the patient to Hex/extend the fingers on the right hand, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ns
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 appropriate, if upper extremity EMG is recorded '&quot; &quot;</br>OPTIONAL	(</br>(</br></br>Adjust EKG signal to provide n clenr wnveform -the R wuve should deflect upward &quot;'0	OPTIONAL	(</br>Perform nnd document n repent impednnce check of the EEG, EOG nnd EMG electrodes nt</br></br>the end of the PSG recording'11</br></br>Repent physiological calibrntions nt the end of the PSG recording&quot; '</br>RECOMMEHDED</br></br>RECOMMENDED	c</br>c</br></br>Note I. Perform physiological calibrations for all patients to the extent that the patient is able to cooperate and	(</br>complete  the requested  maneuvers.	c</br>Note 2.  Document all calibrations. Verify that the signal appropriately responds to the requested patient maneuvers.</br>Repeat calibrations as needed to document a working signal for all recording parameters.</br>Note 3. Measured EEG, EOG and EMG channel impedances should be 5 K n or less and relat ively equal. Limb EMG impedances of 10 K n or less are acceptable, but impedances of 5 K il or less are preferred. Recheck</br>impedances during the recording when any pattern  that might be artifact appears.	c</br>Note 4.  Check EEG channels for blocking, 60 Hz, EKG, and sweat or respiratory artifact and make any necessary</br>adjustments to assure a readable EEG recordi ng.</br>Note 5.  Adjust chin EMG to an adequate sensitivity while patient is awake. In an awake relaxed patient the chin EMG signal should be visible (at least 1-2 mm amplitude). During chewi ng or teeth gritting maneuvers the</br>chin EMG signal should be at least double the size of the basel i ne signal.	c</br>Note 6.   Check the i ntegrity of the snore microphone or sensor by asking the patient to simulate a snore and hum.</br>Adjust as necessary to provide a clear signal with activity. Activity should be negligible with qu iet breathing.</br>Note 7.  Adjust all respiratory channels to provide a large clean signal with each respiration. Observe and document</br>the signal direction during inhalation and exhalation. Ai rflow and effort and signals shou ld be in phase with	C</br>respect to each other. Adjust belt position to attain a readable signal on all airflow and effort channels. Assure	( that airflow and effort signals respond appropriately to a 10 second breath hold.</br>Note 8. Adjust limb EMO signal to reflect a low background; check signal with bilateral limb movements to verify a noticeable deflection with movement.</br>Note 9.  If recording the flexor digitorum superficialis, the patient should flex the fingers at the base (avoid bending at the distal two joints). If recording the extensor digitorum communis, the patient should extend their fingers back without moving their wrist.</br>Note 10.Compare heart rate (HR) to EKG signal (heart rate is collected from pulse oximetry) to assure HR accuracy.	(</br>Note  11. Repeat the impedance check and physiological calibrations after lights on i n the morning.	(_</br></br></br></br></br></br>c</br></br>(</br>c</br>(_</br>(</br>(</br>,.</br>16   AASM Scoring Manual Version 2.5	AU Content © 2018 American Academy of Sleep Medicine	c</br>c</br>IV.Sleep Staging Rules Part 1: Rules for Adults</br></br></br></br></br>A. Technical Specifications for Electroencephalogram (EEG)</br></br></br></br></br></br>D</br>.,.....</br>D</br>0</br>0</br>0</br>The recommended EEG dcrh·ations arc:&quot;l- 1 Recor.1tt,11ENDED</br>F4-MI</br>C4-M I</br>02 M I</br>Backup electrodes should be placed at FJ, CJ, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    0I
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DOSAGE</span>
</mark>
 and M2 to allow display of FJ-M2, CJ-M2 and 01-M2 if electrodes malfunction during the study.(see Figure I A)</br>Accepta ble EEG derivations arc: ''·'?·&quot; ACCEPTABLE</br>Fz-Cz</br>Cz-Oz</br>C4-M I</br>Backup electrodes should be placed at Fpz, CJ, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    0I
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DOSAGE</span>
</mark>
 , and M2 to allow substitution of Fpz for Fz, CJ for Cz or C4, 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    0I
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DOSAGE</span>
</mark>
 for Oz and M2 for M1 if electrodes malfunction during the study.(see Figure I B)</br>EEG electrode position is determined by the International 10-20 S)'Sfem. (see Figure  I)   RECOMMENDED</br></br>A.  RECOMMENDED</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>c</br>0</br>0</br>0</br>Inion</br>0</br>Cl2018 American Academy of Sleep Medicine.All rights 111•erved.</br>M:CEPTABLE</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>Figure  1.Images illustrating the placement of electrodes utilized in the recommended (A) and acceptable (B) derivations</br>for electroencephalography (EEG) during polysomnography.</br>The e ectrode placement and nomenclature follow the International 10-20 System. !Pustralion may not be to scale.</br></br>0	 	</br>0	Note I. At a minimum.frontal, central, and occipital derivations (J EEG channels) are required to stage sleep.</br>0	Note 2.   Ml  and M2 refer to the left and right mastoid processes. M l  is the standard reference electrode for recording</br>0	EEG. If Ml fails during the recordi ng, backup electrodes should be used and referenced to M2.</br>0	Note J. Fz-Cz is not appropriate for measuri ng the amplitude of frontal activity for determination of slow wave activity. When using the acceptable EEG derivations and the accepta ble EOG derivations (Figure 2), the</br>0	El-Fpz derivation should be used to measure frontal slow wave amplit ude. Used i n this way, Fpz will be the</br>0	active electrode recording frontal activity and El the reference electrode in a referential derivation. When using the acceptable EEG derivations and the recommended EOG derivations, EEG amplitude to determine</br>0	slow wave activity shou ld be measured  using the C4-M I  derivation (CJ-M2 if either C4 or M I  electrodes</br>0	malfunction). When using the recommended EEG derivations and recommended EOG derivations, the EEG amplitude is measured usi ng the derivation F4-M I.</br>(</br>(	All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	17</br>(</br>Tech nical Specifications for Electrooculogram (EOG)	(</br>The recommended EOG derivations and electrode positions arc:'1 (see Figure 2A) RECOMMENDED	(</br>Derivations: El-M2 and E2-M2</br>Electrode positions: El is placed  I cm below and I cm lateral to the left outer canthus and E2 is placed  I cm above and</br>I cm lateral to the right outer canthus	(</br>Acceptable EOG dcrh·ations and electrode positions arc: !(see Figure 28) ACCEPTABLE	l</br>Derivations: El-Fpz and E2-Fpz	(</br>Electrode positions: El  is placed  I  cm below and I cm lateral to the outer canthus of the left eye and E2 is placed  I cm</br>below and I cm lateral to the outer canthus of the right eye	(</br>(</br>(</br>c</br>c</br>(</br>(</br>c c c c c c c c</br>(</br>c c c c c</br>Note I. When usi ng the recommended EOG derivations, if the M2 reference electrode fails, El and E2 shou ld be	c</br>referenced to M I.	c</br>Note 2.  When usi ng the recommended electrode derivations, conjugate eye movements result in out-of-phase	c</br>deflections. The acceptable derivations allow determ ination of the direction of eye movements (ie, vertical</br>movements will show in-phase deflections and horizontal eye movements, out-of-phase deflections).</br>c c c c c c c</br>(</br>c</br>18	AASM Scoring Manual Version 2.5	All Content	2018 American Academy of Sleep Medicine	c c</br></br></br>Technical Specifications for Electromyogram (EMG)</br>Th ree electrodes should be placed to record chin EMG:  RECOMMENDED</br>One i n the midline  I  cm above the inferior edge of the mandible (see ChinZ in Figure 3)</br>One 2 cm below the in ferior edge of the mandible and 2 cm to the right of the mid line (sec Ch in2 in Figure 3)</br>One 2 cm below the inferior edge of the mand ible and 2 cm to the left of the midlinc (see Chin 1 in Figure 3)</br></br>2. The standard chin EMG derh•ation consists of either of the electrodes below the mandible referred to the electrode</br>:'hove the mandible. The other inferior electrode is a bnck up electrode to allow for continued display of EMG acth•ity if one of the primary electrodes 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malfu
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 
<mark class="entity" style="background: #f032e6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nctions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ROUTE</span>
</mark>
. I RECOMMENDED</br></br></br>r</br></br>D D D D D 0</br>0</br>0</br>0</br>0</br>0</br>0</br>0 D. General Scoring of Sleep Stages</br>0   I. The following term inology shou ld be used for the stages of sleep in adults:  RECOMMENDED</br>c         a. Stage W (Wakefulness)</br>Stage N I (NR EM I)</br>Stage N 2 ( N R EM 2)</br>0	d. Stage N3 ( N R EM 3)</br>e. Stage R (R EM)&quot;</br>0</br>Score epochs using the following para meters:  RECOMMENDED</br>Score sleep stages in 30-secood.sequential epochs commencing at the start of the study.</br>0	b. Assign a stage to each epoch.</br>I f two or more stages coexist during a single epoch, assign the stage comprising the greatest portion of the epoch.</br>When three or more segments of an epoch meet criteria for different stages (stage W, N I, N2, N3, R):</br>0	i. Score the epoch as sleep if the majority of the epoch meets criteria for stage N 1, N2, N3, or R.</br>0	ii. Assign the sleep stage that occurs for the majority orsleep within the epoch. (see Figure 4)</br>0   3.Score in accordance with the following definitions for EEG frequencies:  RECOMMENDED</br>0	a. Slow wave activity: frequency of0.5-2.0 l-lz and peak-to-peak  amplitude or &gt;75 µV, measured over the frontal regions</br>b. Delta waves are 0-3.99 l-lz</br>0	c. Theta waves are 4-7.99 Hz d. Alpha waves are 8-13 Hz</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    e. Beta waves
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 are greater than 13 Hz</br>(</br></br></br>All Content ' • 2018 Amencan Academy of Steep Medicine	AASM Scoring  Manual Version 2.5	19</br>I</br>c</br>c</br>(</br>(</br>c</br>(</br>(</br>                                                                                                                                                       (</br>(</br>(</br>(</br>c</br>(</br>c</br>(</br> 		c</br>E. Scoring Stage W&quot;•.sz.:-.:.l..... .s!'	c</br>(</br>J. Score in accordance with the following de6nitions: RECOMMENDED	(</br>Alpha rhythm (posterior dominant rhythm  in adu lts 1md older children): An EEG pattern consisting of trains of sinusoidal 8-13 Hz activity recorded over the occipital region with eye closure and attenuating with eye openi ng.</br>Eye bli nks: Conjugate vertical eye movements at a frequency of 0.5 2 Hz present in wakefulness with the eyes open or</br>closed.	c</br>Reading eye movements: Trains of conjugate eye movements consisting of a slow phase followed by a rapid phase in the</br>opposite direction as the ind ividual reads.</br>Rapid eye movements (REMs): Eye movements recorded in the EOG derivations consisting of conjugate, irregular, sharply peaked eye movements with an initial deflection usually lasting &lt;500 msec. While rapid eye movements are characteristic of stage R sleep, they may also be seen in wakefu lness with eyes open when individuals visually scan the environment. (see Figure 5)</br>Slow eye movements (SEM): Conjugate, reasonably regular, sinusoidal eye movements with an initial deflection that usually lasts &gt;500 msec. Slow eye movements may be seen during eyes closed wake and stage NI.</br>Score epochs as stage W when more than 50% of the epoch contains EITHER 2a or 2b or BOTH:	c.</br>(see Figure 6)  RECOMMENDED	c</br>Alpha rhyth m ( posterior dominant rhythm) over the occipital region (individuals generati ng alpha rhythm with eye</br>closure)</br>Other findings consistent with stage W (all individuals)</br>Eye blinks (0.5 to 2 Hz)</br>Rapid eye movements associated with normal or high chin muscle tone i i i. Readi ng eye movements</br>c c c c c c</br>c</br>20   AASM Scoring Manual Version 2.5	All Content e.C&gt; 2018 American Academy of Sleep Medicine	c c</br></br>	</br>0</br>D</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>(_</br>c</br>0</br>0	All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	21</br>J</br> 		(</br>coring Stage Nl	(</br>Score in accordance with the following definitions: RECOMMENDED	(</br>Slow eye mowments (SEM): Conjugate, reasonably regular, sinusoidal eye movements with an initial deflection that		( usually lasts &gt;500 msec. Slow eye movements may be seen during eyes closed wake and stage N I.	c Low-amplitude, mixed-frequency (LA MF) EEG ucth·ity: Low-amplitude, predominantly 4-7 Hz activity.		(</br>Vertex sharp waves (\' wm·es): Sharply contoured waves with du ration &lt;0.5 seconds (as measured at the base of the</br>wave). maximal over the central region and distinguishable from the background act ivity. They are most often seen	(</br>during transition to stage NI  sleep but can occur i n either stage NI  or N2 sleep. These waveforms typically fi rst appear	(</br>at 4-6 months post-term.	c</br>Sleep onset: The start of the fi rst epoch scored as any stage other than stage W. (In most individuals this will usually be the</br>first epoch of stage N I.)	\</br>(</br>I n indi\'iduuls who generate alpha rhyth m, score stage NI  if the alpha rhyth m is attenuated und replaced by low­</br>amplitude, mixed-frequency actil'ity for more than SO'!!,, of the epoch. &quot;']··' RECOMMENDED	(</br>In indi\'iduals who do not generate alpha rhythm, score stuge NI commencing with the earliest of ANY of the following	c</br>phenomena: ......:'l.'.l.''4· !'  RECOMMENDED	(</br>EEG activity in range of 4-7 Hz with slowing of background  frequencies by :!;I  Hz from those of stage W</br>Vertex sharp waves	(</br>Slow eye movements	c</br>A n epoch is scored as stage NI  if the majt1rity of the epoch meets the criteria for stuge NI  (EEG showing LAMF EEG	(</br>activity) in the ubsencc of e\'idence for unothcr sleep stage. Subsequent epochs with un EEG showing LA M F EEG uctivity arc scored as stuge NI u ntil there is e\'idence for another sleep stage (usuully stage W, stage N2 or stage R). (sec Figure 7) RECOMMENDED</br>c</br>(</br></br>A.	Epoch 	</br>I ---·1 •wn 1		I	I</br>B.	Epoch		c</br>, er.. , er.. 1	1	1	c</br></br>50	51	52	53	54</br></br>doMd</br>.,</br>60	61</br></br>open     cloud</br>62	63	64</br></br>l	'</br>(</br></br>F4-M1 I	I</br>F4-M1 I	I	I</br>'iv--1</br></br>C4-M1</br>I	I	I</br>I	,,</br>I	I	I</br>C4-M1 I	--1 .1.........1-..',y---::	(</br></br>I	I	I</br>I	I	I	I	I</br></br>02 M1I</br>lnoa1p11al·</br>SE·M</br>'I·•'</br>02·M1 1	Ina olpha I SEM	I	I	l</br></br>I</br>11	1	1	(</br></br>E1·M2</br>I	I	t	I</br>E1-M2 I	I	I	I</br></br>I</br>I	I	I	I	I	I</br>I   REM    I	I	I	I	I</br>E2 M2 ; v ;	;	\{ . ;&quot;	;</br>I	I</br>Chin EMG -----------</br>I   REM   I	I	I	I</br></br>E2·M2 I</br>I	I	I	I	I	I	(</br>I</br>Chin EMG ------------	(</br></br>w	W	W	N1</br>Stage</br>N2	w	W	N1	N1	N2	(_</br>Stage	(</br></br>Figure 7.Transition from stage W to stage N1 in a patient who does not generate alpha rhythm</br>{posterior dominant rhythm) with eye closure. It is assumed the EEG in epochs 52 and 62 do not meet criteria F.3.a. {that is, stage N1cannot be scored based on the EEG criteria).</br>Epoch 52 continues to be scored as stage W since the slow eye movement occurs in the</br>latter part of the epoch.Stage N1is considered to start with the occurrence of the slow eye	(</br>movement. Therefore, epoch 53 Is scored as stage N1.</br>Epoch 62 is scored as stage N1 since the slow eye movement occurs inthe first half of this	(</br>epoch. Epoch 63 continues as stage N1until there is evidence of stage N2 with the appearance</br>of a K complex in the first half of epoch 64.	(_</br>O2018 American Academy of Sleep Medicine.All rights rHerved.	(</br>c</br>(</br>(</br></br>22	A ASM Scoring Manual Version 2.5</br>A I ContE'nt e 201!! Arneucan Academy of Sleep Md c r1!!	(</br>(.</br>When an arousal interrupts stuge N2 sleep, score subsequent segments of the recording as stage NI if the EEG exh ibits low-amplitude, m ixed-frequency activity without one or more K complexes and/or sleep spindles until there is evidence for another stugc of sleep (sec G. Scoring Stage N2).   Rl!COMMINDEO</br></br>When an arousal interrupts stage R sleep and is followed by a low-amplitude, mixed-frequency EEG without posterior dominant rhythm AND with slow eye MO\'emcnts, score the segments of the record containing the eye mo\·cments as stage NI e\•cn if the chin EMG activity remains low (at the stuge R lc\•el). Continue to score stage NI u ntil there is evidence for another stage of sleep, usually stage N2 (sec G.2) or stage R (sec 1.2 and 1.3). RECOMMENDED</br></br></br></br></br></br></br>,...</br></br>0</br>0</br>0</br>0</br>0</br>0</br>0	G. Scoring Stage N2</br>0	I. Score in accordance with the followi ng definitions:   RECOMMENDED</br>K complex: A well-delineated, negative, sharp wave im mediately followed by a positive component standing out from</br>the background EEG, with total duration &gt;0.5 seconds, usually maximal i n amplitude when recorded usi ng frontal</br>0	derivations. For an arousal to be associated with a K complex, the arousal must either be concurrent with the K complex</br>0	or commence no more than I second after termi nation of the K complex. (see V. Arousal Rule)</br>Sleep spindle: A train of distinct sinusoidal waves with frequency 11-16 Hz (most commonly 12-14 Hz) with a duration</br>0.5 seconds, usually maximal  in amplitude i n the central derivations.</br>0</br>Begin scoring stage N2 (in ubscnce of criteria for NJ) if EITHER OR BOTH of the following occur during the first hulf</br>0	of thut epoch or the last hulf of the previous epoch: &quot;·!.'1 RECOMMENDED</br>0	a. One or more K complexes unassociated with arousals</br>b. One or more sleep spindles</br>0</br>Score a 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ginn
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 epoch ns stnge N2 if the majority of the epoch meets criteriu for stage N2.If the wn\•eforms in rule</br>0	G.2.a or G.2.b arc followed by un arousal in the snme or subsequent epoch (see Figure 8), the segment of the recording</br>0	precedi ng the arousal is considered stage Nl (sec rule G.6.b).''·'   RECOMMENDED</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>(</br>0</br>AU Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	23</br></br></br>Epoch</br></br></br>Epoch</br>c</br>c.	Epoch	(</br></br>    50	51	52	53	60	61	62	63	70	71	72	73	c</br></br></br>F4-M1 I1 l	;  -.:.· A   ;	;</br>F4-M1 1..-..A v!--J_r...!-.</br>-j_l	I·</br>F4  M1 :;.:r:</br>K    IT'(&gt;te•    :	c</br></br>I K corn•	I	K cpiea   I</br>Vt--i</br>C4-M1.</br>I	I	I	I	I</br>I I	I	_1	A  I	I</br></br>C4-M1</br>IK compl:•	a':K cr&quot;ptea I</br></br></br>·	1	1	1	1</br></br>'-&quot;	_. 	,</br></br>C4-M1</br>1</br></br>I	I</br>·	1	1	1	1</br>I	I	I	I	I	(</br></br>02-M1 rv--r----r-</br>I	I	I	I	I</br></br>yr--
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    i
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
</br>02-M1 ;	r;--V:--'</br>I	I	I	I	I</br></br>I</br>02-M1</br>I	I	I	I	I</br>.-rvi-----i-vr--.</br>(&quot;'</br>c</br></br>E1-M2 I A	I	-·	A I	I</br>E1-M2 1j'Y1 -----.--VT - AVJ...	I</br>E1-M2' I  A I-	I	A L	I</br></br>E2-M2</br>I	l	l</br>E2-M2  J	Ar.-A .  -'</br>1	1	1	1</br>E2-M2	t</br></br></br>I	I	I	l	I</br>I</br>Chin EMG</br></br>I	I	I	I	I I</br>Chin EMG1</br></br>I	I	I	I	I I</br>Chin EMG 1</br></br></br></br>N2	N2	N1	N2</br>Stage</br>N2	N2	N1	N2</br>Stage</br>N2	N1	N1	N2</br>(</br>Stage	c</br></br>Figure 8. Start and continuation of stage N2. The EEG is assumed to show LAMF unless otherwise depicted.</br>Start of N2. Epoch 50 is scored as stage N2 as there is a K complex (unassociated with an arousal) in the first half of the epoch	(</br>(rule G.2). Epoch 51 is stage N2 as this stage continues for the majority of the epoch (rule G.3). Following an arousal,epoch 52 is</br>scored as stage N1 (rule G.6.b) until there Is evidence for another stage of sleep.A K complex is noted in the last half of epoch 52	(</br>and epoch 53 is scored as stage N2 (rule G.2).</br>B. At the end of epoch 61,there is a K complex associated with an arousal.Epoch 62 is scored as stage N1 (rule G.6.b). A K complex associated with an arousal is not considered evidence for stage N2.Epoch 63 is scored as stage N2 by rule G.2.</br>C.A K complex occurs in the last half of epoch 70 but stage N2 is considered to be present only up to the arousal nepoch 71. Epoch 71 is scored as stage N1 as the majority of the epoch follows the arousal. Epoch 72 is scored as stage N1 as the K complex does not occur until the second half of the epoch.</br>C 2018 Americ:•n Ac•demv of SIHp Medicine. Alt righbreserved.</br>Continue to score epochs with low-amplitude, mixed-frequency  EEG activity without K complexes or sleep spindles	c</br>as stage N2 if they arc preceded by epochs containing EITH ER of the following and there is no inten·cning</br>arousal:  RECOMMENDED</br>K complexes unassociated with arousals</br>Sleep spindles	c</br>Epochs following an epoch of stage N3 that do not meet criteria for stage NJ arc scored ns stage N2 if there is no	(</br>intervening arousal and the epoch docs not meet criteria for stage W or stage R.(see Figure 9)  RECOMMENDED	c</br>c</br>c</br></br></br></br>F4-M1 C4-M1 02-M1 E1-M2 E2-M2</br>Chin EMG</br>10011v l	c</br>1 sec	c</br>c c c c c c c</br></br>Figure 9.Transition from stage N3 to stage N2.The vertical distance between the lines in F4-M1 is 75 µV.Epoch 201 does not have	c</br>sufficient slow wave activity to meet criteria for stage N3. There is no intervening arousal.Epoch 201 is scored as stage N2.</br>C2018 American Academy of Sleep Medlc:lne. All right. reHrved.</br>c</br>(.</br>c</br>24	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	(</br>(</br>6. End scoring stage N2 sleep when ON E of the following events occurs:  5·''   RECOMMENDED</br>'.::J	a. Transition to stage W</br>An arousal followed by low-amplit ude, mixed-frequency EEG (change to stage N I until a K complex unassociated with an arousal or a sleep spind le occurs) (see Figure 8). This assumes that the epoch does not meet criteria for stage R (ru le 1.3) (see 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Figu
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 re 12C).</br>A major body movement followed by slow eye movements and low-am pl 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    itude
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, m ixed-frequency  EEG without non-arousal associated K complexes or sleep spindles (score the epoch  following the major body movement  as stage N l; score the epoch as stage N2 if there arc no slow eye movements; the epoch contai ning the body movement  is scored using the major</br>,.-	body movement rules under section J) (see Figure  10)</br>Transition to stage N3</br>Transition to stage R</br></br>	</br></br></br></br></br></br></br></br></br>-</br>1</br>I	I</br>Chin EMG ::--..;.....i		Chin EMG--....</br></br></br>N2	N2	N2	N2</br>Stage</br>N2	N1	N1	N2</br>Stage</br></br></br></br></br></br></br></br>c</br>Note I.</br>c	Note 2.</br>(</br>c	Note 3.</br>Note 4.</br>c	Note 5.</br>c	Note 6.</br>(</br>(</br>Figure 10.End of stage N2 due to a major body movement. The EEG is assumed to contain low-amplitude, mixed-frequency activity unless otherwise depicted.</br>Epoch 52 continues to be scored as stage N2 as the major body movement is NOT followed by slow eye movements. Epoch 51 is scored according to the major body movement rules (section J). As epoch 51 does not contain alpha activity</br>and an epoch of stage W does not precede or follow the epoch, the major body movement is scored the same as the epoch that follows it (stage N2; rule J.4).</br>Epoch 62 is scored as stage N1 (stage N2 ends following the major body movement) as the body movement is followed by slow eye movements and low­ amplitude, mixed-frequency EEG (rule G.6.c). Epoch 63 is scored as stage N2 as a K complex unassociated with an arousal occurs In the first half of the epoch.</br>C 2018 American Academy of Sleep Medicine. AH rights 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    reaorved
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br></br></br></br>An epoch of stage N2 meeti ng criteria in rule G.2 is termed definite stage N2. If there is a conflict between a stage N2 and stage R scoring rule, the stage R rule takes precedence (see 1.4).</br>Continue to score stage NI for epochs with arousal-associated K complexes unless they contai n sleep spindles or K complexes not associated with arousals.</br>For the purposes of scoring N2 sleep, arousals are defined according to the arousal rule in chapter V. (V.A.1). For scoring epochs with a m ixture of K complexes and/or sleep spind les and REMs, see rule 1.7.</br>The EOG usually shows no eye movement activity during stage N2 sleep, but slow eye movements may persist i n some individuals.</br>In stage N2, the chin EMG is of variable amplit ude, but is usually lower than in stage W, and may be as low as i n stage R sleep.</br></br></br></br>(</br>(</br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	25</br> 		(</br>H. Scoring Stage N3 &quot;	(</br>t. Score in uccordunce with the following definition: &quot;1 1  RECOMMENDED	c</br>Slow WU\'e ucth·ity: Waves of frequency 0.5 Hz-2 Hz and peak-to-peak ampl itude &gt;75 µV, measured over the frontal	(</br>regions referenced to the contralateral ear or mastoid ( F4-M I , F3-M2).	(</br>2. Score stage N3 when   20% of un epoch consists of slow WU\'e ucti\'ity, irrespective of uge. &quot;&quot;· 5·1   RECOMMENDED	(</br></br></br>(</br>Note I. Stage NJ represents slow wave sleep and replaces the Rechtschatten and Kales nomenclature of stage J and</br>stage 4 sleep.	(</br>Note 2.  K complexes would be considered slow waves if they meet the defi nition of slow wave activity.	c</br>Note 3.   Pathological  wave forms that meet the slow wave activity criteria, such as those generated by metabolic	c</br>encephalopathies, epileptic, or epileptiform activity, are not counted as slow wave activity of sleep. Similarly,</br>waveforms produced by artifact or those of non-cerebral origin should not be included in the scoring of slow</br>waves.	(</br>Note 4. Sleep spindles may persist in stage NJ sleep.	(</br>Note 5.  Eye movements are not typically seen during stage N3 sleep.	c</br>Note 6.   I n stage N3, the chin EMG is of variable amplitude, often lower than in stage N2 sleep and sometimes as low	(</br>as in stage R sleep.	c</br>c</br>(</br>Scoring Stage R	(</br>Score in accordance with the following definitions:  RECOMMENDED	(</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rupid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 eye movements (R EMs): Eye movements recorded in the EOG derivations consisting of conjugate, irregular, sharply peaked eye movements with an initial deflection usually lasting &lt;500 msec. W hile rapid eye movements are characteristic of stage R sleep, they may also be seen in wakefulness with eyes open when individuals visually scan the</br>environment.	c</br>Low chin EMG tone: Baseline EMG activity in the chin derivation no higher than in any other sleep stage and usually at</br>the lowest level of the entire recording.</br>Sawtooth waves: An EEG pattern consisti ng of trains of sharply contoured or triangu lar, often serrated, 2-6 Hz</br>waves maximal in amplitude over the central head regions and often, but not always, preceding a burst of rapid eye	(</br>movements.	c</br>Transient muscle activity: Short irregular bursts of EMG activity usually with duration &lt;0.25 seconds superimposed</br>on low EMG tone. The activity may be seen in the chin or anterior tibial EMG derivations, as well as in EEG or EOG deviations, the latter indicati ng activity of cranial nerve in nervated muscles (facial and scalp muscles). The activity is</br>often maximal when associated with rapid eye movements.	c</br>Score stuge R sleep in epochs with A LL of the following phenomena (definite stuge R):&quot;&quot;1·&quot;&quot;2· 3·&quot;&quot;4·  
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    .-;6
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
    RECOMMENDED</br>Low-amplitude, mixed-frequency (LAM F) EEG activity without K complexes or sleep spind les</br>Low chin EMG tone for the majority of the epoch and concurrent with REMs</br>REMs at any position within the epoch	c</br>Score segments of sleep preceding und contiguous with un epoch of definite stuge R (us defined in 1.2), in the	[</br>ub\.·em:e rif rapid f!J'f! 11uweme11t'.&gt;, us stuge R if ALL of the following ure present: (see Figures 11, 12 and IJ)   RECOMMENDED</br>The EEG shows low-ampl itude, mixed-frequency activity without K complexes or sleep spindles-;</br>The chin EMG tone is low (at the stage R level)	c</br>There is no intervening arousal (sec Figure 12C)</br>Slow eye movements following an arousal or stage W are absent :o;s</br></br>(</br>r</br>c</br>26    AASM Scoring Manual Version 2.5	All Contenl (Cl 2018 American Academy of Sleep Medicine	c c</br></br></br></br>I  LAMF I LAMF I	l LAMF  I LAMF  I</br>I	I LAMF I LAMF I</br></br>F4-M1 ....	....	...	..... 	......</br>F4·M1	-------'---'</br>F4·M1 :	I	I</br>I	I</br></br>,..</br>C4-M1	...	.	,</br>I               	</br>C4·M1 ......    ...   .....__   .._  ..	C4·M1	 	</br>__.</br></br></br>I	I	I</br>.....</br>.....</br>....</br>......_</br></br></br>02·M1</br>..,1·---i 	</br>1 alpha</br>02·M1 .-...</br>1</br>----....--..</br>I   alpha   I</br>02·M1	I</br></br>l	.-....,.</br></br></br>r...</br>D</br>E1-M2</br>E2-M2 l-1'\,t-t-.,...rt--; r+	i</br>I	I  - I	V   l	I</br>I	I</br>E</br></br>E2-M2	r--
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    t
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
</br>I	I	-  I	I V	I</br>I</br></br></br></br>E2·M2	&quot;</br>I	1-	l	I	I</br>I	I</br></br>Chin EMG 1	- ---.---,</br>Chin EMG .---....,.-.</br>-.---</br>Chin EMG</br>:111---11--.-----:----.</br></br>w	W	A</br>0	Stage</br>D	Figure 11.Start or stage R.</br>A	w	N1	R</br>Stage</br>R	w	A	A	A</br>Stage</br></br>Epoch 52 is an epoch of definite stage R. Epoch 53 is scored as stage R by rule 1.5 (REM continuation rule).</br>Epoch 61 is scored as stage N1as alpha is replaced by !ow-amplitude, mixed-frequency (LAMF) EEG activity. A SEMis present in the second half of the epoch. While not required for scoring stage N1, the presence of the SEM prevents the epoch from being scored as stage R (rule 1.3.d). Epoch 62 is scored as stage R by rule 1.3.</br>Epoch 71 is scored as stage R as the majority of the epoch meets the criteria of rule 1.3.</br>02018AmericanAcademy or Sloop Medicine. All rlghl•roHrvod.</br>0</br></br>0	A.</br></br>Epoch</br>B.	Epoch</br>c.	Epoch</br></br>0	50	51	52	53	60	61</br>62	63	64	70	71	72	73</br></br>IK comp1 ._....LLAMF L-_ I</br>F4-M1 ; A	LAMF -;--,</br>0	t'y---f</br>Ittcompa  K	t.11:   I	I	I</br>-LAMF -</br>F4-M1 1'	.     I	I	I	I	I</br>1	1	I	I	I</br>lK com•.,.	.l LAMF_!.	..  I F4-M1 I	...	I	I	I I	I	I	I	I</br></br>A	A	C4-M1</br>11n1u10I	I                I	I</br>_	_</br></br>•..</br>......</br>....._	_,</br></br>C4-M1</br>I	I</br>C4-M1 '.&quot;'</br>l  .	I</br></br>I A	\\</br>02-M11V1</br></br></br>l	1 REM      1</br>02-M1	:</br>I	I	I	I	lREM    I</br>02-M1	&quot;&quot;---&quot;&quot;..	-,	..,___,</br>l	I	I</br></br>I	l	l	I</br>El M I	I	l	I  .	I</br>E1-M2iA 'v</br>I -A-</br>I -rI-'I &quot;	I</br>E1-M2 :-{	i'	·fu</br></br>c	E2-M2 IAv-l  -:I</br>E2-M2 :;A-</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    A'V
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
'&quot;:'</br>1</br>....  .......,r.</br>l</br>E2·M2	,----I•  -- .</br>,,r</br>V I</br></br>I</br>---.------.</br>I</br>Chin EMG ,---...,....-....,--......,.-- -</br>I</br>I	I</br>Chin EMG 1 --,-- -..--..,..-..,_..,..._,</br></br>0	Chin EMG ..------</br>(	N2	R	R</br>0	Stage</br>0	Figure 12. Start of stage R.</br></br></br>R	N2	N2	R	R</br>Stage</br></br></br>A	N2</br></br>A	R	R</br>Stage</br></br>Transition from definite stage N2 (epoch 50) to definite stage A (epoch 53). The EEG of the majority of epoch 51and all of epoch</br>0		52 has low-amplitude, mixed-frequency (LAMF) EEG without sleep spindles or K complexes and chin EMG is at the stage R level. As the epochs 51 and 52 are contiguous with definite stage R (Epoch 53), they are scored as stage A.</br>0	B. Epoch 60 is an epoch of definite stage N2. Epoch 61 is scored as stage N2 by the stage N2 continuation rule. Epochs 62 and 63</br>are scored as stage R as the EEG has LAMF activity without K complexes or sleep spindles, the chin EMG is at the stage R level,</br>0	and the epochs are contiguous with an epoch of definite stage R (epoch 64). Note that, using rule G.2, epoch 62 would be scored</br>as stage N2. However, the stage R rule (1.3) takes precedence.</br>C. Using rule G.6.b, epoch 71 would be scored as stage N1 {arousal ends stage N2). However, REM rule 1.3 takes precedence and</br>0	epochs 72 and 73 are scored as stage R.</br></br>0</br>0</br>0</br>c</br>(</br>-·\</br></br></br></br></br></br></br></br></br></br></br></br>All Content	2018 American Academy or Sleep Medicine</br>C 2018 American Academy of Sleep Medicine. All rlghls roaorvod.</br></br></br></br></br></br></br></br></br></br></br></br></br></br>AASM Scoring Manual Version 2.5	27</br>.... --·- ..,.. ·-._,.,....., .·- ... - -</br>(</br>(</br>c c</br>(</br>(</br>(</br>c c c c</br>(</br>c</br>c</br>(</br>c c c</br>(</br></br>If the majority of un epoch contains a segment of the recording meeting criteria for stuge R (1.2, 1.3, 1.5), the epoch is scored us stage R. Stage R ru les tuke precedence over stage NZ rules. (see Figure 12, epoch 62 and</br>Figure 13, epoch 72) RECOMMENDED	(</br>Continue to score segments of sleep thut follow one or more epochs of definite stuge R (us defined in 1.2), in the	c</br>absence of rapid eye mo,·ements, us stugc R if ALL of the following urc present: (see Figures 14-18) RECOMMENDED	(</br>The EEG shows LA M F EEG activity without K complexes or sleep spindles</br>The chin EMG tone is low (at the stage R level) for the majority of the epoch	c</br>There is no intervening arousal	c</br>c c c</br>(</br>c</br>(</br>(</br>(</br>c</br>c</br>l</br>(</br>(</br>l</br>(</br>28  AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	(</br>c</br></br>	</br></br>D</br></br>D</br></br></br></br></br>D</br>[</br>D D G</br>c</br>0</br>0</br>c</br>[</br>D D 0</br>0</br>D</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>(</br>0</br>0</br>(</br>(</br>(</br></br>All Content © 2018 American Academy of Sleep Medicine</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>AASM Scoring Manual Version 2.5	29</br>(</br>(</br>(</br>(</br>(</br>l</br>c</br>(</br>c c c c</br>(</br>(</br>(</br>c c c c c c c c c c c c c c c c c c c c c c c</br>(</br>c c</br>30 AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>c</br>0</br>r	A.</br></br>Epoch</br></br>Epoch</br></br>c.	Epoch</br></br>Epoch</br></br>(	50	51	52	53 	</br>    60 	61 	62 	63     	     70 	71 	72 	73 	</br>    80 	81 	82 	83 	</br></br>0	F4-M1 :--'\!-------'---'</br>:
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Kcom;•
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 \ :</br>comp•	.:-------·</br>.	A;	A ;</br></br>K comp..1</br></br></br>0	I	I</br>C4-M1</br>I	I	I	I</br>I	I	I	I	I</br>:..\	\.....:.._	._	,</br>I	I</br>I	I	A I</br>rt	I	I	I</br>I	I	I	I	I</br>IA	I	A I</br>K compl•   K cop..a</br>;1	1;	;1</br>v---'</br>A :	:	:</br>;----r</br></br>0	02·M1 1:::-'V	I	I	I</br>0	E1-M2</br>E2·M2 !...  _.\J...--..L..--'- ,.......J</br>I V	VI	I	I	I</br>---S•R...:y..r-</br>---r	i</br>rv	i</br>·v..,.--.I.---.I</br></br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IR£M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 +H2- I	I	I</br>I A  A I	A I	1REM	I</br>,--y--vr--
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ry-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
</br></br>0	Chin EMG	1</br>0</br>0</br>0</br>I	I	I	I</br>I	I1• ···-·I'</br>I	I	I	I	I</br></br>Figure 18. Mixture of REMs and K complexes.</br>0	A. Epoch 
<mark class="entity" style="background: #42d4f4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    51is
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">STRENGTH</span>
</mark>
 scored as stage A as the majority of the epoch is considered stage A (rule 1.7.b). Epochs 51 and 52 are scored as stage</br>R by rule 1.3.</br>Epochs 60 and 61 are scored as stage A as the majority of the epochs are considered stage A (rule 1.7.b).</br>Epoch 71 is scored as N1as the chin EMG is not at the stage R level for the majority of the epoch.Epoch 72 is an epoch of definite stage N2. Note that rule 1.3 does not apply for epoch 72 as the chin EMG is not at the stage A level.</br>D. The majority of epoch 80 is considered stage A (rule 1.7.b) so the epoch is scored as stage R. Most of epoch 81 is considered stage N2 (rule 1.7.a) so the epoch is scored as stage N2. Epoch 82 is scored as stage A by rule 1.3. Rule 1.3 takes precedence over</br>0	the stage N2 rule G.2. Epoch 83 is an epoch of definite stage R.</br>C 2018American Academy of SIHP Medicine. All rights reserved.</br>0</br>End scoring stuge R sleep when ON E OR MOR E of the following occur:   RECOMMENDED</br>There is a transition to stage W or N3</br>0	b. An increase in chin EMG tone above the level of stage R is seen for the majority of the epoch and criteria for stage NI are</br>met (see Figure 14, epoch 62)</br>An arousal occurs followed by low-amplitude, mixed-frequency EEG and slow eye mo\'ements (Score the epoch as stage</br>0	NI ; if there are no slow eye mm•emcnts and chin EMG tone remai ns low, conti nue to score as stage R) (sec Figure 15)</br>A major body movement followed by slow e)'e mo\'cments and low-ampl itude, mixed-frequency  EEG without non-arousal</br>associated K complexes or sleep spindles (Score the epoch following the major body movement as stage N I : if no slow</br>0	eye movements arc present and the EMG tone remains low, cont inue to score as stage R; the epoch containing the body</br>(	movement is scored using the criteria under heading J) (see Figure 16)</br>c. One or more non-arousal associated K complexes or sleep spindles arc present in the first half of the epoch in the absence</br>(	of rapid eye movements, even if chin EMG tone remains low (Score the epoch as stage N2) (see Figure 17)</br>D	7.Score segments of the record with low chin EMG activity nnd n mixture of REMs and sleep spindles und/or</br>D	K complexes Its follows: ..,... ...1.'4·' ·''' RECOMMENDED</br>Segments between two K complexes, two sleep spindles, or a K complex and sleep spindle without interven ing REMs are</br>considered to be stage N2.</br>r­	b. Segments of the record contai ning R EMs without K complexes or sleep spind les and chin tone at the R EM level are considered to be stage R.</br>c. lf the majority of an epoch contains a segment considered to be stage N2, it is scored as stage N2. I f the majority of an epoch contai ns a segment considered to be stage R, it is scored as stage R. (see Figure 18)</br></br></br></br></br></br></br></br></br></br>)</br>J</br></br></br>1 All Content © 2018 American Academy of Sleep Medicine</br>AASM Scoring Manual Version 2.5	31</br>(</br>(</br>(</br>(</br>(</br>c c c</br>(</br>c</br>c</br>(</br>c</br>Scoring Epochs with Major Body Movements	(</br>Score in accordance with the following definition: RECOMMENDED	(</br>Major body movement: Movement and muscle artifact obscuring the EEG for more than half an epoch to the extent that</br>the sleep stage cannot be determined.	c</br>If alpha rhythm is present for part of the epoch (even &lt;15 seconds duration), score as stage W. RECOMMENDED	(</br>If no alpha rhythm is discernible, but an epoch scoreuble as stage W either precedes or follows the epoch with a major</br>body movement, score as stage W.  RECOMMENDED	c</br>Otherwise, score the epoch as the sume stage as the epoch that follows it.  RECOMMENDED		c c c c c c c</br>(</br>c</br>(_</br>c</br>c</br>l</br>c c c c c. c c. c</br>32   AASM Scoring Manual Version 2.5	All Content te&gt; 2018 American Academy of Sleep Medicine		c c</br>IV. Sleep Staging Rules Part 2: Rules for Children</br></br></br></br></br>A. Ages for Which Pediatric Sleep Staging Rules Apply</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    t.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Pediatric sleep staging rules can be used to score sleep and wakefolness in child ren 2 months post-term or older.:.I,:\! RECOMMENDED</br>D</br>D D D D</br>Reference</br>I . Grigg-Damberger M, Goza\ D, Marcus CL, et al. The visual scoring of sleep and arousal in infants and children. J Clin</br>D	Sleep Med. 2007;3(2):201 -240.</br>c	 	</br>D	B.Tech nical Specifications</br>0</br>Sec IV.Sleep Staging Rules Part I: Rules for Adu lts and Ill. Tech nical and Digital Specifications for technical</br>considerations other than those in the note below. ;o.; 1     RECOMMENDED</br>0</br>0</br>(</br>0</br>0</br>0	 	</br>General Scoring of Sleep Stages</br></br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>(;</br>0</br>0</br>-0,</br></br>The following terminology should be used when scoring sleep in child ren 2 months post-term or older:  IRECOMMENDEDJ</br>Stage W (Wakefulness)</br>Stage N I (NREM I)</br>Stage N2 (NREM 2)</br>Stage N3 (NR EM 3)</br>Stage N (NREM)</br>f. Stage R (REM)</br></br>Not all sleep waveforms arc well developed by 2 months post-term, therefore, the following possible scenarios may apply::'\l.:'\!.:'i.\,:'\ ,'\S</br></br>If all epochs of NREM sleep contain no recogn izable sleep spindles, K complexes or high-amplitude 0.5-2 Hz slow wave activity, score all epochs as stage N (NR EM). IRECOMMENDEDl</br></br>If some epochs of N REM sleep contain sleep spindles or K complexes, score those as stage N2 (NREM 2). If in the remaining N REM epochs, there is no slow wave activity comprising more than 20% of the duration of epochs, score as stage N (N REM). IRECOMMENDED )</br></br>H some epochs of NREM sleep contain greater than 20% slow wave activity, score these as stage N3 (NREM 3). If in the remain ing N REM epochs, there arc no K complexes or spindles then score as stage N (NREM). (RECOMMENDED]</br></br>If NREM  is suf6ciently developed that some epochs contain sleep spindles or K complexes and other epochs contain sufficient amou nts of slow wave activity, then score N REM sleep in this infant as either stage N J, N2 or N3 as in an older child or adult. iRECOMMENDED)</br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	33</br>(</br>(</br></br>c</br>c</br>(</br>(</br>(</br>l</br>c</br>(</br>(</br> 		(</br>Scoring Stage W	c</br>Score in  accordance with  the following definitions :&quot;·=·&quot;  RECOMMENDED</br>Eye blinks:Conjugate vertical eye movements at a frequency of 0.5-2 Hz present in wakefulness with eyes open or closed.	(</br>Rending eye movements: Trains of conjugate eye movements consisting of a slow phase followed by a rapid phase in the</br>opposite d irection as the ch ild reads or visually scans the environment.	c</br>Rnpid eye movements (REMs): Eye movements recorded i n the EOG derivations consisti ng of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    conjugate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, i rregular,	l</br>sharply peaked eye movements with an i nitial deftection usually  lasting &lt;500 msec. While rapid eye movements are</br>characteristic of stage R sleep, they may also be seen i n wakefulness with eyes open when individuals visually scan the environment.	(</br>Posterior dom innnt rhythm (PDR): The dominant reactive EEG rhythm over the occipital regions in relaxed wakefu l ness</br>with eyes closed which is slower i n infants and young children and attenuates with eye opening or attention. Frequency is 3.5-4.5 Hz when first seen in infants 3-4 months post-term, 5-6 Hz by 5-6 months, and 7.5-9.5 Hz by 3 years of age and amplitude is usually &gt;50 µV. I n older children and adults, posterior dominant rhythm is often referred to as alpha rhythm.&quot;· 2 (see Table I )</br></br></br>Table 1.Initial age of waveform appearance.</br></br>Waveform		Age ofInitial Appearance	(</br>Sleepspindle s		6 weeks 3 months post-term	--- - .</br>K complexes	3  6 month s post-term</br></br>Slow wave acll\ ity	2 S months post-term</br></br>Posterior dominant rhythm</br>Frequency of 3.5  4.S Hz	3  4 months post-term</br></br>Frequency of 5  6 Hz</br></br>5  6 months post-term</br></br></br>Frequency of 7.5 9.5 Hz	3 years</br></br>Mean frequency of 9 Hz	9 years</br>Mean frequency of JO Hz	IS years</br></br>Vertex sh:irp waves	4 6 month s post-term</br></br>Hypnagogic hypcrsynchrony (H H)	3 6 months post-term</br></br></br></br></br></br></br>34  AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of S</br></br>(</br>c</br>(_</br>c</br>(_</br>c</br>(_</br>1 Med1cine	(</br>0</br>Score epochs as stage w when more than socyo of the epoch contains EITHER or BOTH:  AECOMMENDEii}</br>Age-appropriate posterior dom i nant rhythm over the occipital region (ind ividuals generating alpha rhythm with eye closure)</br>Other find ings consistent with stage W (all individuals)</br>:J	i. Eye blinks (0.5 2 Hz)</br>Rapid eye movements associated with normal or h igh chin muscle tone</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Readi
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 ng eye movements</br></br></br></br></br></br></br></br></br></br></br></br></br>D D 0</br>0</br>0	E. Scoring Stage Nl</br>0	J. Score in accordance with the followi ng definitions: 1!£ecoMMENi?@j</br>0	Slow eye movements (SEM): Conjugate, reasonably regular, sinusoidal eye movements with an initial deflection that usually lasts &gt;500 msec. Slow eye movements may be seen during eyes closed wake and stage N I.</br>0	Low-am plitude, mixed-frequency (LAM F) activity: Low ampl itude, predominantly 4-7 Hz activity.</br>0	Vertex sharp waves (V waves): Sharply contoured waves with duration &lt;0.5 seconds (as measured at the base of the</br>0	wave), maxi mal over the central region and distinguishable from the background  activity. They are most often seen during transition to stage N I  sleep but can occur i n either stage N I or N2 sleep. These waveforms typically first appear</br>at 4  6 months post-term.</br>0	Sleep onset: The start of the fi rst epoch scored as any stage other than stage W. (In most subjects this will usually be the</br>0	fi rst epoch of stage N I.)</br>0	Hypnagogic hypersynch rony (HH): Paroxysmal bursts or runs of diffuse, h igh-amplitude, sinusoidal, 75 350 µV,</br>3  4.5 Hz waves which begin abruptly, are usually widely d istributed  but often arc maxi mal over the central, frontal, or</br>0	frontocentral scalp regions. These waveforms can occur in stage N I and N2.</br>0	2. In individuals n ho generate a posterior dom inant rhythm (PDR), score stage N I if the PDR is attenuated or replaced</br>0	by low-amplitude, mixed-frequency  activity for more than 50% of the 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epoch.:-;1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
·' · 3 '	OMMEND</br>0	3. I n ind ividuals who do not generate a posterior dominant rhyth m, score stage NJ commencing with the earliest of A NY</br>0	of the following phenomena:' f lcoMMENDED</br>Activity in the range of 4 7 Hz with slowing of background frequencies by   1-2 Hz from those of stage W</br>Slow eye movements</br>0	c. Vertex sharp waves</br>Hypnagogic  hypersynch rony</br>Di ffuse or occipital-predominant, high-amplit ude, rhythmic 3 5 Hz activity</br>0</br>0</br>0</br>0</br>(</br>(</br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	35</br>(</br>Note I. In most individuals sleep onset will be the first epoch of stage NI, but in infants younger than 2 months post­	r</br>term, this is often stage R.</br>Note 2.  Drowsi ness in infants up to 6-8 months of age is characterized by the gradual appearance of diffuse, high­</br>amplitude (often 75-200 µV) 3-5 Hz activity which is typically of higher amplitude, more diffuse, and 1-2	(</br>Hz slower than the waking EEG background activity.	(</br>Note 3. Drowsiness in children 8 months to 3 years is characterized by either diffuse runs or bursts of rhythmic or	(</br>semi-rhythmic bisynch ronous 75-200 µV, 3-4 Hz activity often maximal over the occipital regions and/or</br>higher amplitude (&gt;200 µV) 4-6 Hz theta activity maximal over the frontocentral or central regions.	(</br>Note 4. Sleep onset from 3 years on is often characterized by a 1-2 Hz slowing of the PDR frequency and/or the PDR	(</br>often becomes diffusely distributed then is gradually replaced by relatively low-voltage, mixed-frequency EEG activity.</br>(</br>Note 5.  Hypnagogic hypersynchrony is a distinctive EEG pattern of drowsiness and stage Nl that often disappears</br>with deeper stages of N REM sleep. H H is seen in approximately 30% of i nfants at 3 months post-term, 95%</br>of all normal children ages 6-8 months, and is less prevalent after age 4-5 years; it is seen in only 10% of	(</br>healthy children by age I I and is rarely seen after age 12 years.</br></br> 	 c</br>Scoring Stage N2	c</br>c</br>c c c c c c c c c c</br>Scoring Stage N3	c</br>Same as the adult rules found under the adult sleep staging rules heading H.''  Rl!COMMENDED		c c c c c c</br>Scoring Stage R	c</br>Same as the adult rules found under the adu lt sleep staging rules heading I.'1   RECOMMENDED	(</br>c c c</br>(_</br>(</br>c</br>36	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	(</br>(</br>IV.Sleep Staging Rules Part 3: Rules for Infants</br></br></br></br></br>Ages for Which Infant Sleep Staging Rules Apply</br></br></br></br></br></br></br></br></br></br></br></br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>(</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>L</br>0</br>0</br>c</br>(</br>-(_ ,</br>Infant sleep staging rules should be used to score sleep and wakefulness in infants 0-2 months post-term (37-48 weeks conceptional age). 1' '	RECOMMENDED</br>Note I. Conceptional age (CA) is gestational age (GA) at birth plus the number of weeks postpartum. GA is the I</br>time elapsed between the first day of the mother's last menstrual period and the day of delivery expressed i n        \</br>completed weeks. If the pregnancy was achieved usi ng assisted reproductive technology, GA is calculated by adding 2 weeks to the CA. Chronological age (or postnatal or legal age) is the time elapsed since birth (can be expressed in days, months, or years).</br>Note 2.  At birth, an i nfant is classified as one of the following: premature ( 37 weeks gestation); full-term (37-42 weeks); or post-term (born after 42 weeks). A neonate is a child during the first 28 days after birth;an infant is a child age Ito 
<mark class="entity" style="background: #42d4f4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    12 months.•
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">STRENGTH</span>
</mark>
</br>Note 3.  Knowing an infant's CA is crucial for interpreting the normalcy, immaturity or abnormality of an EEG or PSG because the brain and the EEG continue to develop and mature at a similar rate independent of whether the infant is in utero or post-deliver y.</br>Note 4. For premature i nfants ( 37 weeks CA) refer to discussion i n the Pediatric and Infant Scoring Task Force revi.ew  paper.'</br></br>References</br>Engle WA; American Academy of Pediatrics Committee on Fetus and Newborn. Age terminology during the perinatal period. Pediatrics. 2004; 114(5):1362  1364.</br></br>2. Grigg-Damberger M, Gozal D, Marcus CL, et al. The visual scoring of sleep and arousal in infants and children. J C/in</br>Sleep Med. 2007;3(2):201 240.</br></br></br></br>Technical  Specifications</br>Sec IV.Sleep Stuging Ru les Pnrt 1: Rules for Adults and Ill.Technical and Digital Specifications for tech nical considerations other than those below. RECOMMENDED</br></br>Adult electrode derivations for EEG, EOG and chin EMG arc acceptable when  recording sleep except  that the distance between the chin EMG electrodes often needs to be reduced from 2 cm to I cm and the distance from the eyes in EOG electrodes ortcn need to be reduced from 1 to 0.5 cm because or small infunt head sizes.   RECOMMENDED</br></br>Since sleep spindles arc often asynchronous in children u ntil 2 years of age, and may be more prominent in the midline central (C3-Cz, C4-Cz) and central derivations (C3-M2, C4-M l), simultaneous display of the recommended and backup electrodes and Cz (midline central) may be considered (cg, montage to consider: F4-M1, C4-Ml, 02-Ml, F3- M2, C3-M2, 01-M2, C4-Cz, C3-Cz).'1   OPTIONAL</br></br>Since behavioral patterns arc extremely useful, synchronized video and audio recording is h ighly desirable.  OPTIONAL</br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM  Scoring Manual  Version 2.5	37</br>• •• -•....,..,_f'I _ ..... •••-:;t • .  .•.._. , ' &quot;&quot;'  .._. +................. ''W''  ''••Vt 'I'°'</br>r</br>General Scoring of Sleep Stages	(</br>The following term inology should be used when scoring sleep in infants 0-2 months post-term	c</br>(37-48 weeks CA): &quot;1· 2 (RECOMMENDED]	c</br>Stage W (Wakefulness)</br>Stage N  (NREM)</br>Stage R (R EM)	{</br>Stage T (Transitional)</br>(</br>Score epochs using the following rules:  RECOMMENDED	(</br>Score sleep stages i n 30-second, sequential epochs commencing  at the start of the study</br>Assign a stage to each epoch	l</br>If two or more stages coexist, assign the stage comprising the greatest portion of the epoch</br>If two or more PSG characteristics are d iscordant for stage R or stage N sleep, score the epoch as stage T (Transitional) sleep</br>Score sleep onset as the first epoch of sleep'J	c</br>Sleep nnd wnkefulness in infants 38 to 48 weeks CA nre scored based on behaviornl observation; regularity or	c</br>irregularity of respiration; und EEG, EOG, and chin EMG putterns defined in Tables 1-6. RECOMMENDED	[&quot;</br>Score sleep bused on bella••ioral characteristics as defined in Table I.   RECOMMENDED	c c c c c c c c</br>(_</br>Score sleep based on the respiration characteristics us defined in Tuhlc 2.	RECOMMENDED	c</br>Table 2. Respiration characteristics of sleep stages.	c</br>Stage	Respiration Characteristics	 	</br></br>Wake	lrregulur, rapid, and shallo1\</br></br>N	Regular</br></br>R	Irregular, some central pauses (may or may nol meet crnerm for apnea)</br>c c c c</br>(</br>c c</br>(</br>c</br>(_</br>c</br>(_</br>38	\ASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	(</br>0	6. Score sleep based on the EEG churocteristics as defined in Table 3. (see also Figure I)	MMENDED</br>r</br>L1	Table 3. EEG characteristics of sleep stages.  7·&quot;H</br></br>0</br>Patterns	EEG Characteristics</br>0</br>Discontinuous</br></br>This EEG pattern in full·term infants is generally only seen in stage N sleep. It is</br>l Stage</br></br>1</br></br>(s_) _</br></br>[</br>Trace allcrnant (TA)  9· 111</br>characterized by al least 3 alternating runs of bilaterally symmetrical synchronous high</br>rnl1age (50-150 µV) bursts of 1-3 Hz delta activity lasung 5-6 seconds (range 3-8	N</br></br>0	seconds) alternating with periods of lower amplitude (25-50 µV) 4-7 Hz theta activity</br>c			(range 4-12 seconds).</br></br>Lcontlnu     s</br></br>0	Low voltage irregular (LVI)</br></br></br>Continuous low voltage mixed-frequency activity with delta and predominantly 1he1a activity.</br></br>I</br>R, Wake</br></br>0	High rnltage slow (l·IVS) 'il l	Continuous synchronous symmetrical predominantly high rnltage 
<mark class="entity" style="background: #e6194B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    1-3 Hz
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DOSAGE</span>
</mark>
 delta activity.	N, rarely R</br></br>0	Mixed (Ml</br>0	IW:mirorms or lnlercsl</br>0	I</br>0	Sleep spindles&quot;12,'iI.'</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>Both high voltage slow and low voltage polyrhythmic components; these arc intermingled with little periodicity. The ampI itude is lower than seen in the H VS panern.</br></br></br></br>12 to 14 Hz, asynchronous, most prominent in midline central (CZ) and central derivations. Occur only in stage N sleep.</br>Wake, R, rarely N</br></br>-</br>N</br></br>J</br>D</br>r</br>\.._</br></br>(</br>l.</br>,.</br>\..</br>Score sleep in accordance with the following definitions and based on the EOG characteristics as defined in Table 4. RECOMMENDED</br></br>Eye blinks: Conjugate vertical eye movements at a frequency of0.5-2 Hz present in wakefulness with eyes open or closed.</br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	39</br></br></br>Scanning eye movements: Trains of conjugate eye movements  with eyes open consisti ng of a slow phase followed by a	c</br>rapid phase in the opposite direction as the infant visually scans the environment or follows objects.'&quot;	c</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rupid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 eye movements  (REMs): Eye movements  recorded  in the EOG derivations consisting of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    conjugate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
,  irregular,	c</br>sharply peaked eye movements with an initial deflection usually lasting &lt;500 msec. While rapid eye movements are</br>characteristic of stage R sleep, they may also be seen in wakefulness with eyes open when individuals visually scan the environment.	(</br>c</br>c</br>(</br>c</br>(</br>c c</br>(</br>Score sleep in uccordunce with the following definitions and bused on the chin EMG patterns us defined in</br>Table 5. RECOMMENDED</br>(</br>Low chin EMG tone: Baseline EMG activity in the chin derivation no higher than in any other sleep stage and usually at</br>the lowest level of the entire recordi ng.</br>Transient muscle uctivity: Short irregular bursts of EMG activity usually with duration &lt;0.25 seconds superimposed	c on low EMG tone. The activity may be seen in the chin or anterior tibial EMG derivations, as well as i n EEG or EOG	( deviations, the latter indicating activity of cranial nerve innervated muscles (facial and scalp muscles). The activity is</br>often maximal when associated with rapid eye movements.	c</br>c</br>c c c c c c c</br>Table 6 pro\'idcs u summary of Tables I to 5.	c</br>c</br>Table 6. Summary of state characteristics.&quot;'	c</br>Stage	r Behavioral	Respiration	EEG	EOG	ChlnEMG	c</br></br>Wake</br></br></br></br>N</br>Eyes open, crying. feeding</br></br>Reduced mo\'ement rclati\'e to wake (Eyes closed, periodic sucking, occasional startle)</br>Irregular</br></br></br></br>Regular</br>LV I or M	REMs, blinks, scan-	Presenl ning eye mm·emenls</br>(</br>TA. BVS. sleep	Eyes closed wilh no	Presenl or low</br>spindles, or M	EMs	c</br>REMs or	c</br></br>R	Eyes closed</br>Irregular</br>LVI or M</br>Eyes closed with no</br>Low, TMA may	c</br></br>Small mo\'emcnts</br>(ran:ly HVS)	EMs:o.'16	occur</br></br>LVI low \'Ollage irregular, M •mixed. TA trace allernant, BVS high \ollage slow, REMs z rapid eye mo\'emenls.	(</br>c c c</br>40	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>(</br>(</br>r</br></br></br>(</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>' )</br></br></br>...</br></br></br>Note  I.  If NREM  is sufficiently developed so that some epochs contain sleep spindles or K complexes and other epochs contain sufficient amounts of slow wave activity, then score NREM  sleep in this infant as either stage N I , N2 or N3 as in IV. Sleep Staging Rules Part 2: Rules for Children, C.5.</br>Note 2.  Stage N is analogous to the previously used terminology of &quot;quiet sleep,&quot; stage R is analogous to the previously used terminology of &quot;active sleep,&quot;and stage T is analogous to the previously used terminology of &quot;indeterminate  sleep.&quot;</br>Note 3.  Up until 2 to 3 months post-term, the fi rst epoch of sleep in infants is often stage R.</br>Note 4.  The transition to sleep in an i nfant is characterized by relative immobility, absence of focused attention, and intermittent eye closure. lf an infant's eyes are closed for more than 3 minutes, the infant is considered asleep. Theta and delta activity, especially over the frontal derivations, may increase in ampl itude in transitions between W and sleep onset.</br>Note 5.   Regu larity or irregularity of respiration duri ng sleep is the most reliable PSG characteristic  in d ifferentiating stage N and stage R sleep, respectively.</br>Note 6.   Periodic breathing is common during stage R sleep and may rarely occu r during stage N sleep i n normal infants.</br>Note 7.  The EEG patterns of transitional sleep may contain any of the EEG characteristics outl ined in Table 3.</br>Note 8.   Pathological  EEG waveforms, such as those from spike and slow wave, projected rhythms or those generated due to underlyi ng pathology, shou ld not be included in defi ning stage or state as noted in Table 3.</br>Note 9.  It is permissible to look at preceding and following epochs to identify the trace alternant (TA) pattern.</br>Note 10. Trace alternant (TA) fi rst appears at 37 weeks conceptional age (CA), is the predominant EEG pattern in stage N sleep at 40 weeks CA and unl 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    i
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 kely to be seen after 44 weeks CA. After 42 weeks CA, interburst intervals (IBls) of TA last on ly 1-2 seconds and the IBI is of higher ampl itude. TA after 44 weeks CA is replaced by high voltage slow (HVS) activity.</br>Note 11. H igh voltage slow (HVS) activity is the more mature EEG pattern of stage N sleep at term. It is characterized by continuous synchronous symmetrical 100-150 µV 1-3 Hz delta activity which often has an occipital or central predom inance.</br>Note 12. Since rudimentary sleep spind les first appear at 43 to 48 weeks CA at the midl ine central (Cz, vertex) region and are often asynchronous, simultaneous d isplay ofleft, right and midline central EEG channels may be considered (eg, C3-Cz, Cz-C4). I n infants this age, sleep spindles are often low voltage 12-14 Hz, not the wider range of 1 1-16 Hz seen at later ages.</br>Note 13. Since sleep spindles are often asynchronous in children until 2 years of age, simu ltaneous display of the recom mended and back up electrodes may be considered (eg, montage to consider: F3-M2, F4-M I, C3-M2, C4-M l, Oi-M2, 02-M l , C3-Cz, Cz-C4).</br>Note 14. Scanning eye movements can be seen as early as 2 weeks post-term.</br>Note 15. Stage T (Transitional) is scored when 3 N REM and 2 R EM or 2 NREM and 3 REM characteristics are present.</br>Note  16. I n epoch(s) contiguous and following an epoch of defin ite stage R (eg, contai ning REMs).</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	41</br>••• --'•&quot;&quot;'- _._..,.  ·· ......	I Vol ' ...... '''&quot;'&quot;&quot; IV• &quot;,.,_..,,W</br>c</br>Scoring Stage W	(</br>Score epochs as stage W if either a, b, or c is present for the majority of the epoch: '1 &quot;2 (Figure 2)  RECOMMENDED	c</br>Eyes are wide open (for the majority of the epoch)	(</br>Vocalization (whimpering, crying, etc.) or actively feeding</br>All of the following are met:	(</br>Eyes are open intermittently</br>REMs or scanning eye movements</br>Sustained chin EMG tone with bursts of muscle activity</br>Irregular respi ration	(</br>EEG: LVl or M'·1</br>(</br>(</br>(</br>Tech note:</br>op•n.</br>mo•lnghHd	(</br>c</br>c</br>NasalPressure	c</br>Thermal Son&quot;&quot;'	(</br>c</br>(</br></br>M N M M N M W N N N N M M H N N • M N • N N N N • N N M M</br></br></br></br>Figure 2. A 30 second tracing of stage W in an infant. EEG: mixed frequency pattern: EOG: REMs present; Chin EMG:present (high}; Respiration: irregular; Behavior: eyes open, moving head.The thermal sensor is an oronasal flow sensor.</br>C2018Amerlc•n Academy al SleepMedicine.An right• 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rHerYed
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.	c</br>c c c</br>(_</br>c c c c c c c</br>(</br>c</br>(</br>c</br>l</br>c</br>c</br></br>42	AASM Scoring Manual Version 2.5</br>All Content © 2018 American Academy of Sleep Medicine	(</br>c</br>c</br>(	E. Scoring Stage N (NREM)</br>, • • -- --,.. -..-.::1•r ·w r ,.... ,..,_   - • -. •  -·-.•  -</br></br>[	1.Score stage N if fou r or more of the following are present, includ ing regu lar respiration, for the majority of the</br>epoch:'&quot;·'2 (Figures 3 and 4)  (RECOMMENDED)</br>Eyes closed with no eye movements</br>Ch i n EMG tone present</br>f	c. Regular respiration (post sigh respiratory pauses may occur)</br>(	d. Trace alternant (TA), high voltage slow ( H VS), or sleep spindles present</br>e. Reduced movement  relative to wake</br></br>c</br>0</br>(</br></br>()</br>(</br>0</br>0</br>[)</br>[)</br>0</br>(</br>0</br>0</br>0</br>0</br>0</br>0</br>[J</br>0</br>0</br>0</br>c</br>L.</br>t</br></br></br></br>...</br></br></br></br>.... .I</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>Note I.  Chin EMG in stage N is variable; it is generally lower than Wake and higher than in stage R. That is, if chin  EMG activity is present (higher than stage R) this is evidence for stage N (Table 5). However, stage N can still be scored with low EMG tone provided at least four other criteria for stage N including regular respiration are met.</br>Note 2.  Regularity or irregularity of respiration during sleep is the most reliable PSG characteristic in differentiating stage N and stage R sleep, respectively .</br></br>..   ,,	 	</br>,.</br></br>All Content © 2016 American Academy of Sleep Medicine</br>AASM Scoring Manual Version 2.5	43</br></br>IP f  'W' &quot;'W' -of'&quot; ... ....:;2P' fiill   11-•--</br></br> 		(</br>coring Stage R	r</br>Score stage R sleep (definite R) in epochs with 4 or more of the following criteria present, including irregular	(</br>respi ration AN D rapid eye movement: '1 (Figure 5)  RECOMMENDED	(</br>Low chin EMG (for the majority of the epoch) '1</br>Eyes closed with at least one rapid eye movement (concurrent with low ch in tone)</br>Irregular respi ration	(</br>Mouthing, sucking, twitches or brief head movements</br>EEG exhibits a continuous pattern without sleep spindles''	c</br>Score segments of sleep contiguous with and following an epoch of definite R (as defined in F.l) in the ab.'ie111..e t1f rapid</br>f!J'e 111t11'e111e11ts, us stage R if A LL of the followi ng arc present: RECOMMENDED	(</br>The EEG shows low or medium amplitude mixed frequency activity without trace alternant or sleep spind les	c:</br>The ch i n muscle tone is low for the majority of the epoch	c</br>There is no intervening arousa l (see chapter Y. Arousal Rule, same rule as for children and adults)	c</br>c</br>l</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>Chln EMG----------------------------------</br></br></br></br></br></br></br>Abel	</br>SpO,---------------------------------</br>•</br>Tech note:	(</br>tiny movement• of mouth</br>c</br>c</br>(_</br>(</br>c c c</br>(_</br>c</br>c</br></br>Figure 5. A 30 second tracing of stage R sleep in an infant. EEG: LVI; EOG: REMs; Chin EMG: low; Respiration:irregular;</br>Behavior: eye movements noted with small movements of mouth. The thermal sensor is an oronasal flow sensor.	c</br>02018 American Academy of Sleep Medicine. All right• reserved.</br>(</br>(_</br>(</br>c c c c</br>(</br>(_</br>c</br>c</br>(_</br>(</br></br>44 AASM Scoring Manual Version 2.5	All Content e 2018 American Academy of Sleep Medicine	c</br>(_</br>(	 	</br>G. Scoring Stage T</br>0	I.Score an epoch as stage N, stage R or stage W if only one PSG characteristic is discordant for the sleep</br>0	state.:-0l,'li!  [RECpMMENDED)</br>0	2. Score an epoch as stage T (transitional) if it contains either 3 NREM and 2 REM characteristics or 2 NREM and</br>(	3 REM characteristics. (Table 6, Figure 6) iRecoMMENDEDJ</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0	 	</br>0	H.Reference</br>The following reference applies to content throughout chapter IV.Sleep Staging Rules Part 3: Ru les for Infants.</br>0	I.Anders T, Emde R, Parmelee A. A Manual of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Standardi
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
=ed Terminology. Teclrniques and Criteriafor Scoring of States of</br>0	Sleep and Wakefulness in Newborn 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Infanfs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. Los Angeles, CA: UCLA Brain Information Service/BR I Publ ications Office,</br>0	N INOS Neurological Informat ion Network; 1971.</br>0</br>0</br>0</br>0</br>L</br>(</br>c</br>()</br>0</br></br>c</br>...&quot;]</br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	45</br>V. Arousal Rule	(</br>(</br>c</br>(</br>Scoring Arousals	c</br>Score 11rous11I during sleep stnges Nl, N2. NJ, or R if there is un abrupt shift of EEG frequency includ ing ulphn, theta	(</br>and/or frequencies greater than 16 Hz (but not spindles) that lasts ut least 3 seconds, with ut least 10 seconds of stable</br>sleep preceding the change. Scoring of nrousul during REM requires a concurrent increase in submentul EMG Justing	(</br>at lenst 1 second.''·'!.'1,&quot;W, !l RECOMMENDED	c</br>(</br>c</br>(</br>(</br>c c c</br>(</br>(</br>c c c c c c c c c</br>(_</br>(</br>c c c c c c c c c c</br>c</br>c</br>(_</br>46    AASM Scoring Manual Version 2.5	All Content &lt;Cl 2018 American Academy of Sleep Medicine	c</br>(</br>0 VI. Cardiac Rules</br>(</br>0</br>0</br>0 A. Technical Specifications</br>G        I.Use 11 single modified electrocardiogruph Lead II and torso electrode placement.'1· -  l·  4 (see Figure  I)   RECOMMENDED</br>0</br>0</br>0</br>[</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D D 0</br>0</br>0</br></br></br></br></br></br></br></br></br>All Content	2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	47</br>(</br>Scoring Cardiac Events &quot; &quot;:	(</br>Score sinus tachycardia during sleep for a sustained sinus heart rute of greuter than 90 beats per minute for adu lts.	(</br>'\,\,-- RECOMMENDED	(</br>Score brudycardia during sleep for a sustained heart rate of less than 40/minute for ages 6 years through	c</br>adult.'\ RECOMMENDED	(</br>Score asystole for cardiac pauses greater than 3 seconds for ages 6 years through adult. RECOMMENDED	(</br>Score wide complex tachycardia for a rhythm lasting a minimum of 3 consecuth•e beats at a rate greater than 100 per	(</br>mi nute with QRS duration of greater than or equal to 120 mscc. RECOMMENDED	(</br>Score nurrow complex tachycard iu for a rhythm lasting a minimum of 3 consccuti,·e beats at a rate of greater than 100</br>per minute with QRS duration oflcss than 120 msec.   RECOMMENDED	c</br>Score atrial fibrillation if there arc irregularly irregular QRS complexes associated with rcpluccment of consistent	(</br>P wa,•cs by rapid oscillations that vary in size, shape, and timing.   RECOMMENDED</br>(</br>(</br>c c c c c</br>Reference</br>Caples SM, Rosen CL, Shen WK, et al. The scoring of cardiac events during sleep. J Clin Sleep 1Hed. 2007;3(2):147-154.</br>(</br>c</br>(</br>c c c c c c c c</br>(</br>c c c c</br>c c c c</br>48 AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	(</br>c</br>r.	VII.Movement Rules</br>c</br>0</br>r	A. Technical Specifications'1</br>8	1. For monitoring leg movements (LMs), surface electrodes should be placed longitudi nally and symmetrically in the middle of the anterior tibialis muscle so that they arc 2-3 cm apart or 1/3 of the length of the anterior tibialis muscle,</br>whichever is shorter. Both legs should be monitored for the presence of the leg mo\•cmcnts. Separate channels for</br>0	each leg arc strongly prderred. Combining electrodes from the 2 legs to give I recorded channel may suffice for some clin ical settings, although it should be recognized that this strategy may reduce the nu mber of detected LMs.</br>(see Figure I)  RECOMMENDED</br>0</br>n</br>0</br>0</br>0</br>0</br>0</br>D</br>0</br>0</br>0</br>0</br>0</br>0	2. For mon itoring leg movements, use of 60 Hz (notch) filters should be avoided. Impedances need to be less than</br>0	J0,000 il. Less than 5,000 il is preferred but may be d ifticult to obtai n. RECOMMENDED</br>Movements of the upper limbs may be sampled using a similar method as for legs if clin ically indicated.</br>(see Figures 2 and 3)   OPTIONAL</br>0</br>D D 0</br></br>0</br></br></br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	49</br>(</br>c c c</br>(</br>c c c c c c r c</br>For detecting bru xism, in addition to the recommended placement of chin EMG electrodes as noted in the adult	(</br>sleep staging rules chapter (IV.C), add itional massetcr electrodes may be placed if clinically indicated. l</br>(see Figure 4) OPTIONAL</br>(</br>(</br>c</br>(</br>c c c c c c</br>(</br>c c</br>For detecting transient muscle activity in REM sleep, use one of the following EMG recordings:'3    OPTIONAL	(</br>Flexor digitoru m superficialis (see Figure 2)</br>Extensor digitorum communis (see Figure 3)	(</br>For diagnosis of RBO, time-synchronized, aud io-equipped video PSG is essential to document complex motor	c behaviors and vocalizations during REM sleep.A diagnosis of RBO is based on demonstration of such episodes or a	c characteristic clinical history of dream enactment in addition to polysomnographic evidence of REM sleep without</br>atonia. RECOMMENDIO	c</br>For monitoring rhyth mic movement disorder (RMO), bipolar surface electrodes should be placed to record electrical</br>activity of the large muscle groups involved.  ·• (see Figure 5) l oPTIONAL</br></br>For diagnosis of RMO, time-synchronized video PSG is necessary to accurately characterize the disorder,in addition</br>to polysomnographic criteria. RECOMM!NDED	l</br>c</br>(</br>c c</br>50   AASM Scoring Manual Version 2.5	All Content 1&lt; '201B American Academy of Sleep Medicine	c.</br>c</br>(</br>n</br>r</br>0</br>0</br>B</br>c</br>0</br>0</br>[</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D	 	</br></br>D D 0 D</br></br>D</br>.,..</br></br>Scoring Periodic Limb Movements in Sleep (PLMS)</br>The following define a significant leg movement (LM) event:'1  RECOMMENDED</br>The minimum duration of a LM event is 0.5 seconds.</br>The maximum du ration of a LM event is 10 seconds.</br>The minimum amplit ude of a LM event is an 8 µV increase i n EMG voltage above resti ng EMG (duration of at least 0.5 seconds).</br>The timing of the onset of a LM event is defi ned as the point at which there is an 8 µV increase in EMG voltage above resting EMG.</br>The timing of the ending of a LM event is defined as the start of a period lasti ng at least 0.5 seconds during wh ich the EMG does not exceed 2 µV above resti ng EMG.</br></br>The following define a PLM series:'  RECOMMENDED</br>The minimum number of consecutive LM events needed to define a PLM series is 4 LMs.</br>The period length between LMs (defined as the time between onsets of consecutive LMs) to include them as part of a PLM series is 5 to 90 seconds.</br>Leg movements on 2 different legs separated by less than 5 seconds between movement  onsets are counted as a single leg movement. The period length to the next LM followi ng th is group of LMs is measured from the onset of the fi rst LM to the onset of the next. (see Figure 6)</br></br></br></br></br></br></br></br></br></br>All Content 0 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	51</br>(</br>(</br>(</br>(</br>(</br>c</br>c</br>An arousal and a limb movement that occur in a PLM series should be considered associated with each other if they	(</br>occur simultaneously, overlap,or when there is &lt;0.5 seconds between the end of one event und the onset of the other</br>e\·ent regard less of which is first. (see Figure 7) RECOMMENDED	(</br>c</br> 	Epoch 	</br>52	53</br></br></br></br>I</br>F4·M1:_!\,------....-     .	;.,.._ 	</br>C4-M1:1\------&quot;---.----   &quot;&quot;&quot;</br>I</br>02-M1 I</br>I</br> 	_,.,MN'..</br>1 A	PLM ......,	Pl.M •rouNI I	c</br>F4-M1 :J	(</br>C4-M1 :1\----&quot;&quot;&quot;&quot;&quot;&quot;''-----.------......J--:	(</br>I	I</br>02-M1</br>E1-M2 :1V-----'-----'-------&quot;&quot;' o\ :	c</br></br>E1-M2 :J\,-----,..</br>..._</br></br></br>E2-M2	---------,------'w.w--</br>Chin EMG t---------&quot;f'	1</br>I</br>E2-M2	-------.-------&quot;&quot;'\o.\,'.'&quot;·i......     ,	c</br>I</br>Chin EMG ----------------</br>1	Pl.MS	PLMS</br></br>RAT '	----1111---1.-	...._...,__ 	.</br>I</br>RAT '	--t..</br>I</br>.'--	--	-'	(</br></br>I</br>LAT  ..--------........---------.</br>LAT '   --------..,..---------	c</br>c</br></br>0	30</br>60</br></br>Epoch</br>0	30</br>60	c</br>c</br></br> 	54		c</br>c</br></br></br>C4-M1	---------</br>I</br>02-M1	--------</br>MAM	N#N.	c</br>MIW1	NHN-	c</br></br>E1-M2 :	-------- - -MM		(_</br></br></br>E2-M2	--------­</br>'</br>MN/I	Wit'	c</br>c</br></br>Chin EMG  .1......--------------------------------------</br>RATr:----------m. ...-------------------.•..•..-------</br>LATt1------------------------------ --------,</br>0	15	30</br>0.5aec	o.eaec</br>Figure 7.An arousal and LM occurring in a PLM series are considered to be associated if they occur simultaneously (epochs 50 and 51},overlap (epochs 52and 53) or if the time from the end of one event to the start of the next Is less than 0.5 seconds, regardless which event comes first (epoch 54).</br>02018American Academy of Sleep Medicine.All rlghtareserved.	c</br>c c c</br>(</br>52   AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>c</br>c</br>(</br>r,</br>0</br>0</br>B</br>(</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D 0</br>...</br>D</br>,.</br>L</br></br>An LM shou ld not be scored if it occu rs du ring a period from 0.5 seconds preceding an apnea, hypopnea, or R ERA to</br>0.5 seconds following the event.  RECOMMENDED</br></br>When a period of wake &lt;90 seconds separates a series of LMs, th is does not prevent LMs preceding the period of wake from being included with the subseq uent LMs as part of u PLM series. (see Figure 8) [RECOMMENDED]</br></br></br></br></br></br></br></br>Scoring Alternating Leg Muscle Activation  (ALMA)</br>The following define 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ALMA:'1·'1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.') OPTIONAL.</br>The m inimum number of discrete and alternating EMG bursts of leg muscle activity events needed lo score an A LM A series is 4 A LMAs.</br>The minimum  frequency of the alternating EMG bursts i n A LM A is 0.5 Hz.</br>The maxi mum frequency of the alternating EMG bursts in ALMA is 3.0 Hz.</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	53</br>c=</br>Scoring Hypnagogic Foot Tremor (HFT)	(</br>The following define HFT:..,.. 1  OPTIONAL	c</br>The m inimum number of EMG bursts needed to make a train of bursts in a H FT series is 4 H FT bursts.	c</br>The min imum frequency of the EMG bursts in a H FT is 0.3 Hz.</br>The maximum frequency of the EMG bursts i n a H FT is 4.0 Hz.	(</br>e</br>l</br>c</br>c</br>(</br>(</br>Scoring Excessive Fragmentary Myoclonus (EFM)	c</br>The following define EFM: l·&quot;1&quot;,  OPTIONAL.	c</br>The usual maxi mum EMG burst duration seen in fragmentary myoclonus is 150 msec.</br>At least 20 m inutes of NREM sleep with EFM must be recorded.</br>At least 5 EMG potentials per minute must be recorded.	c</br>c c c c c</br>(</br>c</br> 		c</br>F.Scoring Bruxism	c</br>The following define bruxism: &quot;'1·:-;1   RECOMMENDED	c</br>Bruxism may consist of brief (phasic) or sustained (tonic) elevations of ch i n EMG activity that are at least twice the	c</br>ampl itude of background EMG.</br>Brief elevations of ch in or masseter  EMG activity are scored as bruxism  if they are 0.25-2 seconds i n duration and if at least 3 such elevations occur in a regular sequence.</br>Sustained elevations of chin or masseter EMG activity arc scored as bruxism if the duration is more than 2 seconds.</br>A period of at least 3 seconds of stable background  ch in EMG must occur before a new episode of bruxism can be scored.</br>Bruxism can be scored reliably by audio in combination with polysomnography by a minimum of 2 audible tooth grinding episodes/n ight of polysomnography in the absence of epilepsy.	c</br>c c c</br>(</br>(</br>c</br>(_</br>c</br>L</br>c.</br>54   AASM Scoring Manual Version 2.5	All Content © 2016 American Academy of Sleep Medicine	c</br>c</br>(	 	</br>r	G. Scoring PSG Featu res of REM Sleep Behavior Disorder (RBD)</br>0	1. Score in nccordnnce with the following definitions:  IRECOMMENDED]</br>0	Sustnined muscle activity (tonic activity) in REM sleep: An epoch of REM sleep with at least 50% of the duration of the</br>0	epoch havi ng a chin EMG amplitude greater than the min imum amplitude demonstrated i n N REM sleep.</br>Excessive transient muscle activity (phasic activity) in REM sleep: I n a 30-second epoch of R EM sleep divided into</br>IO sequential 3-second mini-epochs, at least 5 (50%) of the min i-epochs contain bursts of transient  muscle activity. I n</br>0	RBD, excessive transient muscle activity bursts are 0.1-5.0 seconds in duration and at least 4 ti mes as high in amplitude</br>0	as the background EMG activity.</br>0	2. The polysomnogrnphic characteristics of RBD are characterized by EITHER or BOTH of the following</br></br>r	fentures: :-.1.&quot;' ·'</br>I RECOMMENDED]</br></br>2   3</br>Sustained muscle activity in REM sleep in the chin EMG</br>0	b. Excessive transient muscle activity during REM in the chin or limb EMG</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D D D</br>D   H. Scoring the PSG Features of Rhythmic Movement Disorder</br>D       1. The following defi ne the polysomnogra phic characteristics of rhyth m ic movement disorder:  DRECOMMENDEDH</br>The minimum frequency for scoring rhythmic movements is 0.5 Hz.</br>The maxi mum frequency for scoring rhythm ic movements is 2.0 Hz.</br>D	c. The m inimum number of individual movements required to make a cluster of rhythmic movements is 4 movements.</br>d. The m inimum ampl itude of an individual rhythm ic burst is 2 times the background  EMG activity.</br></br></br>r</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version  2.5	55</br>VIII. Respiratory Rules Part 1: Rules for Adults	r</br>c</br>(</br>Tech nical Specifications	c</br>For identification of an upnea du ring a diagnostic study, use an oronasal thermal nirflow sensor to monitor	c</br>airflow.&quot;   RECOMMENDED	c</br>For identification of an apnea during a diagnostic study 111/um the t1ro11asa/ thermal airjfm11 !it!1t!it1r is 11t1tft111c.·tim1i11g ,,,</br>tile sig11al is 1wt reliable, use one of the followi ng (allematfre  apnea sensors):':</br>nasal pressure transducer (with or without square root transformation)  RECOMMENDED</br>Respiratory inductance plethysmography  sum (RIPsum) (calibrated or uncal ibrated)   RECOMMENDED</br>Respiratory inductance plethysmography flow (RIPflow) (calibrated or uncal ibrated)  RECOMMENDED</br>PV DFsum   ACCEPTABLE</br></br>For Identification of a hypopnca during a diagnostic study, use a 
<mark class="entity" style="background: #f032e6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nasal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ROUTE</span>
</mark>
 pressu re transducer (with or without square root transformation of the signal) to monitor airflow.	RECOMMENDED</br>For identification of a hypopnca during a diagnostic study 111he11 the trasal pres!l11re tra11.w/11cer is 1wtft111ctitm i11g '&quot;the	c</br>signal is 1wl reliable, use one of the following (altematfre hypopnea sensors):;-.;:	(</br>a.oronasal thermal airflow  RECOMMENDED</br>R IPsum (calibrated or uncalibrated)  RECOMMENDED</br>RI Pflow (calibrated or uncal ibrated)   RECOMMENDED</br>d. dual thoracoabdominal R I P belts (calibrated or uncal ibrated)  RECOMMENDED</br>e. PV DFsurn ACCEPTABLE</br></br>During positive airway pressu re (PA P) titration, use the PAP device flow signal to identify apneas or hypopncas. RECOMMENDED</br>For mon itoring respiratory effort, use one of the following:	c</br>a. esophageal manometry  RECOMMENDED	c</br>dual thoracoabdorninal  R I P belts (calibrated or uncal ibrated)   RECOMMENDED</br>dual thoracoabdorninal  PVDF belts    ACCEPTABLE</br></br>For monitoring oxygen saturation, use pulse oximctry with o maximum acceptable signal averaging time of !::3 seconds at a heart rate of 80 beats per minute.  RECOMMENDED</br>(</br>For monitoring snoring, use an acoustic sensor (cg, microphone), piezoelectric sensor or nasal pressure</br>transd ucer.&quot;4  RECOMMENDED</br>For detection of hypo,·entilation during a diagnostic study, use arterinl PC02, transcutancous PC02 or end-tidal	c.</br>PC02. ;-.;·&quot;&quot;  RECOMMENDED	c</br>For detection of hypoventilation du ring PA P titration, use arterial PC02. or use trnnscutaneous	c</br>PC02.  5.  r.    RECOMMENDED	c</br>c</br>(</br>c c c c</br>(</br>c c c</br>56  AASM Scoring Manual Version 2.5	All Content CC&gt; 2018 American Academy of Sleep Medicine		( (</br>r</br>(</br>0</br>(</br>(</br>B</br>0</br>0</br>c</br>(</br>0</br>0</br>(</br>0</br>0</br>0</br>0</br>0</br>0	B. Measuring Event Duration</br>.. ..... ............,...._.,_,,, ..-....-. -··.. . ·-·-..;- ...... ......... .....</br></br>0	I. For scoring either an 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    apnca
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 or a hypopnca, the event duration is measured from the nadir preceding the first breath</br>0	that is clearly reduced to the begi nning of the first breath that approximates the baseline breathing umplitude. (see red</br>bracket , Figures I and 2)   RECOMMENDED</br>D</br>For npneu duration, the oronasnl thermal sensor signal (diagnostic study) or PA P device flow signul (PA P titration</br>study) should be used to 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    determ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 ine the event du ration.For hypopnea event duration, the nasal pressure signal (dingnostic study) or PA P device flow signal (PA P titration study) should be utilized. When the diagnostic study sensors full or are inaccurate, altemative sensors mny be used (sec Technicnl Specifications for adults A.2 and A.4). RECOMMENDED</br>D</br>When baseline breathing amplitude cannot be easily determined (nnd when underlying breathing variability is large),</br>0	events can also be terminated when either there is a clear nnd sustuined increuse in breathing amplitude, or in the cnsc</br>where a desaturation has occurred, there is event nssociated resaturation or at least 211 o.  R!COMMl!NDEO</br>)</br>0</br></br></br></br></br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	57</br>.... f l\Ol tJU UlVI J f UAfQo,I     ....,   I    I      I  ' .....i,..     •...,., 1·,..._.1,.11o .;1</br>r</br>(</br>(</br>(</br>                                                                               r</br>c</br>c</br>c</br>(</br>c c</br>(</br>c c c c c c c</br>c c c</br>(</br>c c c c c c</br>(_</br>c</br>Scoring of Apneas	(</br>Score a respirutory event as an apnen when BOTH of the following criteria are met:&quot;1.'?-&quot; · 4 (see Figure I)  RECOMMENDED	c</br>There is a drop in the peak signal excursion by :!90% of pre-event baseline using an oronasal thermal sensor (diagnostic</br>study), PAP device flow (titration study) or an alternative apnea sensor (diagnostic study).</br>The duration of the   90% drop in sensor signal is   10 seconds.</br>Score un upnea as obstructive if it meets apneu criteriu and is associated with continued or increased inspiratory effort	c</br>throughout the entire period of absent uirftow. RECOMMENDED	(</br>Score an apnea as central if it meets apnen criteria and is associated with absent inspirntory effort throughout the	(</br>entire period of absent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airHow
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.   RECOMMENDED	(_</br>Score an upneu us mixed  if it meets apneu criteria and is associated with absent inspiratory effort In the initial portion	c</br>of the event, followed by resu mption of inspiratory effort in the second portion of the event. '5  RECOMMENDED	(_</br>58 AASM Scoring Manual Version 2.5	All Content	2018 American Academy of Sleep Medicine	l</br>(</br>..... I u.• Jlt-611 u•u• 7 I lUl -.J  . U• L   1. I •U+U.,.)IVI f&quot;'\VUltJ</br>(</br>r	Note 1.  Identification of an apnea does not require a m inimum desat uration criterion.</br>0	Note 2. lf a portion of a respiratory event that would otherwise meet criteria for a hypopnea meets criteria for apnea,</br>0	the enti re event should be scored as an apnea. See the example below.</br>(	meets hypopnea</br>f3	airflow criteria 	</br>(	Nasal</br>Pressure		35  sec 	</br>0</br>c</br></br>G	Oronasal</br>Thermal airflow</br>(</br>0</br>0</br>24 sec</br></br>•meets apnea	•</br>airflow criteria</br></br>0</br>0</br>0</br>0</br>0</br>D</br>0</br>0</br>0</br>D D</br>u</br>0</br>0</br>0</br>0</br>[J</br></br>D</br>....</br></br></br></br></br></br></br>L.</br></br></br></br></br></br>...</br>The longer duration, depicted by the white arrows in the nasal pressure channel,meets airflow criteria for a hypopnea, whereas the shorter duration, depicted by the black arrows in the oronnasal thermal airflow channel, meets airflow criteria for an apnea. The event would be scored as an apnea.</br></br></br>Note 3.  If the apnea or hypopnea event begins or ends during an epoch that is scored as sleep, then the correspond ing respi ratory event can be scored and included in the computation of the apnea-hypopnea index (AHi). This situation usually occurs when an individual has a high AHi with events occurring so frequently that sleep is severely disrupted and epochs may end up being scored as wake even though &lt;15 seconds of sleep is present during the epoch containing that portion of the respi ratory event. However, if the apnea or hypopnea occurs entirely during an epoch scored as wake, it should not be scored or counted towards the apnea-hypopnea index because of the difficu lty of defin ing a denominator i n this situation. If these occurrences are a           prominent feature of the polysomnogram and/or interfere with sleep onset, their presence should be  mentioned in the narrative summary of the study.</br>Note 4.  For altemative apnea sensors see Technical Specifications for adults (A.2).</br>Note 5.  There is not sufficient evidence to support a specific duration of the central and obstructive components of a mixed apnea; thus, specific durations of these components are not recommended.</br></br></br></br></br>Scoring of Hypopneas</br>Scoring hypopneas as central or obstructive events is optional as noted i n Parameters to be Reported (11.F).</br></br>IA. Score a respiratory event as a hypopnea if A LL or the following criteria arc mct::-.0 1·&quot;'2·:-.:3 (see Figure 2)  RECOMMENDED</br>The peak signal excursions drop by 230% of pre-event baseline usi ng 
<mark class="entity" style="background: #f032e6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nasal pressure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ROUTE</span>
</mark>
 (diagnostic study), PAP device flow (titration study), or an altemative hypopnea sensor (diagnostic study).</br>The duration of the ?30% drop in signal excursion is :::IO seconds.</br>There is a &quot;2:3% oxygen desat uration from pre-event baseline or the event is associated with an arousal.</br></br>I 8.Score a respiratory event as a hypopnca if A LL or the following criteria arc met: &quot;1·1'o;l.S.l   ACCEPTABLE</br>The peak signal excursions drop by 2'.30% of pre-event baseline usi ng 
<mark class="entity" style="background: #f032e6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nasal pressure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ROUTE</span>
</mark>
 (diagnostic study), PAP device flow (titration study), or an altemative hypopnea sensor (diagnostic study).</br>The duration of the  30% drop in signal excursion is :::w seconds.</br>There is a  
<mark class="entity" style="background: #42d4f4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">STRENGTH</span>
</mark>
 oxygen desaturation from pre-event basel i ne.</br></br>Ir electing to score obstructive hypopncas, score u hypopnca as obstructive if ANY of the following criteria ure met: RECOMMENDED</br>There is snoring during the event.</br>There is increased inspiratory flattening of the nasal pressure or PA P device flow signal compared to baseline breathing.</br>There is an associated thoracoabdominal paradox that occurs during the event but not during pre-event breathing.</br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	59</br></br>1' ··I......  ..,•• ,.,..-...... , I.,.,.. ....   I  (.Iii  I   I. I ll.ul.,..,&gt;  
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    l\,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
..U   t·'\._.1,..,hJ</br>If electing to score centrul hypopneas, score u hypopnea us central if NON E of the following criteria ure	c­</br>met:   RECOMMENDED	c</br>There is snoring during the event.</br>There is increased inspiratory flattening of the nasal pressure or PAP device flow signal compared to baseline breathing. c.There is an associated thoracoabdominal paradox that occurs during the event but not during pre-event breathing.</br>c</br>(-</br>(</br>(</br>c c c</br>c</br> 		(</br>Scoring Respiratory Effort-Related Arousal	c</br>Scoring respiratory effort-related arousals is optional as noted in Parameters to be Reported (11.F).	c</br>t. If electing to score respiratory effort-related urousuls, score u respiratory event as a respiratory effort-related arousal	c</br>(RERA) if there is a sequence of breaths lusting  10 seconds characterized by increasi ng respiratory effort or by	c</br>flatteni ng of the inspiratory portion of the nusnl pressu re (diagnostic study) or PA P device flow (titration study)</br>wuveform leadi ng to arousal from sleep when the sequence of breaths does not meet criteria for an apnea or hypopnea.</br>(see Figure 3) RECOMMENDED	(</br>c</br>c c c c c c c c c c c c</br>(_</br>c</br> 		c</br>F.Scoring   Hypoventilation	(_</br>Monitoring hypovenlilalion is optional as noted i n Parameters to be Reported (11.F).	(</br></br>If electing to score hypoventilation, score hypoventilution during sleep if EITHER of the below occur: '1· 2   RECOMMENOED</br>There is an increase in the arterial PC02 (or surrogate) to a value &gt;55 mm Hg for 2:10 m inutes.</br>There is   10 mm Hg increase in arterial PC02 (or surrogate) during sleep (in comparison to an awake supine value) to a</br>value exceeding 50 mm Hg for  10 minutes.	r</br></br></br>60  AASM Scoring ManualVersion 2.5</br>AH Content	2018 American Academy of Sleep Medicine	c</br>(</br>r</br>0</br>0</br>0</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    t
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
</br></br>(</br>Scoring Cheyne-Stokes Breathing</br>0</br>Score a respiratory event ns Cheyne-Stokes breathing if BOTH of the following arc met:  '·? (see Figure 4)   REcoMMENDED</br>L	a. There are episodes of ?;:3 consecutive central apneas and/or central hypopneas separated by a crescendo and decrescendo</br>0	change in breathi ng amplitude with a cycle length of !::40 seconds.</br>b. There are ?;:5 central apneas and/or central hypopneas per hour of sleep associated with the crescendo/decrescendo</br>0	breathing pattern recorded over ?;:2 hours of monitoring.</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D D 0</br>0</br>D D 0 D D D</br></br></br></br></br></br></br></br>All Content © 2016 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	61</br>VIII. Respiratory Rules Part 2: Rules for Children	( (</br>l</br>(</br>Ages for Which Pediatric Respiratory Scoring Rules Apply	(</br>Criteria for respiratory events during sleep for infants and children can be used for children &lt;18 years, but on	c</br>c</br>(</br>c c c c</br>Technical Specifications	c</br>(</br>1. For identification or an apnea during a diagnostic study, use an oronasal thermal airflow sensor to monitor</br>airflow.'1 RECOMMENDED</br>For identification or an apnea during a diagnostic study when the oronasal thermal airflow sensor is not functioning or the signal is not reliable, use one of the following (alternative apnea sensors):'1	</br>nasal pressure transducer (with or without square root transformation) RECOMMENDED</br>Respiratory inductance plethysmograph y sum (RIPsum) (calibrated or uncalibrated) RECOMMENDED</br>Respiratory inductance plethysmography flow (RIPflow) (calibrated or uncalibrated) RECOMMENDED</br>end-tidal PC02 ACCEPTABLE	c</br>For identification or a hypopnea during a diagnostic study, use a nasal pressure transducer (with or without square	c</br>root transformation of the signal) to monitor airflow. '' RECOMMENDED	c</br>For identification of a hypopnea during n diagnostic study when the nasal pressure transducer is not functioning or the</br>signal is not reliable, use one of the following to monitor airflow (alternative hypopnea sensors):'2</br>oronasal thermal airflow    RECOMMENDED</br>RIPsum (calibrated or uncalibrated) RECOMMENDED</br>RIPflow (calibrated or uncalibrated) RECOMMENDED</br>dual thoracoabdominal RIP belts (calibrated or uncalibrated) RECOMMENDED</br>During positive airway pressure (PAP) titration, use the PAP device flow signal to identify apneas or	c</br>hypopneas.   RECOMMENDED	c</br>For monitoring respiratory effort, use one of the following:	l</br>esophageal manometry    RECOMMENDED</br>b. dual thoracoabdominal RIP belts (calibrated or uncalibrated) RECOMMENDED	c</br>For monitoring oxygen saturation, use pulse oximetry with a maximum acceptable signal averaging time of ≤3 seconds</br>at a heart rate of 80 beats per minute. RECOMMENDED</br>(</br>For monitoring snoring, use an acoustic sensor (cg, microphone), piezoelectric sensor or nasal pressure</br>transducer.' RECOMMENDED</br>For detection or hypoventilation du ring a diagnostic study, use arterial PC02, transcutaneous PC02 or end-tidal	c</br>PC02.:\S,'.'in   RECOMMENDED	c</br>For detection or hypoventilation during PAP titration, use arterial PC02, or use transcutaneous	c</br>PC02.:&quot;.:&quot;6 RECOMMENDED</br>c</br>c</br>l.</br></br>62  AASM Scoring Manual Version 2.5</br>All Content © 2018 American Academy of Sleep Medicine	(</br>(</br>c</br>c	Note 1.   Thermal sensors include thermistors, thermocouples, or 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polyvinylidene fluoride
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (PV DF) airflow sensors.</br>(	Note 2.  The RIPsum is the sum of the signals from thoracic and abdominal RI P sensors (belts) and excursions in the signal are an estimate of tidal volume. The RIPflow is the time derivative of the RIPsum and excursions in</br>0	the signal are an estimate of airflow. Recording of RIPsum or RIPflow is optional.</br>l	Note 3. Using the nasal pressure signal without square root transformation for scoring hypopneas will result in a</br>B	slightly higher hypopnea index than scoring using a square root transformation of the signal. This difference is not clinically significant in most patients.</br>(</br>Note 4.  Monitoring snoring is optional, as noted in Parameters to be Reported (11.F).</br>Note 5.   Monitoring hypoventilation during diagnostic study is recommended, as noted in Parameters to be Reported</br>0	(II.F). Monitoring hypoventilation during PAP titration is optional, as noted in Parameters to be Reported</br>0	(II.F)</br>Note 6.  a. Clinical judgment is essential when assessing the accuracy of end-tidal PC02 and transcutaneous PC02</br>readings. The values should not be assumed to be accurate surrogates of the arterial PC02 when the values</br>0	do not fit the clinical picture.</br>0	b. The transcutaneous PC02 sensor should be calibrated with a reference gas according to the manufacturer's recommendations and when the accuracy of the reading is doubtful. Of note, the value of the</br>0	transcutaneous PC02 typically lags behind changes in the arterial PC02 by two minutes or more.</br>0	c. The end-tidal PC02 often malfunctions or provides falsely low values in patients who have marked nasal</br>0	obstruction, profuse nasal secretions, are obligate mouth breathers, or who are receiving supplemental 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 It is crucial to obtain a plateau in the end-tidal waveform for the signal to be considered valid.</br>0</br>0</br>0</br></br>0</br>0</br>0</br>0</br>0</br>D D D 0</br></br></br></br></br>L</br></br></br></br>r</br></br></br></br>....</br>Measuring Event Duration</br>Same as Measuring Event Duration in adults (B.1-3):&quot;1•,:\2    RECOMMENDED</br></br></br></br></br></br>Scoring of Apneas</br>Score a respiratory event as an apnea when A LL of the following criteria are met: :'lil,:'li.:'li3.&quot;·:-;5.w.  RECOMMENDED</br>There is a drop in the peak signal excursion by ≥90% of pre-event baseline using an oronasal thermal sensor (diagnostic study), PAP device flow (titration study), or an alternative apnea sensor (diagnostic study).</br>The duration of the ≥90% drop in sensor signal lasts at least the minimum duration as specified by obstructive, mixed, or central apnea duration criteria.</br>The event meets respiratory effort criteria for obstructive, central or mixed apnea.</br></br>Score on apnea as obstructive if it meets apnea criteria for at least the duration of 2 breaths during baseline breathing AND is associated with the presence of respiratory effort throughout the entire period of absent airflow. RECOMMENDED</br></br>Score on apnea as central if it meets apnea criteria, is associated with absent inspiratory effort throughout the entire duration of the event AND at least one of the following is met:   RECOMMENDED</br>The event lasts ≥20 seconds.</br>The event lasts at least the duration of two breaths during baseline breathing and is associated with an arousal or a ≥3% arterial oxygen desaturation.</br>The event lasts at least the duration of two breaths during baseline breathing and is associated with a decrease in heart rate to less than 50 beats per minute for at least 5 seconds or less than 60 beats per minute for 15 seconds (infants under I year of age only).</br></br></br></br></br>All Content © 2016 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	63</br>...... ............... -...,··-·--·-·-	--- - - .. ..</br>Score an apnea as mixed if it meets apnea criteria for at least the duration of 2 breaths during baseline breathing AND        ( is associated with absent respiratory effort during one portion of the event AN D the presence of inspiratory effort in	( another portion, regardless of which portion comes first.   RECOMMENDED	(</br>c</br>c</br>(-</br>(</br>c c c</br>(</br>(</br>c c c c</br>(</br>c</br> 		(</br>Scoring of Hypopneas	(</br>Scoring hypopneas as central or obstructive events is optional as noted in Parameters to be Reported (11.F).	c</br>Score a respiratory event as a hypopnea if A LL of the following criteria are met:&quot; &quot;'&quot;   RECOMMENDED</br>The peak signal excursions drop by ≥30% of pre-event baseline using nasal pressure (diagnostic study), PA P device flow (titration study) or an alternative hypopnea sensor (diagnostic study).</br>The duration of the ≥30% drop in signal excursion lasts for ≥2 breaths.</br>There is a ≥3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.</br>If electing to score obstructive hypopneas, score a hypopnea as obstructive if AN Y of the following criteria are			c</br>met: RECOMMENDED	c</br>There is snoring during the event.</br>There is increased inspiratory flattening of the nasal pressure or PA P device How signal compared to baseline breathing. c. There is an associated thoracoabdominal paradox that occurs during the event but not during pre-event breathing.</br>If electing to score central hypopneas, score a hypopnea as central if NONE of the following criteria are			c</br>met: RECOMMENDED	c</br>There is snoring during the event.</br>There is increased inspiratory flattening of the nasal pressure or PA P device flow signal compared to baseline breathing.</br>There is an associated thoracoabdominal paradox that occurs during the event but not during pre-event breathing.	c</br>c c c c c</br>l</br>c c</br>64     AASM Scoring Manual Version 2.5	All Content IC&gt; 2018 American Academy of Sleep Medicine		c c</br>c</br>(	F. Scoring Respiratory Effort-Related Arousal</br>(	Scoring respiratory effort-related arousals is optional as noted in Parameters to be Reported (11.F).</br>0	1. If electing to score respiratory effort-related arousals, score a respiratory event as a R ERA if there is a sequence of breaths lasting ≥2 breaths (or the duration of two breaths during baseline breathing) that do not meet criteria for an apnea or hypopnea und lead to un arousal from sleep. The breathing sequence can be characterized when one or more</br>0	of the following is present: RECOMMENDED</br>(	a. Increasing respiratory effort</br>b. Flattening of the inspiratory portion of the nasal pressure (diagnostic study) or PAP device flow (titration study) waveform</br>0	c. Snoring</br>0	d. An elevation in the end-tidal PC02 above pre-event baseline</br>0	 	</br>0	G. Scoring of Hypoventilation</br>0	Monitoring hypoventilation in children is recommended during a diagnostic study and optional during a PA P titration study.</br>(	t. Score us hypoventilation during sleep when &gt;25%, of the total sleep time us measured by either the arterial PC02 or</br>0	surrogate is spent with a PC02 &gt;50 mmHg.'1   ' RECOMMENDED</br>0	Note I. See Technical Specifications for children (8.9 and B.10) for information on surrogate signals for monitoring	</br>hypoventilation.</br>0	Note 2. Use the following conversion factor in order to change the units of the pressures listed from mm Hg to kPa:</br>0	1 mm Hg	0.133 kPA.</br>0</br>0</br>0	H. Scoring of Periodic Breathing</br>D	1. Score a respiratory event as periodic breathing if there are ≥3 episodes of central pauses in respiration (absent airflow</br>0	und inspiratory effort) lusting &gt;3 seconds separated ≤20 seconds of normal breathing.'1 RECOMMENOED</br>0</br>0</br>0</br>0</br>0</br>0</br>D</br>0</br>0</br></br></br></br></br></br></br></br></br></br></br></br>...</br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM  Scoring Manual Version 2.5	65</br>IX. Home Sleep Apnea Testing (HSAT) Rules for Adults	(</br>Part 1: HSAT Utilizing Respiratory Flow and/or Effort Parameters	(</br>Recommended parameters must be reported. Optional parameters may be monitored at the discretion of the clinician or investigator and if monitored, should be reported.</br></br></br></br>	</br>General Parameters to be Reported &quot;</br></br>Type or device</br></br>Type orairflow sensor(s)&quot;</br></br>Type orrespiratory effort sensor(s) (single or dual)</br></br>Oxygen saturation</br></br>Heart rate (ECG or derived from oximeter)</br></br>Body position</br></br>Sleep/wake or monitoring time (method  or determination)''</br></br>Snoring (acoustic or piezoelectric sensor or signal dcri,·ed from nasal pressu re sensor)</br></br></br></br></br></br></br>Recording Data to be Reported if Sleep is NOT Recorded</br></br>Recording start time (h r:min)	RECOMMENDED</br></br>Record ing end time (hr:m in)	RECOMMENDED</br>Total recording time (TRT) min (including wake and artifact)	RECOMMENOED	c</br>(.</br>Monitoring time (MT) &quot;in min (time used to calculate respi ratory event index)'1	RECOMMENDED</br></br>Heart rate (average, highest, lowest)	RECOMMENDED</br>(</br>Nu mber or respiratory events (RE)	RECOMMENDED</br></br>6a. Number or apneas	RECOMMENDED</br></br>6b. Nu mber of hypopneas	RECOMMENDED</br></br></br></br>66   AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine</br>r.</br>(	6c. Number  of obstructive, central, and  mixed  apneas	OPTIONAi..</br>(	7.Respiratory event index {REI) hosed on monitoring time (MT) =</br></br>0	(# respiratory events x 60) I MT in m in</br>RECOMMENDED</br></br>0	8. REI in the supine and non-supine positions	OPTIONAL</br>[	- ---------</br>I</br></br>9.Central apnea index (CAI) = (# central opneas x 60) I MT in min</br>0</br>OPTIONAi..	I</br>!</br></br>0	10. A measure of oxygen saturation (one of these th ree parameters)&quot;	RECOMMENDED	I</br>0	I</br></br>0</br>0	I-</br>0</br>0</br>IOa. Oxygen desaturation index (ODI) ::!3 or ::!4% = (# oxygen desatu rations  3% or  4% x 60) I</br>MT in min [Specify measure of desaturation   3 or ::!4%1&quot;</br>IOb. Arterial oxygen saturation, mean value, maximum value, and minimu m value toe. A rterial oxygen saturation % of time at or below 88% or other thresholds</br>:--1</br>:	I</br></br>j</br></br>0	11. Occurrence of snoring (if recorded)	OPTIONAL	_I</br>0</br>0	Note I. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Monitori
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 ng time (MT) = Total recording time minus periods of artifact and time the patient was awake as</br>0	determined by actigraphy, body position sensor, respiratory pattern, or patient diary. The method used to determine MT should be stated. For reimbursement purposes, ind ividual practitioners may need to indicate</br>in their HSAT report that monitoring time (MT) is being used in place of total recording time (TRT).</br>0	Note 2. Respiratory event index (REI) - Total number of respiratory events scored x 60 divided by monitoring time</br>0	(MT). For reimbursement purposes, individual practitioners may need to indicate in thei r HSAT report that</br>0	REI is a surrogate for A Hi.</br>Note 3.  Reporting all three parameters may provide important information for the clin ician.</br>0</br>Note 4.  ODI shou ld report the same desaturation as used for scoring hypopneas. For example, if hypopnea is scored</br>0	based on a  3° D desaturation, the ODI should be the number of  3° o desaturations x 60 divided by MT.</br>D</br>0	 	</br>D	C. Recording Data to be Reported if Sleep is Recorded</br>0</br>0	I. Recordi ng start time (hr:min)	RECOMMENDED</br>D	2. Recording end time (hr:m in)	RECOMMENDED</br>Total recording time (TRT) m in (including wake and artifact)	RECOMMENDED</br></br>Total sleep time (TST) in min	RECOMMENDED</br></br>Heart rote (overage, highest, lowest)	RECOMMENDED</br></br></br>Nu mber of respiratory events (R E)	RECOMMENDED</br></br></br>611. Number  of apneus	RECOMMENDED</br></br>6b. Number  of hypopneas	RECOMMENDED</br></br>6c. Nu mber of obstructive, central, and mixed apneas	OPTIONAL</br></br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AAS Scoing 11/ arual Versto'l 2.	67</br></br></br>c</br>Apneu-hypopneu index (AH I) = ((# upneus +# hypopneus) x 60) I TST in min&quot;	RECOMMENDED	(</br>AH i in the supine und non-supine positions	OPTIONAL	(</br>c</br>Centrul upneu index (CAI) = (# central upneus x 60) I TST in min	OPTIONAL	(</br>A meusure of oxygen suturution (one or these th ree purumeters)'	RECOMMENDED	(</br>(</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IOu
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. Oxygen desuturution index (ODI)  3 or  41Vo = (# oxygen desuturutions   3% or  4o/., x 60) I</br>TST in min ISpecify measu re of desuturution 3 or 4%) '</br></br>10b. Arterial oxygen sutu rution, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meun
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vulue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    maximu
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 m 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vulue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, und mi nimum vulue	c</br>IOc. 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Arteriul oxygen sutu rution
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
  % of time ut or below 88% or other th resholds	c</br>Occurrence of snoring (if recorded)	OPTIONAL	(</br>c</br></br></br></br></br></br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 2.</br>c</br>Reporting all three parameters may provide important information for the clinician.</br></br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 I. This assumes monitoring EEG, EOG, and submental chin EMG.</br>report the same desaturation as used for scoring hypopneas. For example, if hypopnea is scored	c</br></br>Note 3.</br>OD! should</br>based on a &gt;3°., desatu ration, the 001 should be the number of &gt;3°o desaturations x 60 divided by TST.</br>c</br></br> 	c</br></br>Summary Statements</br></br>Dute of test/d ute of interpretution</br></br>Technical udequucy of study (defined by sleep center policy und procedure)</br>(</br>c</br>RECOMMENDED	c</br>RECOMMENDED	c</br>c</br></br>2u. Document repeut study for technicul failures	RECOMMENDED	c</br>2b.Limitations of study	RECOMMENDED	c</br></br></br>(_</br>lnterpretution of REI (bused on MT) or AH i (if sleep is recorded)	RECOMMENDED</br>(</br>Occurrence of snoring	OPTIONAL	c</br></br></br>I nter pretution</br>RECOMMENDED	c</br>(</br></br>Su. Study supports diagnosis of OSA or not			RECOMMENDED	c</br>Sb. Statement of diugnostic severity (iruppllcuble)	RECOMMENDED	c</br>Sc. If study is non-diugnostic, recommend in-luborutory PSG (if clinically indicuted)	RECOMMENDED</br>(_</br>Printed nume und signature of interpreting physician (\•erifying rc,•iew of raw dutu)	RECOMMENDED	c</br>Recommendation for munagement that meets AASM Clin ical Practice Guidelines und</br>RECOMMENDED</br>Practice Parameters</br></br></br>Chain of custody (if upplicuble)	OPTIONAL	(_</br>l</br>(</br>68	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>c</br>,,..,.• •-•,.•- -•--If'&quot;' ' 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    •f'&quot;'••
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 -- 'w -••••o ,, • -• •• I • • -·-- •-• • ·--• •-</br>(	 	</br>(	E. Technical and Digital Specifications: HSAT Equipment Recording Features</br>r</br>r	I.FDA uppronl of device	RECOMMENDED</br>0	2. Unique identifier for cuch unit	RECOMMENDED</br></br></br>f	3. Must meet min imum definition for CPT codes 95800, 95801 or 95806'&quot;	RECOMMENDED</br>0</br>n	4.Ability to record oximctry	RECOMMENDED</br>0	5.Ability to record u mcusu re of heurt rate	RECOMMENDED</br>0</br>0	6.Ability to displuy ruw data for review, munuul scoring or editing ofautomated scoring !	RECOMMENDED</br></br>0	7.Ability to calculate u respiratory C\'ent index (REI) bused on mon itoring time (MT) as a</br>n	surrogute for the apnea-hypopncu index (AH i) determined by PSG</br></br>RECOMMENDED</br></br>0	8.Ability to determine chain of custody	OPTIONAL</br>0</br>0	Note I. 95800-Slecp study, unattended , simultaneous recording; heart rate, oxygen saturation, respi ratory analysis</br>0	(eg, by airflow or peripheral arterial tone), and sleep time</br>95801-Sleep study, unattended , simultaneous recording; heart rate, oxygen saturation, respi ratory analysis</br>0	(eg, by airflow or peripheral arterial tone)</br>0	95806-Sleep study, unattended , simultaneous recording; heart rate, oxygen saturation, respi ratory airflow</br>0	and respiratory effort (eg, thoracoabdominal movement)</br>Note 2.   Raw tracings must be viewable in detail with the abil ity to edit events.</br>0</br>0	 	</br>0	F. HSAT Respiratory Events Rules: Tech nical Specifications</br>0</br>For identification of rcspirutory C\'cnts (RE) bused on respiratory uirHow during u home sleep apncu test (HSAT)</br>0	diagnostic study, use ut lcust one of the following sensors:•</br>0	a. oronasal thermal airflow sensor:\&quot;! RECOMMENDED</br>b. nasal pressure transducer (with or without square root transformation) &quot;3 &quot; RECOMMENDED</br>0	c. alternative sensors include:</br>0	i. respi ratory inductance plethysmography sum (R I Psum) or flow ( RI Pflow)  RECOMMENDED</br>i i. PVDFsum  ACCEPTABLE</br>0</br>For mon itoring rcspirutory clfort,:\6  use one of the following technologies:</br>dual thoracoabdom i nal  R IP belts'5	RECOMMENDED</br>0	b. single thoracoabdominal RI P belts:-.' 5 ACCEPTABLE</br>[)	c. single or dual thoracoabdominal PV DF belts 5  ACCEPTABl.E</br>d. single or dual thoracoabdominal piezo beltsss  ACcePTABLI</br>0	e. single or dual pneumatic beltsS5   ACCEPTABLE</br>0	3.For monitoring oxygen saturation, use pulse oximctry.-.;7 RECOMMENDED</br>0	4.For monitoring snoring, use an acoustic sensor (cg, microphone), piezoelectric sensor or nasal pressure</br>0	transducer. OflllONAL</br></br></br></br>All Content	2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	69</br>•t •• I 1-•••- _,,,_ -,.. I ,.,..,,.     t _._ ..•••:w •• f.._r 'I' I '----- ._,  ---t •T	-  -  .;J      - -.-  ....  - J	-  - - -  - -</br>(</br>l</br>(</br>c</br>('</br></br>c</br>(</br></br>l</br>c c c</br>(</br></br>c</br>c</br></br></br>HSAT Respiratory Events Rules: Scoring Apnea Utilizing Respiratory Flow	(_</br>and/or Effort Sensors</br>Score a respiratory e\•cnt as an apnea when BOTH of the following criteria arc met:&quot;·-;i,&quot;'·l.&quot; RECOMMENDED</br>There is a drop in the peak signal excursion by   90% of pre-event baseline usi ng a recommended or alternative airflow sensor.</br>The duration of the   90% drop in sensor signal is   10 seconds.	c</br>Score an apnea as obstructive if it meets apnea criteria and is associated with continued or increased inspi ratory effort	c</br>throughout the entire period of absent 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    airHow
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.   RECOMMENDED	c</br>Score an apnen as central ir it meets apnea criteria and is associated with absent inspiratory effort throughout the</br>entire period of absent airflow.   RECOMMENDED	c</br>Score an apnea as m ixed if it meets apnea criteria and is associated with absent inspirntory effort in the in itial portion</br>of the e\'ent, followed by resumption of inspiratory effort in the second portion of the event.  RECOMMENDED</br></br>c c c c c c c c c c</br>(</br>(</br></br>70 AASM Scoring Manual Version 2.5</br>All Content © 2018 American Academy of Sleep Medicine	(</br>(</br>r</br>0	H. HSAT Respiratory Events Rules: Scoring Hypopnea Utilizing Respiratory Flow</br>0	and/or Effort Sensors:\l</br>0	IA. Ifsleep is NOT recorded, score a respi ratory event as a hypopnea if A LL of the followi ng criteria arc</br>met: :\&quot;I RECOMMENDED</br>0	a. The peak signal excursions drop by '2::30% of pre-event baseline using a recommended or alternatfre airflow sensor.</br>(	b. The duration of the ;::30% drop i n signal excursion is ;::JO seconds.</br>0	c. There is a ;::3% oxygen desaturation from pre-event baseline.</br>18.I f sleep is NOT recorded, score a respiratory event as 11 hypopnea if A LL of the following criteria arc</br>1</br></br>c	met: &quot;</br>ACCEPTABLE</br></br>The peak signal excursions drop by ;::30% of pre-event basel i ne using a recom mended or alternatfre airflow sensor.</br>;::JO seconds.</br>0	b. The duration of the ;::30% drop in signal excursion is</br>c. There is a 2:4% oxygen desaturation from pre-event baseline.</br>0</br>1   2</br></br>0	2A. If sleep IS recorded, score a respiratory event as 11 hypopnea if A LL of the following criteria arc met: :-.-·&quot;</br>RECOMMENDED</br></br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br></br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>(</br>0</br>r</br></br>0</br>,</br></br></br>r</br></br>r</br></br></br>....</br>The peak signal excursions drop by ;::30% of pre-event baseline using a recommended or altematiFe airflow sensor.</br>The duration of the ;::30% drop i n signal excursion is 2:10 seconds.</br>There is a 2:3% oxygen desaturation from pre-event basel i ne or the event is associated with an arousal. :\Z</br>Irsleep IS recorded, score a respiratory e\•ent as a hypopnea if A LL of the followi ng criteria are met: :-.-i.:--2     ACCEPTABLE</br>The peak signal excursions drop by ;::30% of pre-event baseline using a recommended or alteriwtil'e airflow sensor.</br>The duration of the ;::30% drop i n signal excursion is ;::10 seconds.</br>There is a :::4% oxygen desatu ration from pre-event baseline.</br></br></br>Note I. The criteria used to score a respi ratory event as a hypopnea should be specified in the report. Note 2. Scoring a hypopnea based on arousals is only possible if sleep is recorded.</br></br></br></br></br></br>I.References</br>The following references apply to content th roughout chapter IX. Home Sleep Apnea Testing (HSAT) Ru les for Adults Part 1: HSAT Utilizi ng Respiratory Flow and/or Effort Parameters.</br>Collop NA, Anderson WM, Boehlecke B, et al.; for the Portable 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Monitori
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 ng Task Force of the American Academy of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sleep Med icine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. J Cli11 Sleep Med. 2007;3(7):737-747.</br>Collop NA, Tracy SL, Kapur V, et al. Obstructive sleep apnea devices for out-of-center (OOC) testi ng: technology evaluation. J Clin Sleep Med. 20l l ;7(5):531-548.</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>All Content © 2018 American Academy of Steep Medicine	AASM Scoring Manual Version 2.5	71</br>IX. Home Sleep Apnea Testing (HSAT) Rules for Adults	l</br>Part 2: HSAT Utillzing Peripheral Arterial Tonometry (PAT)	c</br>Recommended parameters must be reported. Optional parameters may be monitored at the	(</br>discretion of the clinician or investigator and if monitored, should be reported.	c</br>(</br> 		l</br>General Parameters to be Reported	c</br>c</br>Type of device	RECOMMENDED	c</br>Sleep/wake and REM time estimates (derived from actigra phy)	RECOMMENDED</br>(</br>Airflow/effort surrogate (peripheral arterial tone) signals	RECOMMENDED	c</br>Oxygen saturation	RECOMMENDED	(</br>c</br>Heart rate	RECOMMENDED	c</br></br>Occu rrence of snoring (if recorded)</br>OPTIONAL	c</br>I	c</br></br>Body position (if recorded)</br></br></br></br>Recording Data to be Reported</br>_I	OPTIONAL	c</br>c</br>c</br></br>Record ing start time (hr:min)	RECOMMENDED	c</br>Recording end time (hr:min)	RECOMMENDED	c</br>c</br>Duration of recording (hr:m in) (totul recording time, TRT)		RECOMMENDED	c</br>Estimutcd sleep time (in m in)	RECOMMENDED	(_</br>(</br>411. Estimated 0 o REM, deep sleep, light sleep	OPTIONAL</br>(_</br>Heart rate (a\ cragc, highest, lowest)	RECOMMENDED	c</br>Respiratory  event indc'\: (R EI; use peripheral arterial tonometQ  A H i (pAHI) as u surrogate</br>RECOMMENDED</br>for REI)</br>Oxygen desaturation index (ODI) 4°o	(# oxygen desaturations &gt;4° u x 60) I MT in min	 RECOMMENDED	c</br>c c c c c</br>(</br>c</br>c.</br>72	AASM Seo 1	M	Jal Version ? 5	A C..orte,,t	.m18 Amencan Acade'lly of Slee,J Medi inc	c</br>c</br>[</br>C. Summary Statements</br>0</br>Date of test/Date of interpretation	RECOMMENDED</br>0</br>0	2. Technical adequacy of study (defined by sleep center policy and procedure)	RECOMMENDED</br>fJ	2a. Document repeat study for technical failures	RECOMMENDED</br>n</br>Cl	2b. Lim itations of study	RECOMMENDED</br>0	3. Inter pretation of estimated sleep time	RECOMMENDED</br>n</br>0	4. Occurrence of snoring	OPTIONAL</br>0	5.I nter pretation	RECOMMENDED</br>0	5a. Study supports diagnosis of OSA or not	RECOMMENDED</br>0</br>n	5b. Statement of diagnostic severity (if applicable)	RECOMMENDED</br>0	5c. If study is non-diagnostic, recom mend in-laboratory PSG (if clinically indicated)	RECOMMENDED</br>0</br>6. Printed name and signature of interpreti ng physician (\·erifyi ng review of raw data)	RECOMMENDED</br>0	7.Recommendation for management that meets AASM Clinical Practice Gu idelines and</br></br>)	Practice Parameters</br>RECOMMENDED</br></br>0	8.Chain of custody (if applicable)	OPTIONAL</br>0</br>[</br>0	D. Technical and Digital Specifications: HSAT Equipment Recording Featu res</br>FDA approval of device	RECOMMENDED</br>0</br>0	2. Unique identifier for each unit	RECOMMENDED</br>0	3. Must meet m in imum definition for CPT codes 95800 or 95801	RECOMMENDED</br>4. Ability to record oximetry	RECOMMENDED</br>0</br>J	S. Ability to record a measure of heart rate	RECOMMENDED</br>l	6. Ability to display raw data for review, manual scoring or editing of automated scoring &quot;!	RECOMMENDED</br></br></br>Ability to calcu late REI (a surrogate apnea-hypopnea index (AHi))	that is analogous to apnea-hypopnea index (A H i) used for in-laboratory PSG</br></br></br>RECOMMENDED</br></br></br>Ability to determine chain of custody	OPTIONAL</br></br></br></br></br></br></br></br></br></br>AllCont n</br>018 Arr'  n   n A    u  n of S	p II.  d1  ri</br>AASM Scormq Man  al Version 2.':&gt;	73</br>t ••I ......,,,_ -·--... 4 ,,..,,_,_ I_ .........iZ]  \ 4 ·-I' ..' .·-·-... ·-· I·--··- -· - -	;::.    •• 'r</br>(</br>l</br>(</br>(</br>c</br>(</br>(</br>c</br> 		(</br>HSAT Respiratory Event Rules: Technical Specifications	l</br>For Identification ofrespirutory events (RE) based on peripherul arterial tone during n home sleep apnca test (HSAT) c diagnostic study, use peripheral  arterial tone, oxygen  desaturution  and changes in  heart rate derh·ed  from	c oximctry.'1       ACCEPTABLE	c</br>2. For monitoring oxygen  saturation, use pulse oximctry.   RECOMMENDED	c</br>c</br>(</br>c c</br>References	c</br>The followi ng references apply to content th roughou t chapter IX. Home Sleep 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Apnca
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Testing (HSAT) Rules for Ad u lts</br>Part 2: HSAT Utilizing Peripherul A rterial Tonometry (PAT).</br>(</br>Collop NA, Anderson  WM, Boehlecke B, el al.; for the Portable Monitoring Task Force of the American Academy of Sleep</br>Med 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    icine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. Clinical gu idelines for the use of unattended  portable monitors in the diagnosis of obstructive sleep apnea i n	c</br>adult patients. J Clin Sleep Med. 2007;3(7):737-747.	c</br>2. Collop NA, Tracy SL, Kapur V.et al. Obstruct ive sleep apnea devices for out-of-center (OOC) testing: technology</br>evaluation. J Clin Sleep Med. 2011;7(5):531-548.</br>(</br>c</br>(_</br>(</br>c c c c c c c c c c c</br>(_</br>(_</br>74	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>c</br>(</br>c</br>(</br>0</br>CJ</br>B</br>c</br>[</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>D 0</br>0</br>D</br></br></br>r</br>...</br></br></br>..</br>..</br>Development Process</br></br></br></br></br>Development of Version 2.0</br>The principal  participants in the development of Version 2.0 of The AASM Mm111al for the Scoring c?f Sleep a11d Associated El'e111s: Rules, Terminology and Technical Specifications (AASM  Scoring Manual) included: (a) the Scoring Manual Commit­ tee of 5 clinicians with a range of expertise,  I tech nologist and I board l iaison appointed by the A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    merican
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Academy of Sleep Medicine (AASM) Board of Directors. (b) the 13 members of the Sleep Apnea Defin itions (SA D) Task Force appointed by the AASM Board of Di rectors and (c) the science and research, graphics, communications. and  information technology staff of the AASM. All Scoring Manual Com mittee members completed AASM conflict of i nterest statements. Scoring Manual Com mittee members d id not have any level I conflicts of i nterest with any medical device that might be affected by the development of any recom mendation. The SAD Task Force consisted of 9 of the original 13 individuals who authored the evidence review 1 used to develop the 2007 respi ratory scoring rules and 4 additional respiratory scoring experts. After a review of the literature. the task force developed recommendations on the sensors and rules to be used for scoring respiratory events, wh ich were subsequently approved by the AASM Board of Di rectors. More information on the methods used and the evidence examined by the SAD task force may be found in the 2012 review paper publ ished i n the Journal of Clinical Sleep Medici11e.1</br></br>The content of the chapters on parameters to be reported, technical and digital specifications, visual rules (now sleep staging rules), arousal rules, card iac rules and movement rules remains largely unchanged from the first edition of the AASM Scoring Manual published in 2007. The 2007 manual shou ld be consu lted for the development process of these chapters.3 The Scoring Manual Com mittee, two members of which also served on the SAD Task Force, drafted ru les for a new respiratory chapter based on the recommendations i n the SAD Task Force review paper.2 Headings and formatting throughout the manual were edited for clarity and consistency. Critical termi nology was made up-to-date and consistent. The use of certain defi nitions in the manual were made into rules to emphasize their importance. Scoring Manual FAQs from the AASM website were incorporated as notes  i n the appropriate sections of the manual. Al ready existing notes i n the manual were examined for relevance and clarity. New figures were designed for the sleep staging rules chapter that better illustrate the ru les for scoring sleep stages. Upon completion of the edits, all rules, figures and notes were re-edited and re-voted on until there was consensus agreement among the commit­ tee. The AASM Board of Directors approved Version 2.0 of the A ASM Scoring Manual i n July 2012.</br> 	- - - - - - -- -	- - 	</br>Future Versions</br>According to the tenets of evidence-based medici ne, clinical decision-making should be guided by the best evidence from the research field, the expertise of the clin ician, and the expectations and values of the patient. The AASM is comm itted to util izing evidence-based med 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    icine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 in the updating of the A ASM Scoring Manual. Systematic literature searches are conducted to collect all available evidence. Clinician content experts provide guidance and feedback on drafts of potential rules. Sleep technologists and other sleep center staff contribute to expert opin ion and commun icate the priorities of the patient. Fi nally, the online format of the manual makes it particu larly amenda ble to incorporating new evidence and feedback from users and beneficiaries al i ke.</br></br>The Scoring Manual Editorial Board has been tasked to continuously review and update the AASM Scoring Manual i n order lo further clarify existing ru les and notes or to recommend revisions based on new clin ical evidence or advances in technology. The A ASM Board of Directors reviews and approves all revisions before a new version of the manual is published.</br></br></br>References</br></br>Redline S, Budh iraja R, Kapur V, et al. The scoring of respiratory events in sleep: reliability and val id ity. J Clin Sleep Med. 2007;3(2):169 -200.</br>Berry R B, Budh iraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    merican
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Academy of Sleep Medicine. J Cf i11 Sleep Med. 2012;8(5):597-619.</br>lber C, Ancoli-lsrael S, Chesson AL Jr, Quan SF; for the A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    merican
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Academy of Sleep Medicine. The AASM Mcmua/.f&lt;Jr the Scoring of Sleep mu/ Associated</br>Eve/I/, : Rules, Terminology and Technical Specifications. \st ed. Westchester, I L: American Academy of Sleep Medicine; 2007.</br></br></br></br>All Content © 2018 American Academy of Steep Medicine</br>AASM Scoring Manual Version 2.S	75</br>(</br>Procedural Notes	c</br>(</br>c</br>Levels of Evidence	c</br></br>STANDARD</br></br></br></br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GUIDELINE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
</br></br></br></br>CONSENSUS</br></br></br></br></br>ADJUDICATION</br></br></br></br></br></br></br></br></br></br>A .I  9</br>Recommendation based on level I evidence or overwhelming level 2 evidence.	( (</br>Recommendation based on level 2 evidence or a consensus of level 3 evidence.	(</br>c</br>Recommendation with less evidence than guideline for which agreement was reached in a standardized</br>consensus process based on available infonnation.	c</br>Recommendation from the steering committee based on all available infonnation .Adjudication was only</br>perfonned (a) when there was insufficient evidence and no consensus agreement or (b) in conjunction	( with task force leaders on issues regarding minor clarifications and additions to rules.	c c</br>II.Parameters to be Reported for Polysomnography	(</br></br>Parameters. No evidence. Adopted and modified from previous AASM practice parameter. Consensus of Task Force with approval by Steering Committee.</br>c</br></br>8.1 IO</br></br></br></br>C.I  2</br></br></br>D.I 10</br></br></br>E.I 4</br></br></br></br>F.I  25</br></br></br></br></br>G.I  5</br></br></br></br></br></br></br></br>A.I  4</br>Sleep scoring data. No evidence. Adopted and modified from previous AASM</br>practice parameter. Consensus of Task Force with approval by Steering Committee.</br></br>Arousal events. No evidence. Adopted and modified from previous AASM practice parameter and compliant with rules of Arousal Task Force. Consensus of Task Force with approval by Steering Committee.</br></br>Cardiac events. No evidence. Compliant with rules of Cardiac Task Force. Consensus of Cardiac Task Force with approval by Steering Committee.</br></br>Movement  events. No evidence. Compl iant with rules of Movements Task  Force. Consensus of Movements Task Force with approval  by Steering Com mittee.</br></br>Respiratory events. No evidence. Adopted and modified from previous AASM practice parameter and compliant with rules of Respiratory Task Force. Consensus of Respiratory Task Force with approval by Steering Committee. Version 2.0 additions and approval from Scoring Manual Committee (SMC).•</br></br>Summary statements. No evidence. Adopted and modified from previous AASM practice parameter. Consensus of Movements Task Force with approval by Steering Committee.</br></br></br></br>Ill.Technical and Digital Specifications</br></br>Sampling frequency and filter specifications for routi ne PSG recordings. No evidence.Non-systematic review on ECG sampling rates and commonly appl ied principles in practice. Consensus of Digital Task Force with approval by Steering Comm ittee.</br>CONSENSUS	c</br>c</br>(</br>c c c c c c</br>CONSENSUS	c</br>c</br>c</br>CONSENSUS</br>(</br>c</br>(</br>(</br>(_</br>CONSENSUS	c</br>c</br></br>l</br>(</br>76	AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine	c</br>c</br>c</br>[)</br>0</br>(</br>0</br>B</br>0</br>0</br>0</br>n</br>0</br>(_)</br>0</br>0</br>D 0 D 0</br>0</br>0</br>0</br>D</br>D</br>[)</br>D</br></br></br>B.I 8</br></br></br>C.I 10</br></br></br>D.I 4</br></br></br>E.l 21</br></br></br>L</br>A.I</br></br></br>A.2</br></br></br>A .3</br></br></br>B.I</br></br></br>B.2</br></br></br>C.l  2</br></br></br>D.l</br></br></br>D.2.a b,d</br></br></br>D.2.c</br></br></br>D.3</br></br></br>Digital PSG recordi ng systems features. No evidence. Consensus of Digital Task Force with approval by Steering Comm ittee.</br></br>PSG display and display manipu lation. No evidence. Consensus of Digital Task Force with approval by Steering Committee.</br></br>Digital analysis of PSG. No evidence. Consensus of Digital Task Force with approval by Steering Comm ittee.</br></br>Cal ibrations to document appropriate system response. No evidence. Consensus agreement of Scoring Manual Editorial Board and approved by the A ASM Board of Directors.</br></br></br></br>IV.Sleep Staging Rules Part 1: Rules For Adults</br></br>Recommended EEG derivation. Level 4 evidence. Consensus agreement by Visual</br>Task Force approved by Steering Committee.	r</br>I</br>Alternative EEG derivation. Level 4 evidence. Consensus agreement by Visual Task</br>Force approved by Steering Committee.	I</br>Ten-twenty application map. No evidence. Consensus vote was not felt necessary. Steering Com mittee approved as a standardized and u niversally accepted procedure.</br></br>Recommended EOG derivation. Level 4 evidence. Consensus agreement by Visual Task Force approved by Steering Committee.</br></br>Alternative EOG derivation. Level 4 evidence. Consensus agreement by Visual Task Force approved by Steering Committee.</br></br>EMG derivation. No evidence. Consensus agreement with clarification of specific distances and back-up electrode requested by industry and technical review panel and provided by Visual Task Force chair with Steering Committee approval.</br></br>Sleep stage term inology. No evidence. Consensus agreement by Visual Task Force approved by Steering Committee.</br></br>Epoch scoring parameters. No evidence. Consensus agreement by Visual Task Force approved by Steering Committee.</br></br>Assignment of epoch with multiple stages. No evidence. Clarification was provided by agreement of Visual Task Force chair and Steering Committee.</br></br>Limited evidence. Consensus agreement of Scoring Manual Comm ittee and approved by the AASM Board of Directors.</br></br>Stage W defin it ions. Very limited level 3 and 4 evidence. Consensus agreement by Visual Task Force approved by Steering Com mittee.</br></br>Presence of alpha. I nconsistent level I and level 2 evidence for rel iabil ity and level 3 evidence for valid ity. Consensus agreement by Visual Task Force approved by Steering Committee.</br></br>Stage NI definitions. Limited evidence. Consensus agreement by Visual Task Force approved by Steering Com mittee.</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>l</br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>ADJUOICATION</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br>CONSENSUS</br>and</br>ADJUDICATION</br></br></br>CONSENSUS</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	77</br></br></br></br>F.:!</br></br></br></br>F.3</br></br></br>F.4</br></br></br>F.5</br></br></br>F.6</br></br></br>G.I</br></br></br>G.2</br></br></br>G.3</br></br></br>G.4</br></br></br>G.5</br></br></br>G.6</br></br></br>H.I</br></br></br>H.2</br></br></br>I.I</br></br></br>1.2</br></br>Stage NI based on replacement of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. I nconsistent level I and 2 evidence for reliability and level 3 evidence for validity.Consensus agreement by Visual Task Force approved by Steering Committee.</br></br>Stage NI based on frequency slowing, vertex waves, and slow eye movements.</br>Li mited evidence. Consensus agreement of Visual Task Force approved by Steering Committee.</br></br>Limited evidence. Consensus agreement of Scoring Manual Committee and approved by the AASM Board of Directors.</br></br>Limited evidence. Consensus agreement of Scoring Manual Committee and approved by the AASM Board of Directors.</br></br>Limited evidence. Consensus agreement of Scoring Manual Committee and approved by the AASM Board of Directors.</br></br>Stage N2 definitions. Limited level 3 and 4 evidence. Consensus agreement of Visual Task Force approved by Steering Committee.</br></br>Stage N2 based on K complexes and spindles. Consistent level I and 2 evidence. Decision by Steering Comm ittee and consensus agreement of Visual Task Force.</br></br>Limited evidence. Consensus agreement of Scoring Manual Committee and approved by the AASM Board of Directors.</br></br>Stage N2 conti nuation. Limited evidence. Consensus agreement of Visual Task Force approved by Steering Committee.</br></br>Lim ited evidence. Consensus agreement of Scoring Manual Comm ittee and approved by the AASM Board of Directors.</br></br>Stage N2 ending. Limited evidence, inferred from other rules. Consensus agreement of Visual Task Force approved by Steering Committee.</br></br>Stage N3 definition. Consistent levels 3 and 4 evidence. Consensus agreement of Visual Task Force approved by Steering Com mittee.</br></br>Stage N3 rule. Consistent level I and 2 evidence. Decision by Steering Committee and consensus agreement of Visual Task Force.</br></br>Stage R definitions. Limited evidence. Consensus agreement of Visual Task Force approved by Steering Comm ittee.</br></br>Stage R based on rapid eye movements, low EMG and EEG. Consistent level I and 2 evidence. Decision by Steering Committee and consensus agreement of Visual Task</br>Force.</br>(</br></br>CONSENSUS</br>(</br>(</br>CONSENSUS	(</br>(</br>(</br>CONSENSUS</br></br>c</br>CONSENSUS	c</br>(</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c</br>STANDARD	c</br>c</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c</br>CONSENSUS	(</br>c c c c c c c</br>CONSENSUS</br></br>c</br>STANDARD	c</br></br>l</br></br></br>1.3</br></br></br>1.4</br></br></br>1.5</br>1_</br>Limited evidence. Consensus agreement of Scoring Manual Committee and approved by the AASM Board of Directors.</br></br>Limited evidence. Consensus agreement of Scoring Manual Committee and approved by the AASM Board of Directors.</br></br>Continuation of stage R. Limited evidence. Consensus agreement of Visual Task Force approved by Steering Committee.</br>CONSENSUS	c</br>c</br>(</br>CONSENSUS</br></br></br></br>CONSENSUS</br>(</br>(</br></br>78 AASM Scoring Manual Version 2.5	All Corte t	2018 Arr 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rccan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Acad ,,Y of Sle r Mf'd cine	(_</br>(</br>(</br>0	.6</br>0</br>[	1.7</br>0</br>8	!	J.l</br>0	l</br>0	J.2 4</br>0</br>0</br>0	[</br>0	I</br>0	A. I</br>0	I</br>0	B.I</br>0</br>0	C.I</br>0</br>0	C.2 .S</br>[)</br>0	D.I</br>0</br>0	D.1</br>0</br>0	E.I</br></br></br>Stage R end ing. Inferred from other rules. Lim ited evidence. Consensus agreement of Visual Task Force approved by Steering Com mittee.</br></br>Limited evidence. Consensus agreement of Scoring Manual Comm ittee and approved by the AASM Board of Directors.</br></br>Major body movement defin ition. No evidence. Consensus agreement of Visual Task Force approved by Steering Committee.</br></br>Major body movement rules. No evidence. Consensus agreement of Visual Task Force approved by Steering Committee.</br></br></br>IV.Sleep Staging Rules Part 2: Rules for Children</br></br>Ages. Limited evidence. Consensus agreement of Pediatric Task Force approved by Steering Committee.</br></br>Tech nical considerations. Adult rules accepted by Pediatric Task Force with pediatric caveats provided in notes.</br></br>Term inology. No evidence. Consensus agreement of Pediatric Task Force approved by Steering Committee.</br></br>Scoring sleep stages. Li mited evidence. Consensus agreement of Pediatric Task Force approved by Steering Comm ittee.</br></br>Stage W definitions. Limited evidence. Consensus agreement of Pediatric Task Force approved by Steering Comm ittee.</br></br>Stage W rules. Li mited evidence. Consensus agreement of Pediatric Task Force approved by Steering Comm ittee.</br></br>Stage N I  defin itions. Li mited evidence. Consensus agreement of Pediatric Task Force approved by Steering Comm ittee.</br></br></br></br></br></br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br>l</br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br>I</br>- ,. :-·I</br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br>0	--1._</br></br>0	E.2 3</br>0</br>0	F.I</br>0	G.I</br>0</br>0	H.I</br>Stage N I  ru les. Lim ited evidence. Consensus agreement of Pediatric Task Force approved by  Steering Comm ittee.</br></br>Stage N2 rules. Adult rules accepted by Pediatric Task Force. Stage N3. Adult rules accepted by Pediatric Task Force.</br>Stage R. Adult rules accepted by Pediatric Task Force.</br>I	CONSENSUS</br>t</br>CONSENSUS</br></br></br>CONSENSUS</br></br></br>CONSENSUS</br></br>IV.Sleep Staging Rules Part 3: Rules for Infants		J</br></br>A.I</br></br></br>B.l</br></br></br>8.2</br>..</br>Ages. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Technical considerations. Adult rules accepted by Scoring Manual Ed itorial Board.</br></br>Recommended technical considerations. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br>All Content © 2018 Ame• can Academy of Sleep Med cine	AASM Scoring IV'anual Versior 2 .	79</br></br></br></br>B.3 4</br></br></br>C.I</br></br></br>C.2 6</br></br></br>,_ _ _ _</br>C.8</br></br></br>DJ .a  c</br></br></br>Optional technical considerations. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Terminology. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Scoring sleep stages. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>EOG characteristics definitions. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Chin EMG patterns definitions. Consensus agreement of Scoring Manual  Ed itorial Board and approved by the A ASM Board of Directors.</br></br>Stage W rules. Consensus agreement of Scoring Manual Editorial Board and</br></br></br></br>CONSENSUS	c</br>c</br>CONSENSUS	(</br>c:</br>CONSENSUS	c</br>(</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>CONSENSUS</br></br> 	approved  by the AASM Board of Di rectors.	c</br>Stage N rules. Consensus agreement of Scoring Manual Editorial Board and	c</br></br>E. I.a e</br></br></br>FJ 2</br></br>,G-.I-2</br>1</br>A.I</br></br></br></br>A .I</br>[_</br></br></br></br></br>A.I</br></br></br>B.I</br></br></br>B.2</br>approved by the AASM  Board of Di rectors.</br></br>Stage R rules. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Di rectors.</br></br>Stage T rules. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br></br>V. Arousal Rule</br></br>Arousal rule. Duration and EEG change. Level  I and 2 evidence. Decision by Steering Comm ittee and consensus of Arousal Task Force.</br></br>Arousal rule. Specification  for duration of EMG increase was req uested by techn ical industry and recommended  by task force chair. Th is decision was then adjud icated by Steering Com mittee.</br></br></br>VI. Cardiac Rules</br></br>Single lead. No evidence. Consensus agreement by Cardiac Task Force approved by Steering Committee.</br></br>Tachycard ia. Level 3 and 4 evidence. Consensus agreement by Cardiac Task Force approved by Steering Comm ittee.</br></br>Bradycardia. Level 3 and 4 evidence. Consensus agreement by Cardiac Task Force approved by Steering Comm ittee.</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>STANDARD</br></br></br></br>ADJUDICATION</br></br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br>(</br>c c c c</br>c...</br>c c c c c c</br>c.. c c c c c</br>(</br>(</br></br>l</br></br></br>B.3</br></br></br>B.4</br></br>Asysto\e. Li m ited evidence. Consensus agreement by Card iac Task Force approved by Steering Committee.</br></br>Wide complex tachycardia. Li mited evidence. Consensus of Cardiac Task Force and approved by Steering Com mittee.	 	</br>CONSENSUS	c</br>c</br>(_</br>CONSENSUS</br></br>c</br></br>l</br></br>80	AASM Scoring Manual Version 2.5</br>All Content © 2018 American Academy of Sleep Medicine	c</br>(_</br>r</br>c;	B.5</br>c</br>0	B.6</br>0</br>(</br>c</br>(</br>0	A.I</br>0</br>0	A.2</br>0</br>0	A.3</br>0</br>0	AA</br>0</br>0</br>0	A.5</br>0</br>0	A.6</br>0</br>0	A.7</br>0</br>D	A.8</br>0</br>0	B.l.a</br>D</br>0</br>0	B.l.b</br>                  B.l.c  e</br>B.2.a</br></br></br>B.2.b c</br></br></br>B.3</br></br></br>B.4</br></br></br>Narrow complex tachycardia. Limited evidence. Consensus of Cardiac Task Force and approved by Steering Committee.</br></br>Atrial fibrillation. A 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    merican
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 Heart Association consensus modified by consensus of Cardiac Task Force and approved by Steering Committee.</br></br></br>VII.Movement Rules</br></br>Recommended electrode placement for monitori ng leg movements. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Recommended parameters for monitori ng leg movements. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Optional sampling of upper limbs. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br>+</br>Optional masseter electrodes. Consensus agreement of Scoring Manual Ed itorial Board and approved by the AASM Board of Directors.</br></br>Optional EMG recordings for detecti ng transient muscle activity in R EM sleep. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Recommended video PSG for diagnosis of RBD. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Optional electrode placement for monitoring RM D. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Recommended video PSG for diagnosis of RM D. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Leg movements. Evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>Leg movements. Evidence level 5. Rule states 10 seconds instead of the previous 5 second rule based on consensus agreement by Movements Task Force; approved by Steering Com mittee.</br></br>Leg movements. Evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>PLM series. Evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>PLM series. Evidence level 5 based on ICSD Consensus. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>A rousal and l imb movement that occur in a PLM series. Consensus agreement of Scoring Manual Ed itorial Board and approved by the AASM Board of Directors.</br></br>Leg movements preceding a respiratory event. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors .</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>....</br></br>All Content It') :?C18 American Academy of Sleer. Medic 1e	AASM Scoring Manual Version 2.5	81</br>(</br>Wake that separates a series of leg movements. Consensus agreement of Scoring</br></br>B.5</br></br></br></br>C.l</br></br></br></br>C. I.a  c</br></br></br>D.l.a  c</br></br></br>E.l.a c</br></br></br>F.l.a  b</br></br></br>F.l.a,c</br></br></br></br>F.l.a</br></br></br>F.1.d</br></br></br>F.l.e</br></br></br></br>G.I</br></br></br></br>G.I</br></br></br></br>G.2.a  b</br></br></br>I-I.I.a b</br></br></br>H.l.c  d</br>Manual Editorial Board and approved by the AASM Board of Di rectors.</br></br>The min imum duration of the muscle bursts for A LMA was removed due to concerns by the technical panel and Movements Task Force leader and adjudication by</br>Steering Committee.</br></br>Alternati ng leg muscle activation (ALMA). Evidence level 4 based on ICSD Consensus. Consensus agreement by Movements Task Force; approved by Steering Committee.</br></br>Hypnagogic foot tremor (H FT). Evidence level 2 Consensus agreement by Movements Task Force; approved by Steering Com mittee</br></br>Excessive fragmentary myoclonus (EFM). Evidence level 4. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>Bruxism phasic bu rsts. Evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Com mittee.</br></br>Bruxism ton ic bursts. Evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Com mittee.</br></br>Bruxism ampl itude of individual burst. No evidence. Consensus agreement by Movements Task Force plus adjudication by Steering Comm ittee based on techn ical panel input and discussions of the Movements Task Force.</br></br>Bruxism episodes. Evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Com mittee.</br></br>Bruxism scoring. Evidence level 2 and evidence level 5. Consensus agreement by Movements Task Force, approved by Steering Com mittee.</br></br>Definitions for R EM Sleep Behavior Disorder. REM sleep without atonia and duration of bursts of transient muscle activity. Evidence level 3. Consensus agreement by Movements Task Force, approved by Steering Comm ittee.</br></br>Definitions for R EM Sleep Behavior Disorder. Amplitude criterion and 3 second sequences of transient muscle activity. Evidence level 3. Recommended by task force chair and approved by Steering Committee.</br></br>Rule for REM Sleep Behavior Disorder. Evidence level 3. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>Rhythmic movement disorder ( RMD) frequency. Evidence level 4. Consensus agreement by Movements Task Force, approved by Steering Committee.</br></br>Rhythm ic movement disorder ( RMD). No evidence. Consensus agreement by Movements Task Force approved by Steering Comm ittee.</br></br></br>VIII.Respiratory Rules Part 1: Rules For Adults</br>CONSENSUS	l</br>c</br>(</br>CONSENSUS</br></br>(</br>CONSENSUS	c</br>(</br>c</br>
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GUIDELINE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
	c</br>(</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c</br>o\DJUDICATION</br>(</br>c</br>CONSENSUS</br>_ __j</br>STANDARD	c</br>c</br>CONSENSUS	c</br>c</br>(</br>ADJUDICATION	c</br>CONSENSUS	c</br>c</br>(</br>CONSENSUS</br>(</br></br>CONSENSUS</br>(</br>( (.</br></br></br>A.I</br>Recomme11ded airflow sensor for apnea detection. Consensus agreement by	_J_ coNSENsus	c</br>Respi ratory Task Force approved by Scoring Manual Com mittee (SMC).</br>-	----	(.</br>c</br></br>82  AASM Scoring Manual Version 2.5	A  Cont rt	201&amp; Am  tc	A ad my 01 SI ep Med c-  e	(_</br>(</br>(</br>A .2.a c	Alternatil'e airflow sensors for apnea detection . Consensus agreement by Respiratory	CONSENSUS</br>Task Force approved by SMC.</br>[</br>0	PVDFsum a/ternatiw and acceptable for apnea detection .No agreement by</br>A .2.d	Respiratory Task Force, adjudicated by AASM Board of Di rectors, approved by	AOJIJDICATION</br>0	SMC.</br>(</br></br>0	A .3</br>0</br>Recommended airflow sensor for detection of a hypopnea. Consensus agreement by	CONSENSUS</br>Respiratory Task Force approved by SMC.</br></br>A.4.a  d	Altenwtil'e  airflow sensors for hypopnea detection. Consensus agreement by	CONSENSUS</br>Respiratory Task Force approved by SMC.</br>0</br>PVDFsum altemative and acceptable for hypopnea detection. No agreement by</br>A.4 .e	Respiratory Task Force, adjudicated by AASM Board of Directors, approved by	ADJUDICATION</br>0	SMC.</br>0</br></br>0	A.5</br>0</br>Airflow sensor for apnea and hypopnea detection during PAP titration. Consensus</br>agreement by Respiratory Task Force approved by SMC.</br>CONSENSUS</br></br>0	A.6.a b</br>0</br>Sensors for monitoring respiratory effort. Consensus agreement by Respiratory Task	CONSENSUS</br>Force approved by SMC.</br></br>Thoracoabdominal PVDF belts acceptable for monitoring respiratory effort. No</br>A.6.c	agreement by Respi ratory Task Force, adjud icated by AASM  Board of Directors,	ADJUDICATION</br>0	approved by SMC.</br></br>[)</br>Preferred sensor for detection of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blood oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
. Use of pulse oximetry and pulse</br>0	A .7	oximetry averaging times. Consensus agreement by Respiratory Task Force,	CONSENSUS</br>D	approved by SMC.</br></br>D</br>A.8</br>Preferred sensors for mon itoring snoring. Consensus agreement by Respiratory Task	CONSENSUS</br></br>0	Force, approved by SMC.</br>[</br>A.9	Preferred sensors for detecting hypoventilation du ring diagnostic study. Consensus	CONSENSUS</br>0	agreement by Respiratory Task Force, approved by SMC.</br>0	Preferred sensors for detecting hypoventilation during a PA P titration study.</br>A.10	CONSENSUS</br>0		Consensus agreement by Respiratory Task Force, approved by SMC.</br>0	Identification of breaths begi nning and ending events. Consensus agreement by</br></br>0	BJ</br>Respi ratory Task Force, approved by SMC.</br>CONSENSUS</br></br></br>B.2	Sensors used to measure duration of apneas and hypopneas. Consensus agreement by	CONSENSUS</br>Respi ratory Task Force, approved by SMC.</br></br>B.3	Identification of beginning and end of events with  large variability. Consensus	CONSENSUS</br>agreement by Respiratory Task Force, approved by SMC.</br>..</br></br>C.l.a  b</br>Apnea ampl itude criterion and duration of event criterion. Consensus agreement by</br>Respiratory Task Force, approved by SMC.</br>CONSENSUS</br></br>---&lt;</br></br>C.2	Scoring criteria for obstructive apneas.Consensus agreement by Respiratory Task	CONSENSUS</br>Force, approved by SMC.</br></br>C.3	Scoring criteria for central apneas. Consensus agreement by Respiratory Task Force,	CONSENSUS</br>approved by SMC.</br></br></br></br>All Content	r A	rtty of SI ep Med   In	AAS Scoring Ma'1ual Version :? ! 83</br>J</br></br></br>C.4</br></br></br>D.IA.a c</br>D.I B.a c</br></br>D.2.a c</br></br></br>D.3.a c</br></br></br>E.I</br></br>Scoring criteria for mixed apneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Hypopnea amplitude, duration and mini mum oxygen desat uration criterion. Consensus agreement by SMC.</br></br>Scoring criteria for obstructive hypopneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for central hypopneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for respiratory effort-related arousals. Consensus agreement by</br>(</br>CONSENSUS	c</br>(</br>CONSENSUS	(</br>c</br>CONSENSUS	r</br>c</br>CONSENSUS	(</br>c</br>CONSENSUS	l</br></br></br></br></br>F.l.a  b</br></br></br>G.La b</br></br></br></br></br></br>A.I</br></br></br>B.l</br></br></br>B.2.a  c</br></br></br>B.2.d</br></br></br>B.3</br></br></br>B.4.11 d</br></br></br>B.S</br></br></br>8.6.a  b</br></br></br>B.7</br></br></br>B.8</br>Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for hypoventilation. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for Cheyne-Stokes breathi ng. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br></br>VIII.Respiratory Rules Part 2: Rules for Children</br></br>Ages for which pediatric respiratory scoring rules apply. Consensus agreement by Respiratory Task Force approved by Scoring Manual Committee (SMC).</br></br>Recommended airflow sensor for apnea detection. Consensus agreement by Respiratory Task Force approved by SMC.</br></br>Altenwti l'e airflow sensors for apnea detection. Consensus agreement by Respiratory Task Force approved by SMC.</br></br>End-tidal PC02 acceptable for apnea detection. Consensus agreement by Respi ratory Task Force approved by SMC.</br></br>Recommended airflow sensor for detection of a hypopnea. Consensus agreement by Respiratory Task Force approved by SMC.</br></br>Alternative airflow sensors for hypopnea detection. Consensu s agreement by Respiratory Task Force approved by SMC.</br></br>Airflow sensor for apnea and hypopnea detection during PA P titration . Consensus agreement by Respiratory Task Force approved by SMC.</br></br>Sensors for monitoring respiratory effort. Consensus agreement by Respiratory Task Force approved by SMC.</br></br>Preferred sensor for detection of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blood oxygen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 . Use of pu lse oximetry and pulse oximetry averaging ti mes. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Preferred sensors for monitoring snoring. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br></br></br></br>CONSENSUS</br>c</br>c</br>(</br>c c c c</br>(</br>c c c</br></br>c c c c</br>(.</br>c c c c</br>(_</br>(</br>c.</br>(</br>c c c</br>c..</br></br>84	AAS</br></br>Seo '1Q \Ila ual Vers10'1 2.5	018 Amer can Acad</br>ISleep Med c ne	c</br>(</br>n</br>0</br>c	I_</br>0</br>0</br>0</br>0</br>0</br>c</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br>0</br></br></br></br>B.9</br></br></br>B.lO</br></br></br>C.I</br></br></br>D.l..a c</br></br></br>D.2</br></br></br>D.3.a  c</br></br></br>D.4</br></br></br>E.1.a c</br></br></br>E.2.a c</br></br></br>Preferred sensors for detecti ng hypoventilation during diagnostic study. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Preferred sensors for detecting hypoventilation during a PA P titration study. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Measuring event du ration same as adults. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Apnea ampl itude criterion, duration of event and respiratory effort criterion. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for obstructive apneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for central apneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for m ixed apneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Hypopnea amplitude, duration and min imum oxygen desaturation criterion. Consensus agreement by Respi ratory Task Force, approved by SMC.</br></br>Scoring criteria for obstructive hypopneas. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br>+-	- - - ---,,</br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br>l</br>CONSENSUS	I</br>---i</br></br>CONSENSUS</br></br></br></br>CONSENSUS	j</br></br>0	--</br>Scoring criteria for central hypopneas. Consensus agreement by Respiratory Task</br></br>0</br>r L</br>D</br>r</br>0</br></br>0</br>D 0</br>,..</br></br>....</br>E.3.a c</br></br></br>F.l.a  d</br></br></br>G.1</br></br></br>H.I</br></br></br></br></br></br></br></br>A.1 8</br></br></br>B.1 11</br>Force, approved by SMC.</br></br>Scoring criteria for respi ratory effort-related arousals. Consensus agreement by Respiratory Task Force, approved by SMC.</br></br>Scoring criteria for hypoventilation. Consensus agreement by Respiratory Tasl.. Force, approved by SMC.</br></br>Scoring criteria for periodic breathing. Consensus agreement by Respi ratory Tasl.. Force, approved by SMC.</br></br></br>IX. Home Sleep Apnea Testing (HSAT) Rules for Adults</br>Part 1: HSAT Utilizing Respiratory Flow and/or Effort Parameters</br></br>Parameters. Consensus agreement of Scoring Manual Ed itorial Board and approved by the AASM Board of Directors.</br></br>Recording data if sleep is NOT recorded. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br>CONSENSUS</br>J</br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br></br></br></br></br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br>CJ 1l</br></br></br>D.I 8</br></br>Recording data if sleep is recorded. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Summary statements. Consensus agreement of Scoring Manual Ed itorial Board and approved by the AASM Board of Directors.</br>-----;</br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br></br></br>All Content © 2C18 Arieric1n Acadc&quot;Tiy of Sleep Medic 'le	AASM Scoring Ma'lJal Version 2..	85</br></br></br></br>E.I  8</br></br></br></br>F.l.a  b</br></br></br></br>F.l.c.i</br></br></br></br>F.l.c.ii</br></br></br></br>F.2.a</br></br></br>F.2.b</br></br></br></br>F.2.c  d</br></br></br></br>F.2.e</br></br></br>F.3</br></br></br>F.4</br></br></br>G.l.a  b</br></br></br>G.2</br></br></br>G.3</br></br></br>G.4</br></br></br>H.IA.a  c</br>H.I B.a  c</br></br></br>H.2A.a  c H.2B.a  c</br></br></br>Recording data. Adopted and modified from previous AASM practice parameters. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Recommended airflow sensors for respiratory event detection. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Di rectors.</br></br>Altemative Recommended airflow sensor for respi ratory event detection. Consensus agreement of Scoring Manual Ed itorial Board and approved by the AASM Board of Directors.</br></br>Altemative Acceptable airflow sensor for respiratory event detection. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Di rectors.</br></br>Recommended sensor for monitoring respi ratory effort. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Acceptable sensor for monitoring respiratory effort. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Acceptable thoracoabdominal belts for monitoring respiratory effort. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Di rectors.</br></br>Acceptable thoracoabdominal belts for monitoring respiratory effort. No agreement by Scoring Manual Editorial Board, adjudicated by the AASM Board of Di rectors.</br></br>Recommended sensor for monitoring oxygen saturation. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Optional sensors for monitoring snoring. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>HSAT apnea amplitude criterion and duration of event criterion. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Di rectors.</br></br>HSAT scoring criteria for obstructive apneas. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>HSAT scoring criteria for central apneas. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>HSAT scoring criteria for mixed apneas. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>HSAT hypopnea amplitude, duration and minimum oxygen desaturation criterion if sleep is NOT recorded. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>HSAT hypopnea amplitude,duration and mini mum oxygen desaturation criterion if sleep IS recorded. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br>(</br>(</br>(</br>(_</br>c</br>c</br>CONSENSUS	c</br>(</br>c</br>CONSENSUS	c</br>c c c</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c c c</br>CONSENSUS</br></br></br></br>CONSENSUS</br></br>c</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c</br>CONSENSUS	c</br>c</br>c</br>(</br>c c c c c c c c</br></br>86 AASM Seo	J Manual Version 2.5	All Cont nt © 2018 Amencan 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Acadc
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
-my of S1eep Medicine	c c</br></br>..	IX. Home Sleep Apnea Testing (HSAT) Rules for Adults</br>Part 2: HSAT Utilizing Peripheral Arterial Tonometry (PAT)</br></br></br></br></br>0</br>.r.</br>0</br></br>0</br>n</br>D</br>0</br>0</br>D D</br></br>A.I  7</br></br></br>8.1 7</br></br></br>C.l 8</br></br></br></br>D.l  8</br></br></br></br>E.l</br></br></br>E.2</br>Parameters. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Recording data. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Summary statements. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Recordi ng data. Adopted and modified  from previous AASM practice parameters. Consensus agreement of Scoring Manual Editorial Board and approved by the AASM Board of Directors.</br></br>Acceptable sensors for respiratory event detection. Consensus agreement of Scoring Manual Ed itorial Board and approved by the AASM Board of Directors.</br></br>Reco111me11ded sensor for monitoring oxygen saturation. Consensus agreement of Scoring Manual  Editorial Board and approved by the AASM  Board of Directors.</br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br></br>CONSENSUS</br></br></br></br></br>CONSENSUS</br></br>D      •Jn 2015, the name of the Scoring Manual Committee (SMC) was changed to the Scoring Manual Editorial Board.</br>D 0 D D</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>All Content Ct&gt; 2018 American Academy of Steep Medicine	AASM Scoring Manual Version 2.5	87</br>XII.Glossary of Terms	l</br>(</br>Alphn rhythm (posterior dominant rhythm in adults and older children): An EEG pattern consisti ng of trains of	(</br>sinusoidal 8-13 Hz activity recorded over the occipital region with eye closure and attenuating with eye opening.	(</br>Apnen: Cessation of airflow (;::90% decrease in apnea sensor excursions compared to baseline) of a minimum duration as defi ned by adu lt (Vlll.C.I ) and pediatric rules (Vll l.D.1). Apneas are classified as obstructive, mixed, or central based</br>on the pattern of respi ratory effort.	G</br>Asystole: An interr uption of cardiac rhyth m lasti ng more than 3 seconds.		( Atrial fibrillution: Irregularly irregular QRS complexes associated with replacement of consistent P waves by rapid		c oscillations that vary in size, shape and timing.	c</br>Beta rhyth m: An EEG rhyth m consisting of 13-30 Hz activity.	c</br>Brudycard iu (during sleep): A sustained (&gt;30 seconds) heart rate less than 40 beats per minute for ages 6 years through</br>adulthood.</br>Bruxism :Grinding or clenching of the teeth during sleep that is often associated with arousal. (Scoring rule VI LE.I)	(</br>Central hypopnea: A specified reduction in airflow lasting at least 10 seconds in adults or the equivalent of 2 breaths in	c</br>children during which there is no evidence of snoring, increased inspiratory flattening of the nasal pressure or PAP	(</br>device flow signal compared to baseline breathing, or associated thoracoabdominal paradox.</br>(</br>Cheyne-Stokes breathing: A breathing rhythm with a specified crescendo and decrescendo change in breathing amplitude</br>separating central apneas or hypopneas. (Scoring rule for adults VII l.G.I )</br>Chronological  age: The time elapsed since birth expressed in either days, months, or years; also referred  to as postnatal or	c</br>legal age.	c</br>Conceptionnl age (CA):Gestational age (GA) at birth plus the number of weeks postpartum.</br>Deltn frequency: An EEG rhyth m consisting of0-3.99 M z activity. (See defi nition of slow wave activity.) Derivation: The recorded voltage difference between two electrodes (eg, EEG, EOG, chin EMG derivations).</br>Excessh•e fragmentary myoclonus: Limb EMG activity of a specified frequency and duration often unassociated with visible movement. This polysomnographic finding is not thought to have physiological significance.</br>Excessive transient muscle activity (phnsic activity) in REM sleep: I n a 30-second epoch of R EM sleep divided into	c</br>10 sequential 3-second min i-epochs, al least 5 (50%) of the min i-epochs contain bursts of transient muscle activity.</br>Excessive transient muscle activity bursts are 0.1-5.0 seconds in duration and at least 4 ti mes as high in amplitude as the background  EMG activity.</br>Eye blin ks:Conjugate vertical eye movements at a frequency of 0.5-2 Hz present in wakefu lness with the eyes open or	c</br>closed.</br>Gestntionul age (GA): The time elapsed between the fi rst day of the mother's last menstrual period and the day of delivery expressed in completed weeks. lf the pregnancy was achieved using assisted reproductive technology, GA is calculated</br>by adding 2 weeks to the conceptional age.	c</br>High voltage slow (HVS): Continuous synchronous symmetrical predominantly high voltage 1-3 Hz delta activity.	c</br>Hypnagogic foot tremor: Trains of EMG activity of the lower limb with a specified frequency; not a defi ned disorder.	c</br>Hypnugogic hypersynchrony (HH): Paroxysmal bursts or runs of diffuse, high-amplitude, sinusoidal, 75-350 µV, 3-4.5</br>Hz waves which begin abruptly, are usually widely distributed but often are maximal over the central, frontal, or</br>frontocentral  scalp regions.These waveforms can occur in stage N 1 and N2.	c</br>Hypnogrum: A graphical representation of sleep stages which occur throughout the night.	c</br>Hypopnen: A reduction in airflow with the minimum amplitude and duration as specified in the hypopnea rules for adu lts (Vlll.D.I A and I 8) and children (VI 11.E.I). The reduction in airflow must be accompanied by a ;::3% desaturation or an arousal (Vlll.D.I A and Vll l.E.I) or a ;::4% desaturation (Vlll.D.18).</br>Hypoventilation:  A specified period of increased PC02 of &gt;50 mm Hg in children or &gt;55 mm Hg in adults, or a rise of	c</br>PC02 during sleep of =::to mm Hg that exceeds 50 mmHg for a specified period of time in adults.	(</br>K complex: A well-delineated, negative, sharp wave immediately followed by a positive component standing out from	(</br>the background  EEG, with total duration ;::0.5 seconds, usually maximal in amplitude when recorded using frontal</br>derivations. For an arousal to be associated with a K complex, the arousal must either be concurrent with the K complex</br>or commence no more than  I second after termi nation of the K complex. (see V. Arousal  Rule).	c</br>88   AASM Scoring Manual Version 2.5	Ah Content © 2018 Amer ican Academy of Sleep Medicine	c</br>c</br>(</br>[</br>0</br>0</br>0</br>n</br>0</br>0</br>0</br>D</br>0</br>0</br>0</br>:1</br>D</br>J</br></br>0·-</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br>.J</br></br>Low-amplitude, mixed-frequency (LAM F) activity: Low amplitude, predom inantly 4-7 Hz activity.</br>Low chin EMG tone: Baseline EMG activity in the chin derivation no h igher than i n any other sleep stage and usually at the lowest level of the entire record ing.</br>Low voltage irregular (LV I): Conti nuous low voltage m ixed-frequency activity with delta and predominantly theta activity.</br>Major body movement: Movement and muscle artifact obscuring the EEG for more than half an epoch to the extent that the sleep stage cannot be determi ned.</br>Monitoring time (MT): Total recording time m inus periods of arti fact and ti me the patient was awake as determ ined by actigraphy, body position sensor, respiratory pattern, or patient diary.</br>Narrow complex tachycardia: A cardiac rhythm lasting a m inimum of 3 consecutive beats with QRS duration of &lt;l 20 msec and a rate of &gt;\00 per m i nute.</br>Nasal  pressu re transducer: A pressu re transducer that measu res the pressu re (relative to atmospheric pressure)  inside the nasal orifice using a nasal cannula. The pressure difference across the nasal in let during breathing is proportional  to</br>the magnitude of airflow squared. A square root transformation of the nasal pressure signal is proportional to airflow. The inspi ratory waveform of the nasal pressure signal exhibits a flattened pattern duri ng airflow l im itation provided the signal from the transducer is recorded as a DC signal or as an AC signal with an appropriate low filter setting.</br>Oxygen desaturation index (ODI): The number of oxygen desatu rations x 60 divided by the monitoring time (for HSAT) or total sleep time (for in-laboratory PSG).</br>Periodic breathing: &gt;3 episodes of central apnea lasting &gt;3 seconds separated by no more than 20 seconds of normal breathing in children.</br>Periodic limb movements of sleep: Movements of the limbs during sleep occurring with a specified frequency, duration, and amplitude.</br>Peripheral arterial tone: A measure of pulsatile volume changes at the finger tip that reflects changes in sympathetic tone.</br>Peripheral arterial tonometry (PAT): A technique allowi ng noninvasive moment-to-moment  measurement of</br>sympathetic tone using finger plethysmography  (measurement of pu lsatile volume changes in the finger tip that reflects changes i n sympathetic tone). Increases in sympathetic tone resu lt in peripheral arterial constriction and reduced blood flow to the digit. The reduced volu me at the finger is detected by the probe. The combination of a decrease in PAT signal (sympathetic tone increase following respiratory events), a fa[[ in Sa02 (oximetry), and an increase i n heart rate is used to detect  respiratory  events.</br>Positiw airway pressure (PA P) How: An airflow signal derived from a pressure transducer built in to the PA P device.</br>Posterior dominant rhythm (PDR): The dom i nant reactive EEG rhythm over the occipital regions in relaxed wakefulness with eyes closed wh ich is slower i n infants and young children and attenuates with eye open ing or attention. Frequency is 3.5-4.5 Hz when first seen i n infants 3-4 months post-term, 5-6 Hz by 5-6 months, and 7.5-9.5 Hz by 3 years of age and ampl itude is usually &gt;50 µV. I n older children and adults, posterior dominant rhythm is often referred to as alpha rhythm.</br>Posterior slow waves of youth (PSW): Interm ittent runs of bilateral but often asymmetric 2.5-4.5 Hz slow waves superimposed, 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ridi
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 ng upon, or fused with the PDR, are usually &lt;120% of PDR voltage, block with eye opening and disappear with drowsiness and sleep. PSW are uncom mon in children &lt;2 years of age, have a maxi mal incidence between ages 8-14 years, and are uncommon after age 21 years.</br>PV DF sensor: Polyvinylidene fluoride (PVDF) film  is a fluoropolymer substance that reacts to changes in tem perat ure when used as a thermal airflow sensor and to impedance changes when used as an effort sensor.</br>PV DFsum: PVDFsum is the electrical sum of signals recorded from the thoracic and abdominal PVDF sensors.</br>Rapid eye movements (R EMs): Eye movements recorded in the EOG derivations consisti ng of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    conjugate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, irregular, sharply peaked eye movements with an in itial deflection usually lasti ng &lt;500 msec. While rapid eye movements are characterist ic of stage R sleep, they may also be seen in wakefulness with eyes open when ind ividuals visually scan the environment.</br>Read ing eye movements:  Eye movements  recorded  i n the EOG derivations consisting of trai 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ns
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 of 
<mark class="entity" style="background: #3cb44b; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    conjugate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 eye movements characterized by an initial slow phase followed by a rapid phase in the opposite d irection as the i nd ividual reads.</br>REM Sleep Behavior Disorder: A parasornn ia characterized by abnormal behaviors emerging from REM sleep and EMG abnormalities during R EM sleep (REM sleep without atonia).</br></br></br></br>All Content © 2018 American Academy of Sleep Medicine	AASM Scoring Manual Version 2.5	89</br>(</br>Respi ratory effort-related arousal: A sequence of breaths characterized by increasi ng respiratory effort (esophageal</br>manometry); inspiratory flatten ing in the nasal pressure or PAP device ftow chan nel; or an increase in end-tidal  PC02 (children) leading to an arousal from sleep. Respiratory effort-related  arousals do not meet criteria for hypopnea and have a mi nimum duration of ::::IO seconds i n adults or the duration of at least two breaths in children.</br>Respi ratory e\•ent index (R EI): Total number of respiratory events scored x 60 divided by monitori ng time (MT).	(</br>Respi ratory inductance plethysmography (RI P): A technology that uses alternating current in belts surround ing the	c</br>thorax and abdomen to generate a signal based on changes in the inductance of belts duri ng breath ing. The band	(</br>inductance depends on the cross-sectional area encircled by the band.</br>Rhythmic Movement Disorder: Repetitive, stereotyped and rhyth mic motor behaviors that occur predom inantly during drowsi ness or sleep and involve large muscle groups.</br>RIPHow: RI Pflow is the time derivative of the R!Psum signal; excursions in the signal are an estimate of airflow.	c</br>RIPsu m: R!Psum is the electrical sum of the signals from the thoracic and abdominal RI P sensors; excu rsions 
<mark class="entity" style="background: #42d4f4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    i
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">STRENGTH</span>
</mark>
 n the signal	c</br>are an estimate of tidal volume.	c</br>Sawtooth wa\·es: An EEG pattern consisting of trains of sharply contoured or triangular, often serrated, 2-6 Hz</br>waves maximal in amplitude over the central head regions and often, but not always, preced ing a burst of rapid eye	(</br>movements.	c</br>Scann ing eye movements: Trains of conjugate eye movements  with eyes open consisting of a slow phase followed by a	c</br>rapid phase in the opposite direction as the infant visually scans the environment or follows objects.</br>l</br></br>Sleep onset: The start of the fi rst epoch scored as any stage other than stage W. (In most subjects th is will usually be the</br>first epoch of stage N I.)</br>Sleep spindle: A train of distinct waves with frequency  11-16 Hz (most commonly  12-14 Hz) w ith a duration ::::o.5 seconds, usually maximal in ampl itude over the central regions.</br>Slow eye movements (SEM): Conjugate, reasonably regu lar, sinusoidal eye movements with an in itial deflection that usually lasts &gt;500 msec. Slow eye movements may be seen during eyes closed wake and stage N l.</br>Slow wave activity: Waves of frequency 0.5-2 Hz and peak-to-peak  amplitude &gt;75 µV, measured over the fronta l regions referenced  to the contra lateral car or mastoid (F4-M I , F3-M2).</br>Sustained muscle activity (tonic activity) in REM sleep: An epoch of REM sleep with at least 50% of the duration of the epoch having a chin EMG amplitude greater than the minimum amplitude demonstrated i n N R EM sleep.</br>Tachycardia or sinus tachycard ia (during sleep): A sustained (&gt;30 seconds) sinus heart rate &gt;90 beats per minute for adults.</br>Thermal sensor: A thermally  sensitive device that detects changes i n nasal and/or oral airflow based on changes i n temperature; thermal  sensors include therm istors, thermocouples,  or polyvi nyl idenc fluoride (PYDF) airftow  sensors.</br>Theta rhythm: A n EEG rhythm consisting of 4-7.99 Hz activity.</br>Trace alternant (TA): Generally only seen in stage N sleep; characterized by at least 3 alternati ng runs of bilaterally synchronous h igh voltage (50-150 µY) bursts of 1-3 Hz delta activity lasti ng 5-6 seconds (range 3-8 seconds) alternating with period of lower amplitude (25-50 µV) 4-7 Hz theta activity (range 4-12 seconds).</br>Transient muscle activity: Short irregu lar bursts of EMG activity usually with duration &lt;0.25 seconds superimposed</br>on low EMG tone. The activity may be seen i n the chin or anterior tibial EMG derivations, as well as in EEG or EOG deviations, the latter indicating activity of cranial nerve innervated muscles (facial and scalp muscles). The activity is often maxi mal when associated with rapid eye movements.</br>Vertex sharp waves (V waves): Sharply contoured waves with duration &lt;0.5 seconds (as measured at the base of the wave), maximal over the central region and distinguishable from the background activity. They are most often seen during transition to stage NI sleep but can occur in either stage N I or N2 sleep. These waveforms typically fi rst appear at 4-6 months post-term.</br>Wide complex tachycardia: A cardiac rhythm lasting a mini mum of 3 consecutive beats with QRS duration =::t 20 msec and a rate of &gt;IOO per minute.</br></br></br></br></br></br></br></br></br></br>90 AASM Scoring Manual Version 2.5	All Content © 2018 American Academy of Sleep Medicine</br>c c c c c c c c c c c c</br>C..</br>c c c</br>(_</br>c c c c</br>(_</br>c c c c c c</div></span>